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Abstract 
Economic evaluation has now been applied to health care for over 50 years, 
sometimes to good effect, sometimes for ill. This study seeks to give an 
understanding of what ‘economic evaluation’ can offer decision-makers, but 
also sets out to acknowledge its problems and pitfalls. In addition, this thesis 
applies one approach to economic evaluation, utilising data from the Finnish 
Randomised Study of Screening for Prostate Cancer (FinRSPC) after 20 years 
of the trial. Started in 1996, the FinRSPC is a pragmatic population-based trial 
investigating invitation to prostate-specific antigen (PSA) testing as a basis 
for mass screening to detect prostate cancer. Although the last invitations to 
screening were sent in 2007, health-care registers provide almost complete and 
almost continuous follow-up of some of the subsequent costs and effects, for 
up to 20 years in total.  
This thesis includes four peer-reviewed articles related to economic 
evaluation or the FinRSPC, as well as a synthesis of those articles in a 
summary, which includes an integrated assessment of the development and 
current state of economic evaluation in the field of health care. The main 
rationale for much of this study is that care should be taken when interpreting 
economic evaluation. This is mainly because the language and terminology 
surrounding economic evaluation is often ambiguous and it often oversells 
what research can credibly offer. One main finding from this study is that 
there should be humility about our ability to adequately evaluate prostate-
cancer screening. Data on costs and effects looks likely to remain deficient in 
some respects, due to problems in measuring outcomes, as well as due to 
problems in conducting trials on this topic. A second main finding is that 
economic approaches to evaluation inescapably include their own judgments 
about value; far from being a value-neutral form of assessment, these values 
determine its scope, content and appropriateness, to an important extent. 
Together with other findings, this study suggests a more classical approach to 
valuation would be useful: deliberative analysis. Such deliberative processes 
would include comprehensive quality assessment of information offered by any 
economic evaluation, integrating sources of information as and when necessary. 
x 
The articles which constitute this thesis each provide some evidence to 
support the suggestion of greater use of deliberative analysis. The 
measurement of health-related quality-of-life effects related to prostate-cancer 
screening in Article I faces challenges due to the timing and mode of data 
collection, due to the ‘measures’ used, as well as that much of the analysis is 
prone to biases. Article II mainly focuses on differences in average costs 
between the arms, as estimated from the accessible healthcare registers, for 
the men in the FinRSPC after 20 years. However, it should be noted that those 
estimates cannot account for, e.g., the potential impact of overdiagnosis or 
variations in treatment practices. Article III surveys a wide range of 
methodological literature and concludes that language and terminology 
related to health-economic evaluation should be used with sufficient humility 
to prevent it being oversold. It strongly recommends that the qualities of any 
‘economic’ evidence be thoroughly checked for quality and relevance, 
especially if that evidence is to be utilised as part of priority setting processes. 
Article IV uses cost-effectiveness analysis to combine cost information from 
registers with analysis of data on effectiveness, in terms of different indicators 
of mortality, from the FinRSPC. The approach to economic evaluation used 
here revealed a (non-statistically significant) increase in mortality in the 
screening arm, but perhaps more importantly, it highlighted the uncertainties 
surrounding the evaluation of overdiagnosis associated with prostate-cancer 
mass screening. 
In summary, although it is often claimed that economic evaluation can be 
useful in informing decision-making, in practice such claims are conditional on 
the qualities of the content of each economic evaluation. This thesis provides 
a rationale for assessing the qualities of all economic evaluations: their 
credibility should always be checked. Such quality assessment should look 
carefully at the uncertainties surrounding the evidence base, including any 
potential for medico-industrial influence. Every stakeholder should bear 
responsibility for appropriate interpretation of the available evidence, 
especially if interventions have consequences which are complicated, complex, 
or are simply not amenable to quantification or robust evaluation. Judging the 
appropriateness of the information from economic evaluation to any policy 
question should be approached with humility about what is, or can be, known.  
This thesis concludes with three propositions. Firstly, that economic 
evaluation should continue almost unchanged, with an important exception 
being that the current overselling of economic evaluation, both in principle and 
xi 
in practice, should be curbed. Secondly, attempts to improve the estimation of 
the likely costs and effects of interventions should continue, but with increased 
humility about the extent to which costs and effects can, in the foreseeable 
future, ever be ‘measured’ comprehensively. Finally, and perhaps most 
importantly, given that health-economic evaluation easily neglects many 
important impacts and, given the difficulties in changing language, terminology 
or research practices, those wishing to use information from economic 
evaluation should always engage in thorough critical assessment of its qualities.  
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Tiivistelmä 
Taloudellista arviointia on sovellettu terveydenhuoltoon jo yli 50 vuoden ajan, 
joskus hyvin ja joskus huonoin tuloksin. Tämä väitöskirja pyrkii selittämään, 
mitä ‘taloudellinen arviointi’ voi tarjota päätöksentekijöille, huomioiden myös 
siihen liittyvät ongelmat ja karikot. Lisäksi väitöskirjassa sovelletaan yhtä ta-
loudellisen arvioinnin lähestymistapaa FinRSPC-dataan tutkimuksen jatkuttua 
20 vuoden ajan. FinRSPC (Finnish Randomized Study of Screening for Prostate 
Cancer) on vuonna 1996 alkanut pragmaattinen väestöpohjainen tutkimus, joka 
koskee miesten kutsumista PSA-testiin (prostataspesifinen antigeeni) eturau-
hassyövän systemaattisena joukkoseulontamuotona. Vaikka viimeiset seulonta-
kutsut lähetettiin jo vuonna 2007, terveydenhuollon rekisterit mahdollistavat 
monien seulonnan aiheuttamien myöhempien kustannusten ja vaikutusten lähes 
katkeamattoman seurannan enimmillään 20 vuoden ajalta.   
Tähän väitöskirjaan kuuluu neljä vertaisarvioitua FinRSPC-tutkimuksen ta-
loudelliseen arviointiin liittyvää artikkelia, artikkelien synteesi yhteenvetona 
sekä integroitu arviointi terveydenhuollon taloudellisen arvioinnin kehityksestä 
ja nykytilasta. Väitöskirjan keskeisin lähtökohta on, että taloudelliset arvioinnit 
on syytä tulkita huolellisesti. Huolellisuutta tarvitaan, koska taloudellisessa ar-
vioinnissa käytetty kieli on usein monitulkintaista ja sillä usein liioitellaan 
tutkimuksen mahdollisuuksia. Yksi tärkeä tulos tässä työssä onkin, että etu-
rauhassyövän seulonnan arviointia varten saatavilla olevat tiedot voivat olla 
puutteellisia eikä tämä tilanne todennäköisesti ole muuttumassa. Tietojen puut-
teellisuus johtuu ongelmista sekä tulosten mittaamisessa että tutkimusten 
suorittamisessa. Toinen tärkeä löydös on, että taloudelliset arvioinnit väistä-
mättä sisältävät omat arvoarvostelmansa. Taloudellinen arviointi on kaukana 
arvovapaasta tutkimuksesta, koska nämä sisäänrakennetut arvot määrittävät 
arviointien laajuuden, sisällön ja soveltuvuuden tarkoitukseensa. Yhdessä tä-
män tutkimuksen löydökset tukevat ajatusta, että klassinen harkitseva 
analyysi olisi arviointitapana hyödyllisempi. Harkitseviin prosesseihin tulisi si-
sältyä taloudellisen arvioinnin tarjoamien tietojen kattava laatuarviointi ja 
tarvittaessa lisätietojen huomioiminen. 
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Tämän väitöskirjan sisältämissä artikkeleissa esitetään näyttöä, joka tukee 
harkitsevan analyysin laajempaa käyttöä. Ensimmäisessä artikkelissa eturau-
hassyövän seulontaa koskevien terveyteen liittyvien elämänlaatuvaikutusten 
mittaaminen on haasteellista tietojen keräämisen ajankohtien, keräämistapojen 
ja kuvattujen mittarien vuoksi. Suuri osa analyysistä on lisäksi altis harhoille. 
Toinen artikkeli keskittyy lähinnä terveydenhuollon rekistereistä saataviin kes-
kimääräisiin kustannuseroihin FinRSPC-tutkimukseen osallistuneiden miesten 
välillä 20 vuoden jälkeen. On kuitenkin huomattava, että näissä arvioissa ei 
voida huomioida mm. ylidiagnosoinnin tai vaihtelevien hoitokäytäntöjen mah-
dollisia vaikutuksia. Kolmannessa artikkelissa tarkastellaan monenlaista 
menetelmäkirjallisuutta ja todetaan, että terveystaloustieteellisten arviointien 
kielenkäytön ja terminologian tulisi olla riittävän asiallista, jotta vältyttäisiin 
liioittelulta. Artikkelissa suositellaan vahvasti, että ‘taloudellisen’ näytön laatu 
ja relevanssi tarkastettaisiin aina huolellisesti, erityisesti jos näyttöä käytetään 
priorisointiprosesseissa. Neljäs artikkeli hyödyntää kustannusvaikuttavuusana-
lyysiä yhdistäessään rekisterien kustannustietoja FinRSPC-tutkimuksen 
vaikuttavuusanalyysidataan hyödyntäen eri kuolleisuusmittareita. Tässä yh-
teydessä käytetty taloudellisen arvioinnin menetelmä paljasti (tilastollisesti 
merkityksettömän) lisäyksen seulontaryhmän kuolleisuudessa sekä toi esiin 
epävarmuustekijöitä, joita eturauhassyövän seulontaan liittyvän ylidiagnosoin-
nin arviointiin liittyy. 
Yhteenvetona todetaan, että vaikka taloudellisen arvioinnin usein väitetään 
olevan hyödyllinen päätöksenteon apuväline, käytännössä hyöty riippuu kunkin 
yksittäisen arvioinnin sisällöstä ja kontekstista. Tämä väitös esittää vahvat pe-
rustelut kaikkien eturauhassyövän seulontaa koskevien taloudellisten 
arviointien piirteiden arvioinnille: niiden uskottavuus pitäisi tarkistaa kaikissa 
tapauksissa. Kaikkien sidosryhmien tulee kantaa vastuuta saatavilla olevan 
näytön tulkinnasta erityisesti silloin, kun interventiolla on monimutkaisia, 
komplisoituneita seurauksia tai näitä seurauksia on vaikea mitata. Taloudelli-
sesta arvioinnista saatujen tietojen soveltuvuus päätösten perustaksi tulisi aina 
varmistaa ja pysyä nöyränä sen suhteen, mitä asiasta tiedetään tai edes voidaan 
tietää.  
Väitöskirjassa päädytään esittämään kolme ehdotusta. Ensinnäkin, taloudel-
lisia arviointeja ei ole syytä juurikaan muuttaa, mutta niihin liittyvää 
kielenkäyttöä tulisi tarkentaa ja liioiteltuja väitteitä vähentää. Toiseksi, työtä 
kustannusten ja vaikutusten arvioinnin parantamiseksi tulee jatkaa, pysyen 
nöyränä sen suhteen, missä laajuudessa kustannuksia ja vaikutuksia voidaan 
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kattavasti mitata. Viimeisenä ja kenties tärkeimpänä löydöksenä todetaan, että 
ottaen huomioon kuinka helppoa terveystaloustieteellisessä arvioinnissa on jät-
tää monia tärkeitä vaikutuksia huomioimatta ja mitä vaikeuksia muuttuva 
terminologia, kielenkäyttö ja tutkimuskäytännöt aiheuttavat, terveystaloustie-
teelliseen arviointiin perustuvia tietoja käyttävien tahojen pitäisi aina arvioida 
huolellisesti kyseisten arviointien laatu.   
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1 Introduction 
This introductory section sets out the some of the main reasons why this 
study, an article-based doctoral dissertation, aims to have two key roles. The 
first role of this study is to clarify what health-economic evaluation can mean 
in principle. The second role is one related to its potential role in informing 
decision-making through a specific application of health-economic evaluation 
to screening for prostate cancer in practice. With these dual roles, this thesis 
aims to provide sufficiently thorough guidance as to what economic evaluation 
can mean, at least in the context of its application to information relating to 
the health-economic evaluation of the Finnish Randomised Study of Screening 
for Prostate Cancer (FinRSPC). 
There are three main reasons for proceeding in this way, the first is the 
originally planned content of this study, the second reason is the nature of the 
information which may be most suitable for the target audience, and the third 
reason relates to the apparent misuse and abuse of terminology in the field of 
health-economic evaluation.  
The first reason for investigating both principles and practice is that this 
study will attempt, as far as possible, to follow the purpose set out in my 
application to begin undertaking doctoral research from the year 2002: 
“A cost-effectiveness analysis and an investigation into the long-term effects 
on health-related quality of life of screening will be undertaken as effectiveness 
and cost data is collected alongside the randomised FinRSPC. These 
investigations will then be combined with a description and assessment of the 
health-economic methodology used”.  
A second reason for the necessity of a description of both principles and 
practice is that the intended audience for the current study is any stakeholder 
involved in related decision-making processes. This conscious choice is made, 
firstly, from a belief that decision-making should ideally involve multiple 
stakeholders. Secondly, at the time of writing, the Finnish Ministry of Social 
Affairs and Health screening workgroup (16/10/2003–31/12/2007 and 
1/9/2008–30/6/2015) has been dismantled, and screening-related appraisal-
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processes appear to now be arranged on a case-by-case basis as part of the 
workings of the Council for Choices in Health Care in Finland (COHERE 
Finland). Given the current absence of any clear primary decision-making 
entity in Finland, this thesis aims towards providing, to decision-makers and 
the general public alike, information about the ‘relevant’ principles and the 
practical ‘quality’ of the evidence it presents. Therefore, this study aims to 
make both the principles and practice of health-economic evaluation more 
accessible and understandable by any stakeholder, regardless of their prior 
background knowledge about economic evaluation.  
A third main reason for describing the principles which relate to health-
economic evaluation in some detail is to avoid what can be seen as an 
overselling of health-economic evaluation through the ambiguity and 
corruption of terminology. Therefore, an integral part of ensuring that the 
results of this study can be more easily understood and interpreted correctly 
involves a clarification of some of the terminology used in and around health-
economic evaluation.  
As to the second role of this thesis, i.e., an application of health-economic 
evaluation to screening for prostate cancer in practice, here it will suffice to 
say that the original trial protocol for the FinRSPC included an assessment of 
cost-effectiveness as its secondary aim. The FinRSPC not only gave an 
opportunity to apply CEA using real-world data relating to a large cohort of 
men from a pragmatic population-based mass-screening trial, but, in 
conjunction with the relative flexibility of doctoral study in Finland, also gave 
wide scope as to the specific type of health-economic evaluation which could 
be undertaken. The articles presented as part of this thesis attempt to form a 
coherent whole, and one which is primarily aimed at promoting a deeper 
understanding of health-economic evaluation.  
This thesis is organised as follows: Section 2 provides a background to the 
study. Section 3 briefly states the specific aims and formulates the general 
research questions for which answers will be sought in this study. Section 4 
mainly reviews the methods applied, and techniques used, in principle. 
Section 5 turns to the practical application of those principles, as well as to 
briefly summarising the information this study adds to the literature. Some of 
the lessons learnt from this application health-economic evaluation, with 
accompanying suggestions and recommendations, are discussed in Section 6, 
with conclusions drawn in Section 7.  
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2 Background 
As the focus of this study is, first and foremost, ‘health-economic evaluation’, 
the Background section sets out to define a working definition of what that 
can mean (Sub-section 2.1), and investigates both its development (Sub-section 
2.2) and its conceptualisations (Sub-section 2.3). 
2.1 A working definition of health-economic evaluation 
The term health-economic evaluation has three intertwined parts: ‘evaluation’, 
‘economic’ and ‘health’. Although there seems to be no widely agreed definition 
of ‘evaluation’ (Stern, 2004), evaluation here refers to some form of assessment 
which assigns value, i.e., some process by which an estimate of, a calculation 
of, or statement of value is made or placed on an entity or intervention (Fox 
et al., 2016). Inherent in evaluative approaches are assumptions or statements 
about sources of value, often referred to as ‘value judgements’ (Neumann et 
al., 2016, p. 44). In the current study the normative, typically comparative, 
term ‘evaluation’ is qualified by the term ‘economic’. ‘Economic’, here, is taken 
to mean any of the three main types of economics-based evaluative approaches 
(see, e.g., (Booth, 2019a)). Next, the term ‘economic evaluation’ needs per se 
to be qualified by the prefix ‘health’. In this working definition, health refers 
to the topic or field to which the ‘discipline’ of ‘economic evaluation’ is applied 
(Culyer, 1981). Hence, health-economic evaluation (HEE) refers to applying 
some form of ‘economic evaluation’ to some topic related to ‘health’. However, 
this is only a working definition, and it will immediately be suggested that the 
term is, in fact, too broad to be very useful, unless it is specified more fully in 
practice. This is because different approaches to economics define value in such 
disparate ways. As an alternative, simply referring to ‘economic evaluation’, 
as per the title of this study, is intended to highlight a need to understand the 
vagaries of gauging ‘benefits’ and ‘costs’, i.e., of placing a ‘societal’ value on 
an entity or intervention (see, e.g., (Hammond, 1958) and (Wildavsky, 1993)). 
An attempt to defend these claims will form a central part of this study. 
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2.2 Understanding the history of (health-)economic 
evaluation 
Although we now have a working definition for health-economic evaluation, 
here the view is taken that it is only possible to properly understand health-
economic evaluation when we are informed about its history and development 
(in accordance with, e.g., (Keynes, 1924) or (Hodgson, 2001)). Of course a 
caveat is required here, a variety of histories can be written, each with its own 
legitimacy, and none will be wholly adequate (Backhouse, 2005). However, this 
thesis contends it is important to reflect not only on the most recent trends 
and developments in health-economic evaluation, but also to put those into 
perspective. Current health-economic evaluation may be understood better 
with an appreciation of the challenges ‘economic evaluation’ has already faced.  
Different types of evaluative research, and different ways of informing 
policy and planning, have likely been central components in the development 
of society throughout recorded history (Trefethen, 1954). Groups such as 
civil servants, academics, and private analysts have long provided 
information, evidence or advice to government planners, decision-makers or 
societies on a variety of policy-related, i.e., politico-economic, problems. 
Although the history of the use of ‘cost-benefit thinking’ dates back at least 
a millennium (see, e.g., (Quade, 1971b) or (Campbell & Pryce, 2003, p. 30)), 
one of the first printed records relating to ‘political economy’ is only just 
over 400 years old (de Mayerne Turquet, 1611). One way to interpret such 
early examples of political economy is the “specific advice given ... to 
governments or to the public at large either on broad policy issues or on 
particular proposals” (Mishan, 1982a, p. 13). It is in this sense, as the 
application of economic principles to practical research in order to provide 
information for decision-making (Bentham, 1843), which the ‘economics’ or 
‘political economy’ of policy analysis will be understood here (see, e.g., 
(Meade & Hitch, 1938, p. 221) or (Wildavsky, 1993, p. 122-123).  
From the perspective of economic-evaluation frameworks, two of the most 
important concepts within political economy received much impetus in their 
development during the European Enlightenment of the 18th Century, 
namely, the related evaluative notions of both ‘cost-benefit thinking’ (see, 
e.g., (Steuart, 1769, pp. 317–345), (Franklin, 1772), and (Bentham, 1843) and 
‘opportunity cost’ (see, e.g., (Franklin, 1748, pp. 375–377), (Cantillon, 1755) 
& (Smith, 1776: Book I, Chapter VI, p. 1)). Closely related to both of these 
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ideas is a third concept which came into wider use only after the start of the 
19th Century, namely, ‘efficiency’. It is important to note that here the term 
efficiency does not refer to the earlier philosophical or religious usage, in the 
sense of fitness or power to accomplish, or success in accomplishing, the 
purpose intended (Browne, 1658). Instead, the main meaning of efficiency in 
this current study can be found from its ‘technical’ usage, when employed by 
engineers and physicists to express or measure the performance or 
productive capacity of machines, i.e., a means of assessment of the ability of 
something to achieve specified goals (Alexander, 2008, p. 2; Franklin, 1748). 
The interrelated notions of ‘cost-benefit thinking’, efficiency and 
opportunity cost form an evaluative triad of particular importance to 
valuation in general, as well as to health-economic evaluation in particular. 
It is also useful to have a working definition for ‘opportunity cost’, here. 
Central to almost all definitions of opportunity cost is the idea that it 
represents “the opportunities foregone in accepting a certain line of action” 
(Green, 1894). However, it is important to note that alternative approaches 
to health-economic evaluation tend to place very different emphasis as to 
what constitutes opportunity cost, i.e., alternative valuation frameworks 
within economic evaluation vary in their approaches to the valuation of 
“opportunities forgone” (Article III, (Booth, 2019a)). 
Of course, it is necessary to operationalise the above evaluative triad in 
practice, too; otherwise these notions remain little more than empty concepts 
or abstract principles which in practice can offer anything from “an infallible 
means of reaching the new Utopia to a waste of resources in measuring the 
unmeasurable” (Prest & Turvey, 1965). One set of approaches to the 
operationalisation of the notions of cost-benefit thinking, efficiency and 
opportunity cost, is through the formalisation (of one notion) of ‘value’ via 
neoclassical economics and subsequent developments in welfare economics 
(Mazzucato, 2018; Mirowski, 1990). However, it should be noted that this set 
of approaches would come to be used mainly in those health-economic 
evaluations based on the aggregated ‘utility’ of affected individuals, i.e., in 
welfarist approaches to economic evaluation. An alternative, second route 
attempting to address the evaluative triad was developed, which has been 
referred to as both ‘non-welfarist’ and ‘extra-welfarist’, which involves the 
possibility of overruling the above individual judgements of ‘utility’ (Culyer, 
1989). In this way the ‘extra-welfarist’ approach fundamentally diverges 
from, neoclassical economics in general, and from Paretian welfare economics 
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in particular, by focussing on some notion of ‘societal utility’, instead of the 
welfarist notion of ‘individual utility’. It should be noted here that the 
majority of health-economic evaluations would come to follow the extra-
welfarist approach in the first 50 years of the regular application of economic 
evaluation to the field of health. Although early examples of cost-
effectiveness analysis can be found (Priestley, 1831; Rumford, 1876; 
Editorial, 1899), more formal mathematical approaches would have to wait 
until operations research became popular (see, e.g., (Dantzig, 1951, pp. 339—
347) and (Smith Jr et al., 1953)). Important elements in the rise of popularity 
of operations research and related methods include their application to 
military planning after the second world war (Specht, 1960); the large-scale 
incursion of mathematicians and physicists, in particular, into neoclassical 
economics (Mirowski, 1999); the promotion of a doctrine of ‘rationality’ 
(Colvin, 1987, p. 13); as well as that its results seemed to promise both 
stability in, and the ranking of, input-output relationships (Alexander, 2008, 
p. 64). It should be remembered that the utilisation of cost-benefit thinking 
occurs via a multitude of different forms of efficiency analysis (under a 
variety of names including operations research; systems analysis; cost-
benefit analysis; cost-effectiveness analysis; and cost-utility analysis (Fisher, 
1965)), radically expanded in the early 1960s (see, e.g., (Quade, 1971b)). 
However, approaches to cost-benefit and systems -thinking became 
somewhat less popular in some of its applications, as the 1960s progressed 
(Worthley, 1974). Its limited applicability to certain topics is one reason for 
its fall from popularity (Quade, 1971b), e.g., when straying away from its 
traditional roots in application to the technical realm (Godin, 2007). Moving 
into the social realm brought with it difficulties such as identifying an 
acceptable goal or goals, as well as difficulties in measuring to what extent 
the chosen goals were being achieved (see, e.g., (Hitch, 1967) or (Rickover, 
1967)). Subsequently, in addition to the differing formal approaches to 
operationalising cost-benefit thinking outlined above, a more nuanced 
understanding of the pitfalls and potentials of efficiency measures had been 
achieved (Quade, 1970; Schultze, 1968).  
Indeed, for some, the application of more informal cost-benefit thinking, 
with its accompanying judgement and deliberation, have retained an 
important role to this day (Daniels & van der Wilt, 2016). Such nuanced 
understanding and concern for case-by-case assessment of the qualities of 
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health-economic evaluation is referred to below, and in Article III, as 
deliberative analysis (Booth, 2019a). 
As set out below, in Sub-section 6.2.3, deliberative analysis will include 
comprehensive quality assessment of health-economic information, 
integrating other sources of information as and when necessary. Wherein both 
the information underlying any CEA, as well as the CEA itself, should be 
checked for its credibility and appropriateness; judgment; thought and 
expertise will likely be an advantage (Culyer, 2015; Dror, 1970). As a brief 
summary of this section, it is useful to note that different forms of CEA-
related analysis have long provided information to politico-economic, 
planning and policy processes, and has the ability to do so without 
jeopardising the role of analysts as analysts (Quade, 1971a, p. 295), rather 
than as advisers or mongers.  
2.3 Conceptualising health-economic evaluation 
Health-economic evaluation (HEE) can be classed as either an applied social 
science (Williams, 1989), or, alternatively, simply as an example of the 
application of social research or evaluation (Sculpher et al., 2005). For this 
reason alone conceptualising HEE is challenging: it covers a multitude of ideas. 
Regardless of which label is used, such research is generally conceptualised as 
an attempt to inform the type of problem which asks: “What should we do?”. 
In line with a Knightian view of economics (see, e.g., (Knight, 1951) or (Hicks, 
1986)), the claim will first be made here that many of the concepts of 
neoclassical economics are inherently restricted in their applicability to 
applied policy analysis, such as that undertaken in extra-welfarist HEE (Klein, 
1989). This is largely due to the imperfections of the market for health care, 
such as asymmetry, or lack, of information about health-care (Arrow, 1963). 
Such a restriction would suggest extra-welfarist HEE (EWHEE) would lack 
any clear legitimacy for a prescriptive role in decision-making processes and, 
moreover, suggest EWHEE is merely applied research (Sculpher et al., 2005).  
Welfarist forms of health-economic evaluation (WHEE) of course do 
include elements of neoclassical economics (Birch & Donaldson, 1987), but it 
is argued here that grounding health-economic evaluation firmly in 
conventional welfare economics would overlook the numerous objections to 
its practical use: whether in the form of orthodox cost-benefit analysis 
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(CBA), contingent valuation, or in the form of mathematical programming. 
Objections include the refuted separation of inquiries into economic welfare 
from inquiries into freedom, rights, equality and justice (Hausman et al., 
2017), the market-mimicking tendencies of these approaches (Sandel, 2013), 
in addition to the problems of measuring individuals’ utility and the 
informational requirements of a mathematical-programming approach 
(Drummond et al., 2015, pp. 116—118).  
Indeed, rather than being classed as a decision-making tool, it would seem 
more appropriate to suggest WHEE and EWHEE merely produce 
information. Further, it is suggested here that this information can inform, 
or misinform, decision-making processes. Suggesting this rather limited role 
as a source of information restriction seems appropriate given the inherent 
dependence of any research on the definition of the relevant ‘ends’, i.e., on 
the need for the definition of the objective(s) or goal(s) of policy (Knight, 
1956, p. 134). According to this viewpoint, health-economic evaluation has 
little reason to claim that it provides a solution to decision-making problems 
(Ashmore et al., 1989). The response from proponents of EWHEE is typically 
that the ‘solution’ they offer is only one of a number of possible solutions to 
priority-setting problems (Williams, 1991). Nevertheless, proponents, of 
EWHEE in particular, often use a lexicon which includes concepts framed in 
terms of ‘decision rules’, ‘solutions’ and ‘efficiency’ (see, e.g., (Karlsson & 
Johannesson, 1996) or (Weinstein, 2012)), even if many authors do not 
typically recommended strict adherence to such ‘rules’ (see, e.g., 
(Drummond, 1980), (Lord et al., 2004) or (Sculpher et al., 2005)). For 
example, the term ‘efficiency’: originally restricted to physics and 
engineering, may be much less appropriate when applied to matters of 
political economy (de Santos, 2009). Efficiency is not only a problematic 
label, in order to achieve successful conceptualisation or operationalization 
it demands careful measurement and determinable input-output 
relationships, a point which will be returned to in Sub-section 4.4. below. 
These terms not only have a specific meaning within HEE, but can also be 
misinterpreted by the laity who may not be aware of their specific and 
technical nature when they are similar to terms used in contexts unrelated 
to HEE (Meade & Hitch, 1938, p. 221). One key point which can be drawn 
here is that technical solutions related to ‘efficiency’ have been borrowed 
from the natural sciences and then, largely unchanged, have been reused, i.e., 
reused with their nomenclature largely intact (Knight, 1923). A second key 
 29 
point is that a ‘market-mimicking’ element of EWHEE (see, e.g., the library-
bookshelf metaphor in (Culyer, 2016a)), is a construct which drives the 
potentially misleading notion that ‘use’ of EWHEE for public policy choices 
would necessarily have considerable political significance (Culyer, 2016b). 
Such an apparent lack of humility seems even more strange given that HEE 
had already been practiced for many years (Drew, 1967) before quasi-
theoretical justifications for EWHEE appeared (see, e.g., (Culyer, 1989) and 
(Garber & Phelps, 1997) or (Meltzer, 1997)). There would also seem to be a 
trade-off to be faced: if effort is expended on making data and assumptions 
fit into the logical and ‘empirical’ constraints of some theoretical EWHEE 
framework, less effort will be available for ensuring that other informational 
needs are served.  
Practitioners of EWHEE, for example, can, of course, claim CEA is akin 
to the ‘utility maximization’ underlying WHEE. However, doing so they 
would need to accept some fairly heroic axioms relating to expected utility 
theory and ‘presumed’ Pareto efficiency. For many commentators, these 
axioms are violated too often to be an acceptable rationale for using CEA for 
‘utility maximization’ (McGuire, 2001, p. 10; Sculpher et al., 2005, p. 10). 
The view taken here follows Blaug, in that it assumes policy debates will 
typically turn into fuzzy comparisons between slightly incommensurate 
entities, and that any dependence on welfare economics, or for that matter 
WHEE, would be unwarranted (Blaug, 2007). 
As an alternative, two main strategies for undertaking CEA outside the 
constraints of orthodox welfare economics have flourished in the literature 
(see, e.g., (Drummond et al., 2015, pp. 267—339)). One is more reliant on the 
aforementioned extra-welfarist theorising and has strong foundations in 
decision science (see, e.g., (Weinstein & Zeckhauser, 1973) and (Claxton, 
1999)), and a second is not strictly bound to any economic theory per se, but 
is still faithful to the concept of efficiency and can still be highly pertinent 
when informing the decision-making process (see, e.g., (Quade, 1971a, p. 1) 
and (Sugden & Williams, 1978, p. 191)). The strategy which is largely based 
on decision science, with its reliance on the concept of expected value (Arrow 
& Lind, 1970), has been challenged in the literature (see, e.g., (McKean & 
Moore, 1972) and (Mishan, 1972)). Decision-analytic approaches have also 
been subjected to criticism with respect to a number of assumptions (Krahn 
et al., 1997). Firstly, the assumption that sufficiently clear and consistent 
input-output relationships exist seems unlikely to hold in applications to 
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health care (see, e.g., (Kothari & Birch, 1998), (Kristiansen & Mooney, 2004) 
and (Lessard & Birch, 2010)). Secondly, in respect of the assumption that 
efficiency is, per se, a desirable end. The desirability of the chosen efficiency 
indicator can be criticised if the relevance to the decision-maker of that 
indicator is diminished, either due to the content of the indicator or due to 
flaws in measurement or analysis of that indicator (see, e.g., (Mugford, 1989), 
(Kristiansen & Gyrd-Hansen, 2006), (Alexander, 2009, p. 1019) and (Adami 
et al., 2018)). Such measurement flaws can be used to critique the ‘theory’ 
underlying EWHEE, given its reliance on a price-per-effectiveness unit being 
determinable, determined and an appropriate measure for systematic 
comparison (Culyer, 1989). Another important reason to question the 
EWHEE approach to defining ‘value’ is that its definition of value seems 
unduly based on neoclassical market-clearing notions; in short, price 
connotes value, (i.e., value is assumed to relate to price, e.g., ‘price per 
QALY’, (Claxton et al., 2008)). Of course, as already noted above, ‘markets’ 
for health care typically do not function smoothly, amongst other things, due 
to severely impacted and asymmetric information; imperfect agency 
relationships; inherently monopolistic tendencies among suppliers; absence 
of prices for all entities; substantial scope for both moral hazard and adverse 
selection; and a host of issues related to a multitude of equity considerations; 
as well as due to related to possible externalities, spillovers or higher-order 
effects (Culyer, 2008, p. 60). However, even in the absence of a functioning 
market, many ardent extra-welfarist health economists typically choose to 
define value through such a ‘price’. This also means EWHEE requires the 
creation of something that resembles a ‘market-clearing price’ via the 
location of, or the fabrication of, an efficiency threshold (Caro, 2009). In 
other words ‘fixing’ a threshold price, a pseudo-price, in terms of some form 
of efficiency, for any technology being assessed. Applying a standard 
EWHEE approach is avoided in the current study, in part because such 
reductionist marketization of would de facto be antithetic to a strict 
interpretation of health-economic evaluation being able to inform decision 
makers about allocation (Lübbe, 2011, p. 108). Indeed, although statements 
about such a ‘market-clearing solution’ may have meaning within academic 
extra-welfarist health-economic evaluation, justification for adherence to 
them in any wider societal discourse is much less apparent. Insistence on 
economic-textbook notions of the use of the EWHEE (Culyer, 2016a), would 
seem to be highly arrogant, given the absence of some aspects of morality 
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from much of EWHEE (Smith, 1761). Further reasons for treating CEA 
based on the EWHEE approach with a great deal of scepticism will be set out 
in Sub-section 6.1. and will include practical problems associated with 
modelling, e.g., practical issues which arise due to problems with 
measurement, inadequate data, the assumptions often required to underpin 
EWHEE, or any combination of these. 
A second form of CEA does not necessarily resort to the above EWHEE 
framework, but instead can rest on the simple concept of a comparison of 
alternative courses of action in terms of their costs and their effectiveness in 
attaining a specified objective (Quade, 1971a, p. 294). When using this 
approach, comparisons are often based on the available resource use and 
outcome data, collected via, e.g., health services research, on all, or on a 
subset of, trial participants, often in the form of an analysis of patient-level 
data from randomised, controlled trials (RCTs) (O'Brien, 1996). Just as 
Drummond et al. eschew references to microeconomics in their latest 
textbook (Drummond et al., 2015), the single-study based approach to CEA 
used here is not necessarily reliant on any theoretical microeconomic 
framework (Ramsey et al., 2015). When free of microeconomic postulates, 
the appropriateness of the evaluation will largely depend on the qualities of 
the RCT in question (Lessard & Birch, 2010). In this second form of CEA, 
as knowledge from the discipline of economics no longer needs be combined 
with knowledge from some other discipline, the problem of ‘discipline mix’ 
may be largely avoided (Valtonen, 1993). One point to note here is that 
positivist clinical epidemiology and decision sciences seem to dominate much 
of applied HEE, with methods in HEE typically no longer being those of 
economics per se (Birch & Gafni, 2004, p. 55; Lessard & Birch, 2010; Sheldon, 
2005). In CEA in particular, although some of the items to be included in the 
evaluation can be given an economic foundation, CEA per se does not rely 
on economics, of course, economics is sometimes used to offer guidance when 
conducting a CEA, but economics does not tend to dictate the economic 
evaluation process per se (Neumann et al., 2018). To be clear, although quasi-
economic theory can be fitted to EWHEE approaches, it is only WHEE 
approaches which ensure adherence to orthodox economic principles, and 
then only to welfare-economic principles. More will be said about the 
limitations of positivist approaches to evaluation below.  
In addition, although it is now widely accepted that the assumption of 
‘utility’-maximising CEA is almost impossible to justify within the health 
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sector (Hurley, 1998), as noted above some heroic assumptions would also be 
needed to justify the assumption of ‘health’-maximising CEA. This is 
because, in practice, the measure of effectiveness, i.e., some measure of 
health impact, would need to be acceptable to society as a whole (Valtonen, 
1993, p. 195). In Knightian terms, unless society can agree on the ‘end’, i.e., 
unless society can agree on a single desired measure of effectiveness, CEA 
will not maximise ‘utility’ or ‘health’ (Hammond, 1991). Instead, any single 
CEA will only inform us what can, given the assumptions, data and analysis 
used, be classed as ‘efficient’, in terms of the particular measure(s) of 
effectiveness used. This interpretation of CEA as a form of efficiency 
analysis brings with it its own potentials and problems, and how these 
interact with the concept of opportunity cost will be returned to below. 
The two main points from this second section are, firstly, that the 
concepts of cost-benefit thinking and efficiency existed long before they 
became cloaked in any form of formalised economics or comparative analysis. 
It is primarily for this reason that the current thesis does not employ or 
describe formal theory related to CBA, CEA or health-economic evaluation, 
but instead, promotes a pragmatic appreciation of both CEA and cost-benefit 
thinking. Secondly, HEE is too ambiguous a concept to be categorised with 
any brevity, if at all, it will therefore be necessary to further investigate the 
idea in Section 4.  
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3 Study questions and objectives 
The principle aim of this study is the presentation of understandable 
information relating to ‘economic’ evaluation and prostate-specific antigen 
screening for prostate cancer from the FinRSPC. In line with these aims, this 
study sets out to achieve two central objectives: 1) increasing understanding 
about what economic evaluation can mean, as well as 2) increasing 
understanding about the results from the application of CEA to the FinRSPC 
after 20 years of the trial. These two objectives are achieved via the three 
research questions described below, one focussing mainly on principles relating 
to economic evaluation, a second relating mainly to the practice of economic 
evaluation, as well as a third, turning to how the information from this study, 
and similar studies, might be best interpreted.  
1) How should (health-)economic evaluation be understood, and what are 
some of the ways it can be misunderstood? 
2) What can be known about the costs, effects and cost-effectiveness of 
prostate-cancer screening after 20 years of the FinRSPC? 
3) What are some of the problems, pitfalls and potentials of the application 
of economic evaluation to a topic such as screening for prostate cancer? 
Research question 1) is addressed by Article III and by Section 4. Research 
question 2) is addressed by Articles I; II & IV, as well as by Section 5. Research 
question 3) is addressed to some extent in all articles, but is also discussed in 
Section 6. Together, the three research questions above also have the objective 
of providing a response to a broader practical question: “Can economic 
evaluation help us to know if prostate-cancer screening is ‘worthwhile’?”. 
However, although some discussion of this broader (policy) question will run 
throughout Section 6 of this study, it should be noted at the outset that the 
answers to such questions should be treated as preliminary, as they transcend 
‘scientific’ or research evidence. It has long been acknowledged that applied 
social research cannot typically provide answers to questions of value, instead 
the role for a study such as this is to provide evidence which stakeholders can 
then deliberate upon (Weinberg, 1972). 
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4 Applying ‘economic evaluation’ to the 
FinRSPC: Some principles 
After describing the broad principles of health-economic evaluation above, but 
before setting out the way in which health-economic evaluation is applied here, 
it will be useful to describe cost-effectiveness analysis (CEA) in a little more 
detail. Although early examples of crude CEA in health care can be found (see, 
e.g., (Editorial, 1899)), this brief review attempts to explain what CEA 
typically means today, by reference to both its wider use in decision-making 
and planning during the last century (see, e.g., (Hitch, 1953)), as well as to its 
more recent history. This section touches upon some of the content of 
Article III, but the main focus here is on the problems and potentials of 
applying ‘economic evaluation’ to the FinRSPC. The interested reader can, 
e.g., in Article III, find more detailed explanation and critique of the different 
‘economic’ standpoints from which economic evaluation can be undertaken. 
4.1 Cost-effectiveness analysis (CEA) in principle 
Cost-effectiveness analysis evaluates a ratio of some indicator of average 
effectiveness for two (or more) interventions relative to some indicator of the 
(mean) costs associated with those interventions. In simple terms CEA 
calculates or, rather, typically estimates, the incremental cost-effectiveness 
ratio (ICER) using the following generic formula: 
 
ܫܥܧܴ ൌ ∆େ∆୉ ൌ
େ೔೙೟೐ೝೡ೐೙೟೔೚೙ିେ೎೚೙೟ೝ೚೗
୉೔೙೟೐ೝೡ೐೙೟೔೚೙ି୉೎೚೙೟ೝ೚೗	, 
 
The numerator in the above formula is an estimate of the difference in some 
of the costs between the two alternatives and is divided by the denominator, 
i.e., an estimate of the difference in one, or some, of the health-related 
outcomes. In the rightmost part of the equation above, two alternatives are 
denoted by their subscripts, first, an intervention (e.g., in the current study it 
where C is some measure of average cost and 
E is some measure of average effectiveness. 
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will refer to the screening arm of the FinRSPC) and, second, a control or 
reference group (which refers to the control arm of the FinRSPC in the current 
study). In principle, the CEA ratio can be used to help maximize the estimated 
units of effectiveness produced from a given level of resources or, 
alternatively, minimise resource use for a given estimated number of units of 
effectiveness (Gafni & Birch, 2006). 
4.2 A wider review of health-economic evaluation 
In many industrialised countries healthcare has, since the end of World War II, 
and especially since the end of the cold war, received increasing amounts of 
support and investment from government. Just as the ‘military-industrial 
complex’ before it, this ‘medical-industrial complex’ has generally included 
arrangements for the evaluation of proposed investments (see, e.g., (Steiner, 
1965), (Butterfield, 1968), (Pole, 1972) and (Relman, 1980)). However, the 
extent to which industry is involved in current governance processes in health 
care in any jurisdiction, and the extent to which there is regulatory capture, 
remains difficult to ascertain with any certainty (Banta, 2018; Berry, 2017, 
pp. 199—214). What is more certain is that the 1960s brought with it an 
increased interest in what analysis and evidence could offer, or could be offered 
to, planning authorities (Specht, 1960). The level and type of research to be 
undertaken was closely intertwined with what the state deems necessary for 
underwriting the technology of modern industrial enterprise (Galbraith, 1979). 
Such state involvement was exemplified in the US with the establishment there 
of both the Planning, Programming, and Budgeting (PPB) -system and 
‘technology assessment’ itself (see, e.g., (Schick, 1966) and (Daddario, 1967)). 
A number of other countries gradually followed this US lead, for example, the 
principles relating to the application of CEA to health care were set out in the 
UK by the early 1970s (see, e.g., (Walsh & Williams, 1969), (Culyer et al., 1971) 
and (Cochrane, 1972 (2004))). However, it would be over two decades before a 
health technology assessment (HTA) programme was set up as part of the first 
explicit research and development strategy of the (then UK) National Health 
Service (NHS) (Department of Health, 1993). On the basis of the review of the 
literature undertaken for the current study, it is claimed here that, combined 
with other influences (e.g., (Torrance, 1970: p. 44)), much of the practical 
application of health-economic evaluation was largely pushed forward, by the 
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more general advancement of CEA, the PPB, and the Office of Technology 
Assessment in the US (see, e.g., (Office of Technology Assessment, 1976) and 
(Office of Technology Assessment, 1980)), with some of those early influences 
mirrored by more specific development of CEA in the health sector in the UK 
(see, e.g., (Williams, 1967), (Drummond, 1978) and (Sugden & Williams, 1978)).  
4.3 How is CEA related to cost-benefit thinking? 
At present, the most prominent approach to health-economic evaluation and 
CEA, which was largely developed in York, by Williams, Culyer and 
Drummond, among others, is extra-welfarist. This approach is centred around 
the measurement of ‘health-related quality of life’ (HRQoL), often with 
durations in HRQoL states as the chosen indicator of medical output, i.e., as 
the denominator in the ICER (see, e.g., (Culyer et al., 1971), (Pole, 1974) and 
(Culyer, 1989)). As already noted above, such ‘non-welfarist’ approaches 
diverged from neoclassical welfare-economic traditions, which were deemed to 
have outlived their usefulness (Williams, 1976). Therefore, CEA was 
recommended as a more practical form of cost-benefit thinking (Drummond, 
1981) or, to put it in the blunt words of Mishan: “CEA is a truncated form of 
CBA” (Mishan, 1988, p. 110). The important point here is that, by moving 
away from an ‘all-encompassing’ welfarist approach of cost-benefit analysis or 
analysis through mathematical programming, EWHEE would develop into a 
rather disordered set of approaches only loosely related either to economics, 
or to each other (Gerard, 1992). Despite efforts to standardise EWHEE 
through guidelines and the issuing of articles on best-practice (see, e.g., (The 
Professional Society for Health Economics and Outcomes Research (ISPOR))), 
it remains a rather diverse set of approaches in practice because it could accept 
any maximand: the maximand may be whatever the analyst or policy-maker 
deems appropriate (Culyer, 2014, p. 203). It should be carefully noted that in 
the absence of a decision-maker with a known objective or maximand, the 
analyst may suggest and use their favoured maximand. More worryingly 
perhaps, even in the presence of a maximand or maximands chosen by a 
decision-maker, analysts may for the sake of convention or convenience still 
supplant their own indicator to approximate that maximand. The flexibility in 
scope of any specific instance of economic evaluation brings with it judgement 
and decision (Culyer, 2008), i.e., it requires value judgements rather than 
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necessarily being an objective choice in advance (Hitch, 1971; McIntosh et al., 
1999). Although one maximand is customary in HEE, the most appropriate 
maximand(s) will depend on specific contexts of culture, history and political 
aspiration (Culyer, 2008; Mishan, 1982b). However, if HEE attempts to serve 
the information needs of planning problems, a single maximand will rarely 
suffice. Indeed, truncation in scope means that EWHEE serves only some of 
the information needs of cost-benefit thinking. To fully meet the needs of 
broad evaluation the chosen maximand in CEA would be required to be ‘all 
encompassing’, i.e., the chosen indicator or measure would need to encompass 
the value which should be attached to programme impacts (Klarman, 1982, p. 
594). CEA in general, and EWHEE in particular, rarely succeed in producing 
a broad evaluation, and to presume otherwise can be seen as a mere illusion 
(Wolff, 2004). 
Given the above divergence between the information provided by CEA 
and the information which would ideally be available for social planning 
problems, two main approaches have been followed (Orr & Wolff, 2015). The 
first approach could be described as humble in its ambitions, with the second 
seeming somewhat more arrogant. The first is that information from CEA is 
presented without extensive interpretation through a theoretical framework, 
ICER-related information stands on its own merits, leaving the users of that 
information to interpret it in a manner in line with their values. The second 
approach, the approach typically taken under EWHEE, is to use some 
threshold to create or mimic a market (Galbraith, 1973; McCabe et al., 2008). 
Such thresholds, i.e., efficiency standards, are compared to ICER estimates, 
and can immediately take on a (non-Paretian) allocative aura (Gyrd-Hansen, 
2014). The result of an EWHEE, an estimate of economic efficiency in the 
form of a cost-effectiveness ratio, is typically only a partial indicator of the 
term efficiency as it used in every-day language. Thus the ICER is a partial 
indicator, an indicator of economic- or pseudo- efficiency (Green & Barker, 
1988). Despite this some have claimed that EWHEE approaches approximate 
an interventions value (Garrison et al., 2018), phrases akin to ‘the ICER 
shows whether or not the intervention represents value for money’ are used 
in place of stricter language ‘the ICER estimate is an indicator of the 
efficiency of the intervention, albeit incomplete’ (see, e.g., (Maynard & Bloor, 
1997), (Moore et al., 2010) or (National Institute for Health and Care 
Excellence, 2019)). In engineering, almost all relevant aspects of efficiency 
can be quantified in an accurate, if not precise manner. In contrast, especially 
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in the politico-economic realm, many dimensions of importance will lie 
outside CEA-based indicators of efficiency (Alexander, 2009, p. 1011). In the 
field of orthodox cost-benefit analysis it may be appropriate to talk about 
‘value for money’, e.g., ‘optimising net social costs and benefits’ (Lowe, 
2008), but does not seem so appropriate in the field of health-economic 
evaluation (Birch & Gafni, 2006), or in the field of medicine (Gusmano & 
Callahan, 2011). 
Despite the concerns outlined above, CEAs serving extra-welfarist goals, 
using QALY-based approaches, have gained a dominant position as the most 
popular form of health-economic evaluation in practice (McIntosh et al., 
2010, p. 2). Nevertheless, it is important to note that all approaches to CEA 
can also serve more ‘classical’ cost-benefit thinking, a point which will be 
returned to below (see also Article III for further details).  
4.4 The (almost) central role of efficiency? 
Although economic efficiency, in its neoclassical economic form, has been seen 
as having a primary role in health-economic evaluation, it will not always have 
primacy when planning resource allocation (see, e.g., (Maynard, 1999), 
(Musgrove, 1999) and (Robinson, 1999)). Of course, as a ‘measure’ of 
efficiency, CEA can be an indicator of value, but CEA is typically merely only 
an indicator of an already truncated or restricted notion of value, rather than 
necessarily providing a broad evaluation (see, e.g., (Quade, 1971a), (Konu et 
al., 2009), (Häkkinen, 2011) or (Hämäläinen et al., 2019)). The ability of CEA 
to produce relevant information will depend both on what goals are being 
assessed and on the responsiveness of each effectiveness metric used (Porta, 
2014; Waddington, 1986).  
The type of efficiency which is estimated by EWHEE or WHEE receives 
much of its meaning in relation to the achievement of goals (often simplified, 
measurable or pre-specified). Nuanced ‘higher-level efficiency’, i.e., societal 
value, must embody some procedure to include the respective goals of all 
stakeholders, to some extent (Wiseman, 1989b). To aim uncritically for 
efficiency has been seen by many as a mistake: most people would need look 
no further than highly-efficient National Socialist German Workers’ Party’s 
extermination camps to realise that (Culyer, 2015). It follows that any 
intrinsic goodness in any ‘efficiency’ metric depends on elements of the value 
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we attach to the goal(s) we are being efficient at (Churchman et al., 1954). 
Efficiency metrics cover, to a greater or lesser extent, relevant elements of 
value (Culyer, 2015). To the extent that some element of value which is 
considered to be important is not included in the effectiveness or efficiency 
metric, it fails as a valuation mechanism (see, e.g., (Ruskin, 1872, pp. ix-xiv) 
and (Knight, 1923)). In every case, if the operationalised ‘measure’, metric 
or indicator does not adequately measure what we hope it to measure, it will 
also fail as a comprehensive valuation mechanism (Joint Economic 
Committee, 1967). Although, on the one hand, cost-per-QALY efficiency 
metrics offer one popular approach to economic evaluation, on the other hand 
the policy context is also seen as central in determining what is the 
appropriate methodology to use (Tsuchiya & Williams, 2001, p. 43). One 
problem in choosing the most appropriate efficiency ‘metric’ on the basis of 
policy context is that ‘decision-makers’ who are purported to have a clear 
goal, or set of goals, are likely to be conspicuous by their absence (Coast, 
2004). A second major stumbling block in obtaining a suitable efficiency 
metric is the lack of universally agreed ‘measure’ of the diverse and often 
intangible effectiveness objectives of health care (Brazier et al., 2019; 
Mooney & Lange, 1993; Valtonen, 1993, p. 195; Wildavsky, 1969). A third 
issue in a triad of problems relating to efficiency indicators, which is of 
paramount importance, is the extent to which intangibles might impinge on 
the solutions to policy questions (Quade, 1967). These points will be 
elaborated upon in Section 6. 
4.5 Producing information on ‘efficiency’ in practice 
As noted in the previous sub-section, context, which often defines the goal 
towards which the efficiency indicator is aiming, is one important 
consideration when producing information on efficiency. However, it is 
important to keep in mind that there are numerous other important 
considerations, such as the credibility of the data or research underlying, i.e., 
the strength of the evidence on costs and effectiveness. When choosing the 
most appropriate way to operationalise the estimation of the cost per unit of 
effectiveness using CEA, there is necessarily a move from principles to 
practice, and also often from concepts and ideals towards constraints and 
pragmatism. The first main reason for such constraints and pragmatism is a 
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rather inconvenient truth for HEE; two major practical problems exist when 
undertaking health-economic evaluation: measuring the costs and the 
measuring the benefits (McPake et al., 2013, p. 80). Even if a goal is both 
known and universally supported, the best available methods of measurement 
and analysis may still thwart the assessment of that goal (Evans, 1984, p. 243). 
For example, practical limitations in the measurement of ‘benefits’ include 
difficulties surrounding the measurement of effectiveness, such as difficulties 
in observing effectiveness over time due to loss to follow-up, as well as a host 
of other difficulties in obtaining robust estimates of the relative effectiveness 
of different health technologies. A second reason for such constraints and 
pragmatism is that key health-economic evaluation texts and guidelines do not 
generally prescribe exactly what should be measured, i.e., what the numerator 
and denominator in ICERs should contain (see, e.g., (Neumann et al., 2016), 
(Drummond et al., 2015), (European Network for Health Technology 
Assessment (EUnetHTA), 2015), (National Institute for Health and Care 
Excellence, 2013), and (Ministry of Social Affairs and Health (Finland), 2003)). 
Despite valiant efforts it seems impossible to propose uniform context-
independent guidelines or suggestions as to what might constitute the most 
appropriate measures of costs and effectiveness to use when applying CEA in 
health and social care (see, e.g., (Culyer, 2018), (Weatherly et al., 2017) and 
(Heintz et al., 2016)). Despite over 50 years of practicing health-economic 
evaluation, just as Steiner predicted (Steiner, 1965), there still seems not to be 
a single definitive methodology available. Therefore, the study presented here 
has approached the application of health-economic evaluation to the FinRSPC 
by adhering closely to the following advice: 
“So the first (and perhaps the most important) job of the analyst is to ensure 
that all feasible alternative methods of performing a task are under 
consideration from the outset, and that vision is not restricted by conscious or 
unconscious preconceptions about what is the best (or the only practical) way 
of doing things.” (Williams, 1967) 
It should be noted here that the use of such judgment and intuition in CEA 
can, in principle, be seen as quite normal for health-economic evaluation (see, 
e.g., (Quade, 1967), (Drew, 1967) and (Klarman, 1967)). Indeed, rather than 
being value-free or context-free evidence, or being a value-neutral or context-
neutral process, economic evaluation is value-laden, i.e., normative, research 
(see, e.g., (Culyer, 2015) and Article III). The reason for this seems clear, each 
methodological guideline merely represents a collection of value judgments, 
even if these judgments are consensus statements by august, renowned or 
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erudite collections of experts (Mulkay et al., 1987). The review of the literature 
undertaken for this thesis would seem to strongly indicate that no practical 
economic evaluation can be definitive, each will be based on its own underlying 
perspective(s), each economic evaluation will be contingent on, e.g., the 
methodological value judgements, data, and assumptions used. Therefore, 
approaches to economic evaluation can indicate some of the implications of 
choices, but typically cannot provide a comprehensive evaluation (Dror, 1970). 
This being the case should not detract from the present study per se, but it 
does provide a strong rationale for taking these matters into account when 
interpreting the results of health-economic evaluation. 
The current study will not follow the current dominant approaches of 
EWHEE or decision modelling, and reasons for this will be set out in the next 
section.  
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5 Applying ‘economic evaluation’ to the 
FinRSPC in practice 
The general topic to which a form of HEE will be applied here is ‘systematic 
mass prostate cancer screening based on prostate-specific antigen (PSA) 
testing’, for brevity this will, hereafter, be referred to as either ‘PSA 
screening’, ‘PSA-based mass screening’, ‘prostate-cancer screening’ or 
‘screening for prostate cancer’. More specifically, CEA will be applied to a 
randomised controlled trial (RCT) of screening for prostate cancer, the 
Finnish Randomised Study of Screening for Prostate Cancer. This trial, and 
its continuous register-based follow-up, has been underway in Finland since 
1996, hereafter this will be referred to as the ‘FinRSPC’. In order to facilitate 
economic evaluation of the FinRSPC, postal questionnaires which included a 
range of questions both about health status and economic impact of screening 
were administered to men diagnosed with PCa in 1998, 1999, 2003 and 2011. 
Similar questionnaires were also sent to a trial subsample, consisting of 2,200 
men: a random sample of 1,100 men from the screening arm and 1100 men 
from the control arm (see Article II (Booth et al., 2014a) for further details). 
5.1 Collection and utilisation of materials 
The start of the FinRSPC coincided with a period when the Finnish economy 
was boosted by a successful investment by Finnish government in mobile-
phone technologies, namely in Nokia Ltd. and related businesses. This meant 
that time, resources and materials were, in principle, readily available for 
research. Prior to the turn of the millennium, obtaining data from registries 
was relatively easy for those working in the predecessor to THL, and data-
protection processes controlling the use of questionnaire responses was 
demanding, but manageable, for researchers. Around the turn of the 
millennium there were changes in Finnish data-protection legislation and in 
the personnel conducting the health-economic research for the FinRSPC. After 
the first year or so of my involvement with the FinRSPC, a third round of 
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postal questionnaires was administered in 2004. A lack of Finnish language 
skills on my own part, as well as the aforementioned changes in rules governing 
the collation and use of registry and questionnaire data, contributed to an 
elongated application process for updating research permissions. In fact, the 
granting of permissions had to wait until a minor legislative reform in registry 
data handling had been implemented by the THL in 2010. During this period 
of waiting for permissions to link the questionnaire data and register data 
(2005-2010), preliminary analysis was undertaken on comparison of the 
information available from questionnaires and from those registers for which 
permission had already been granted. This analysis of data from the health-
economic study alone showed fairly extensive opportunistic PSA-testing, often 
referred to as ‘contamination’, in the control arm. A large part of the review 
of the methodological literature for this study was also conducted in that 
period. After it was confirmed that all previous data could be used, a fourth 
round of postal questionnaires was undertaken in 2011. This fourth survey was 
undertaken whilst waiting for the administrative data itself on outpatient 
visits to be released from the participating hospitals (which finally arrived in 
2012). The first article for the current study, mainly utilising the 
questionnaire data, was accepted for publication in 2012 and published in 2014. 
Between 2012 and 2015 a deeper understanding of the HTA literature was 
obtained during my work at THL, and various research permissions and 
register data were updated again between 2015 and 2017. In 2017 analysis of 
the registry data began in earnest and resulted in the publication of Article II 
in 2018, and the production of Article IV in 2018. The background research for 
Article III was developed between 2008 and its publication in 2019. 
5.2 Literature review of economic evaluation of PSA 
screening 
A literature search was conducted in April 2019 to find published studies 
related to the economic evaluation of PSA-based mass screening from the 
following databases: US National Library of Medicine PubMed database; 
databases created by the Centre for Reviews and Dissemination; Cochrane 
Database of Systematic Reviews; SCOPUS; Journals@Ovid Full Text; 
CINAHL and PsycInfo (via EBSCOhost); Web of Science and Tufts Medical 
Centre’s CEA Registry (see (Booth, 2016) for further details of the search 
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strategy). The search was deliberately sensitive in scope, in an attempt to 
include all potentially relevant economic evaluation -related studies from 
these databases. On the other hand, e.g., after the search, exclusion criteria 
included systematic reviews of economic evaluations (Anderson, 2010). In 
addition, e.g., a number of earlier studies were excluded on the basis that the 
evidence from the two main randomised controlled trials on PSA screening 
was not yet available, both of which first reported their results in 2009 
(Schroder et al., 2009) and (Andriole et al., 2009). Given the above, six 
relevant peer-reviewed articles describing economic evaluations were thus 
selected, from the 57 potentially relevant records identified through 
reviewing the searches from the above databases.  
The following health-economic evaluations were selected from the search 
results (Shteynshlyuger & Andriole, 2011); (Pataky et al., 2014); (Shin et al., 
2014); (Heijnsdijk et al., 2015); (Roth et al., 2016) and (Keller et al., 2017). 
These were all modelling studies, none of the studies located were similar to 
the current study, although some were based on data which, in part, came from 
earlier stages of the FinRSPC (Schroder et al., 2009). 
It might already be clear from sub-section 4.5 that major differences can be 
expected between model-based health-economic evaluations or simulations 
using aggregate-level data and health-economic evaluations based on 
individual-level data from a single trial (Melnikow et al., 2013). For this reason, 
in an attempt to obtain further detail about the models and their results (in 
order to better assess them for credibility and comparability), e-mails were 
sent to the corresponding authors of the peer-reviewed publications identified. 
The corresponding authors of two of the articles identified by the systematic 
search responded and were willing to provide extra details (Pataky on behalf 
of (Pataky et al., 2014) and Heijnsdijk on behalf of (Heijnsdijk et al., 2015)), 
the other authors did not respond (with any useful information) to attempts to 
contact them. Although some of the modelling and the some of the data upon 
which the work by Pataky et al. and Heijnsdijk et al. were based, are open to 
scrutiny, in practice, as noted elsewhere, there seems to be a dearth of 
opportunities to fully assess models in many respects (Kaltenthaler et al., 
2013). In part this may be the result of pressures to maintain a monopoly on 
the use of datasets within a research group or pressures to publish relatively 
short manuscripts in highly-regarded, peer-reviewed medical journals (Angell, 
1986; Silverberg & Ray, 2018). However, it should also be noted that the 
development of tools or checklists for assessing the quality and congruence 
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health-economic-evaluation models is problematic, given the variation of 
approaches already noted in earlier sections (see, e.g., (Glick et al., 1994) or 
(Tappenden, 2014)). Due to the above, this thesis refrains from describing the 
results of the six studies located by this systematic search, given that they 
each fail, in one or more respects, to provide comparable information (Welte et 
al., 2004). Even with only the rather limited information about these six PSA-
based mass screening studies, it is clear that the methods used in the located 
papers are testament to the pervasive heterogeneity in economic evaluations, 
especially when compared to the CEA presented as part of the current study. 
Therefore, any suggestion to compare the results would require extensive 
further investigation of the methods used in those studies, an investigation 
which, to a large extent, would likely be futile given their acontextual nature 
(Anderson, 2010). For example, all previous economic evaluations took clinical 
epidemiology as their cornerstone, in combination with assumptions, and it is 
that information which, to a large extent, drives their models. However, social 
epidemiology is likely to be of importance, too. When reviewing the empirical 
results from the current study it would be wise to note that “health is not just 
the product of health care, at the very least it involves environmental, 
economic and social factors.” (Small & Mannion, 2005). For instance, screening 
for prostate cancer may appear to have had positive impact, in terms of 
prostate-cancer mortality, on average, but this does not mean that similar 
impacts of screening would be observed in all settings, or in all subgroups (see, 
e.g., (Cartwright & Hardie, 2012, p. 127)). Of course, ideally, analysis of the 
potential impact of socioeconomic status on outcomes would also be 
undertaken (see, e.g., (Ratcliffe & Gonzalez-Del-Valle, 1988), (Birch, 1997) and 
(Birch, 2002)). However, only in the last months of finalising analysis for the 
current study was more extensive socio-economic status data available from 
the statutory authority (Statistics Finland). Previously, socio-economic status 
data were only available for diagnosed men, thus preventing potentially crucial 
analysis of the potential impacts of socio-economic status.  
Failure to take considerations such as those noted above into account may 
lead to overly parsimonious models, which fail to focus on those types of 
uncertainty which are more commonly acknowledged to be harder to assess 
(Briggs et al., 2012). Treating the underlying clinical epidemiology as a given 
also tends to exclude the possibility that they could provide novel 
contributions to underlying epidemiological debates (Glick et al., 1994), or be 
able to take into account important environmental or socio-economic factors 
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(Kothari & Birch, 1998). Of course, there is a recognised tension between 
extending the features or structure of models and obtaining the data or 
estimates needed to populate a model in a more meaningful manner (Roberts 
et al., 2012), as can be seen from the following quote:  
“Calculating quantitative solutions using the wrong criteria is equivalent to 
answering the wrong questions. Unless operations research develops 
methods of evaluating criteria and choosing good ones, its quantitative 
methods may prove worse than useless to its clients in its new applications 
in government and industry.” (Hitch, 1953) 
According to Glick et al. (1994), it is often stated, apparently often without 
justification, that information based on synthesis and modelling offers 
improvement over information from any single RCT. The claim is made here 
that, rather than relying on dogmatic reasoning about the usefulness of 
modelling, a more nuanced approach should be taken. This would include 
broader acknowledgment that one goal of analysis is to find optimum 
solutions, whilst assuming that appropriate predictions can be made (Lessard 
& Birch, 2010). When confronted with data or assumptions that contradict the 
generalisability or transferability of modelling, e.g., as set out in the current 
study, there would seem to be a moral duty for proponents of modelling to 
provide empirical support for such assumptions. The view taken here is that 
the results of the CEA of the FinRSPC cannot easily be compared to results 
from previous modelling studies, because although they represent the same 
general construct, they do so in fundamentally different ways. Given the 
difficulties, in general, in the evaluation of the effectiveness of prostate-cancer 
screening, a more thorough investigation and assessment of the usefulness of 
modelling should be undertaken. However, that was not possible within the 
scope of this thesis. Of course, methodological choices are of importance, such 
choices may be made on the basis of, amongst other things, the data available, 
ideological proclivities or pragmatism (see, e.g., (Naylor, 1996), (Krahn, 1996) 
and (Russell & Sinha, 2016)). The further claim is made here that the context 
specific nature of the FinRSPC results should not be forgotten, there are 
numerous reasons why it might not necessarily be prudent to generalise from 
the findings of either the ERSPC or the FinRSPC (Pawson, 2006, p. 180). 
Indeed, it is noted here that the findings in Article IV about the impact of 
screening for prostate cancer in terms of prostate-cancer mortality are of 
similar direction, but of smaller magnitude, than those found elsewhere in the 
ERSPC (Hugosson et al., 2019). Despite the fact that Article IV does not 
incorporate an estimate the HRQoL impact of screening for prostate cancer, 
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research seems to indicate that there is a strong interrelation between any 
prostate-cancer-mortality benefits associated with screening for prostate 
cancer on the one hand, and the unnecessary diagnosis and harms of treatment 
on the other (Auvinen et al., 2016). A rather cursory reading of the modelling 
studies suggests they do not undertake extensive sensitivity analysis, even 
given wide-ranging evidence on the possible extent of length bias, lead-time 
bias or overdiagnosis. For example, in one of the six studies identified by the 
review (Heijnsdijk et al., 2015), it appears that extensive testing of the 
sensitivity of results to less conservative assumptions about the potential 
impact of screening on overdiagnosis was not undertaken. Further, although 
the modelling studies located by the systematic search typically do attempt to 
validate the results of modelling exercises against observed prostate-cancer 
mortality, they do not appear to attempt to validate their results with respect 
to either observed HRQoL outcomes or costs.  
Another potentially important factor which modelling studies could 
investigate further is any PSA testing which takes place outside systematic 
screening programme, i.e., opportunistic PSA testing. Limited sensitivity 
analysis on this factor seems odd, even given a relative dearth of evidence on 
opportunistic testing from epidemiological studies between publications by 
Ciatto et al. (Ciatto et al., 2003) and Kilpeläinen et al. (Kilpeläinen et al., 2017). 
After reviewing the retrieved literature it seems that many model-based 
analyses utilise a comparator of ‘no screening’ rather than the de facto 
situation in many jurisdictions of unorganised or non-systematic screening, 
often referred to as opportunistic PSA testing. Despite controversy over the 
impact of opportunistic PSA testing on the effectiveness estimates coming 
from studies of prostate cancer screening (see, e.g., (Arnsrud Godtman et al., 
2015)), opportunistic PSA testing in the control arm seems likely to dilute the 
relative effects reported by PSA-screening trials (Roobol, 2015). One other 
pitfall in the use of modelling is that the focus of intellectual effort is on the 
model, rather than on the policy question (Quade, 1967). For example, there is 
a tendency to focus on describing the effect of stochastic uncertainty via 
sensitivity analysis within most models, rather than on structural uncertainty, 
which is less amenable to description (Afzali & Karnon, 2015). Modellers may 
also choose to accept, perhaps somewhat unthinkingly, the information 
stemming from ‘disciplines’ such as clinical epidemiology. This brings with it 
the potential of drawing attention away from any potentially important effects 
of screening which are not addressed by clinico-epidemiological research.  
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In summary, taken together with findings from the current study, the 
observations above cast some doubt on the credibility of the six studies located 
by the systematic search. Further, the ability to sensibly compare the 
approaches of the identified studies, to the approach taken by the current 
study, is also limited. For these two reasons, no further extensive comparison 
between the results of these dissimilar analytical strategies will be entertained 
here. 
5.3 Pragmatic considerations in the CEA of the 
FinRSPC 
While waiting (between 2005 and 2010) for the relevant research permissions 
to be granted, and while waiting for delivery of the bulk of the cost-related 
register data in 2011 (from THL and Kela), time was available to ponder the 
many different potential approaches to health-economic evaluation which 
could be used with the data available from the FinRSPC. Of course modelling, 
either with the HRQoL data from the FinRSPC questionnaires or with HRQoL 
evidence from the literature would be possible, but given the nature of the 
topic this would involve the use of strong assumptions and would not 
necessarily make best use of the available register data (Sheldon, 1996). 
On balance, given that a substantial period of real-world follow up had been 
amassed, the decision was made to undertake a wholly register-based CEA in 
order to highlight the ‘real-world’ evidence on the costs, effects and cost-
effectiveness of the FinRSPC. This application of CEA to the FinRSPC will be 
described in the section after next. Before that, however, it will be useful to 
briefly present the findings from the review of the methodological literature 
with respect to the conduct of health-economic evaluation. 
5.4 CEA as part of iterative application of economic 
evaluation 
As seen in the previous sub-section, research relies on choices made by the 
analyst(s) about data to be used, the approach to economic evaluation and 
associated assumptions. A policy question must first be translated into a 
research question. Of course a direct link can be drawn between the chosen 
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research question (often referred to as a ‘decision-problem’, when used in a 
decision-analytic sense) and the policy question (the latter often framed as 
being holistic in nature, i.e., akin to holistic evaluation). However, it is widely 
recognised that a link between the two should only be made at the discretion 
of a decision maker, if at all. One aside to note here is that when economists 
conflate a research question and a policy question, they run a grave risk of 
“repudiating their claim to any independent norms of economic expertise” 
(Mishan, 1982b, p. 43). To try to help to clarify the above concerns Figure 1, 
below, summarises my reading of the existing health-economic evaluation 
literature and suggests that evaluation processes should be iterative, and the 
answers to research questions should not automatically be considered as 
single-shot solutions to policy questions. It should be noted from the figure 
that there is not necessarily a direct link between the ‘decision problem’, i.e., 
the research, on the one hand, and the policy question on the other. Given 
abstractions typically made in research, the separation of the policy question 
and the iterative cycle of evidence generation in Figure 1 is intentional: it is 
justified by, e.g., the observation from the literature that it is generally not 
sensible to conflate health-economic evaluation with the solution to any policy 
question (see, e.g., (Williams, 1991)).  
Any ‘economic’ research question, on the topic of screening for prostate 
cancer at least, would tend to be an abstracted, partial or truncated one, thus 
ensuring separation from the policy question per se. All new information added 
to the evidence base as part of the cyclical process of evaluation would, per se, 
seem to require assessment and any appropriate qualifications. The idea here 
is that the cycle of evidence generation would ideally gravitate towards the 
policy question over time, but this may take multiple iterations and may be 
thwarted if the focus of some research is less than wholly inappropriate, or if 
the research questions are unanswerable due to lack of appropriate data or 
extant research evidence. As with any attempt to provide robust information, 
or improved approaches to policy-planning processes (Dewey, 1929, p. 41), the 
use of health-economic evaluation should be promoted by a suitably resourced 
multidisciplinary team.  
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Figure 1.  A proposal for at least six stages in an iterative cycle in the contribution of economic 
evaluation in informing holistic evaluation (mainly developed using (Tugwell et al., 1986), Figure 4.1, as 
well as (Quade, 1971a), Figure 2, (Sculpher et al., 2006), Figure 1 and (HM Treasury, 2018), Figure 2. 
In line with the above proposal, as well as with earlier suggestions (see, e.g., 
(Cochrane, 1972 (2004))), the economic evaluation of the FinRSPC is an 
attempt to provide additional information to the existing body of evidence on 
screening for prostate cancer. It is not the aim of the current study to undertake 
a wide-ranging HTA (as set out, e.g., by (The European network for Health 
Technology Assessment (EUnetHTA) project, 2016)), but hopefully the current 
study can provide some useful evidence for use in research in future.  
policy 
question 
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5.5 Choosing the type of economic evaluation for the 
FinRSPC 
According to the original trial protocol HRQoL, costs and CEA are the 
secondary foci of the FinRSPC (Miller et al., 2001). The first piece of health-
economic information, Article I concerning health-economic HRQoL in the 
FinRSPC, was published after the last set of health-economic questionnaires 
was collected in 2011 (Booth et al., 2014a). Only one article appears to have 
been published about HRQoL in the FinRSPC after that (Vasarainen et al., 
2013), although at least two more are currently being processed for peer-
review. An article relating to the second health-economic component, i.e., costs 
associated with the two arms of the FinRSPC, was published after the registry 
data became available in 2017 (Article II). Given the above timelines for the 
first two components of this health-economic study, in combination with the 
drafting of Article III, the process of deciding what type of analyses would be 
undertaken was a gradual one. Sub-sections 5.3 to 5.5 of this thesis provide a 
rationale for the choice of the type of health-economic evaluation undertaken 
here, and some further reasons for the eventual choice of methodology can also 
be found in Article III. The decision was made with useful hindsight about the 
extent and qualities of the data available from the FinRSPC, and with 
awareness of the subjective nature of judgments concerning how to approach 
health-economic evaluation (Quade, 1967). For instance, after much 
deliberation, the deficiencies of the questionnaire data suggested that little 
robust evidence on HRQoL would be available from the FinRSPC itself. 
However, although it is always possible to try and incorporate a wide range of 
data from various sources, at some point potentially relevant data for future 
models also has to be produced. Given the efforts of the FinRSPC research 
group, the efforts necessary to obtain the register data, as well as the 
completeness of coverage (but not of scope) of the register data, the 
multidisciplinary decision was taken to concentrate analysis on the most robust 
source of information, however incomplete in terms of scope. 
As the main published evidence concerning the primary outcome of the 
FinRSPC as a stand-alone trial (mortality from prostate cancer) was over five 
years old (Kilpeläinen et al., 2013), the health-economic evaluation of the 
FinRSPC updated those results. No other articles have so far been published 
about the cost-effectiveness of the FinRSPC. After describing the FinRSPC in 
the next sub-section, the subsequent four sub-sections will briefly summarise 
and review the four FinRSPC-related articles.  
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5.6 Background information related to the FinRSPC 
This sub-section briefly describes the nature of the FinRSPC study, its 
design, methods and results related to the health-economic evaluation of the 
FinRSPC. In order to do that, it may be useful for the reader to understand, 
in simple terms, a little more about screening for prostate cancer (PCa). In 
the current study the term ‘screening’ is used to refer to PSA testing of the 
kind that is undertaken as part of an organised, systematic, public-health 
screening programme, often referred to as ‘mass screening’ (Hakama, 1991). 
PSA screening can be classed as an early-detection screening test, which aims 
at diagnosing early-stage cancers, in principle to subject them to life-
prolonging treatments or even potential cure. Diagnosis of PCa has increased 
rapidly in the past 25 years or so in Finland (see Figure 2), just as in most 
industrialized countries (Auvinen & Hakama, 2017).  
 
 
Figure 2.  A figure showing the development of prostate-cancer incidence and mortality in Finland 
 (Source data: https://cancerregistry.fi/statistics/cancer-statistics/ ) 
 
Given that the usual rationale for investigating screening for prostate 
cancer, is that it could detect early cases of invasive (or pre-invasive) 
0
50
10
0
15
0
20
0
R
at
e 
p
er
 1
00
,0
00
 m
en
 54 
prostate cancer, with the aim being to decrease prostate-cancer mortality 
(Auvinen & Hugosson, 2003), ideally, this rationale should be thoroughly 
tested (Malm, 1999), at the very least due to the potential harms associated 
with overdiagnosis. Overdiagnosis is an important consideration in all forms 
of screening, and, e.g., its definition can include the anxiety associated with 
being labelled with diagnosis of cancer, any harms which result from being 
subjected to intensive surveillance for any advancement of the disease 
(Kalager et al., 2018), as well as any lack of benefit, unnecessary cost or harm 
from treatment of an overdiagnosed case (Loeb et al., 2014). More will be said 
about overdiagnosis below. 
 
Figure 3.  A graphic depicting the location of the prostate (courtesy of Prostate Cancer UK) 
The prostate is a gland and on average, in healthy adult males, is typically 
similar in size to a walnut. It is located under the bladder in males and wraps 
round the urethra (see Figure 3). Its size tends to increase with age and, 
although it can also become enlarged due to benign and/or malignant disease, 
there is much variation between individuals. The prostate itself is more 
susceptible than many other organs to development of cancer, however it is 
rare to die of PCa before the age of 55 (currently less than 1 in 100,000 Finnish 
men per year). Most men over 75 will have some cancerous lesions in their 
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prostate and most of these men would be unaware of its presence, given PCa 
is often asymptomatic in its less virulent forms. Therefore, unless men seek 
out PCa using a medical technology such as PSA testing or magnetic resonance 
imaging (MRI) (Bell et al., 2015), indolent forms of PCa typically remain 
undetected. PCa is thus relatively common in older men and, although it poses 
no serious threat to most men, for some, PCa will be life-threatening or fatal.  
Prostate‐specific antigen (PSA) is a protein produced exclusively by the 
prostate, and PSA in the bloodstream may indicate disease in the prostate, be 
it cancerous or benign. By the end of the 1980s the testing of serum PSA levels 
was increasingly being used to identify otherwise undetectable prostate cancer 
(Stamey et al., 1987). PSA not a tumour marker, i.e., there is no level of PSA 
that would definitively indicate the presence or absence of PCa (Haythorn & 
Ablin, 2011). On the one hand, if serum PSA is low (‘low’ PSA is typically 
defined in relation to the size of the prostate) it means that aggressive prostate 
cancer is less likely, even if it does not rule it out completely. On the other 
hand, high PSA can provide an early warning for PCa and the chance to pick 
cancerous lesions up early, particularly for men who have a more aggressive 
and significant form of the disease (Manvar et al., 2013).  
The potential benefit of a screening programme is related to the lead-time 
‘gained’ by early diagnosis, but this relationship is not straightforward, e.g., 
because of the interrelation between lead-time and overdiagnosis (Finne et al., 
2010). To understand cancer overdiagnosis, it is first useful to understand the 
heterogeneity of cancer progression, which is first highlighted by a quote, and 
then depicted in Figure 4, below (modified from Figure 1, Welch & Black 
(2010), reproduced with permission).  
“Cancer is not a single entity. It is a broad spectrum of diseases related each 
other only in name.” Crile (1955) 
In line with the above quote, one of many definitions of overdiagnosis 
relates directly to the identification of one end of a spectrum of prostate 
cancer, i.e., those slow-growing or non-progressive cancers which would only 
rarely spread or cause harm, even though ‘correctly’ diagnosed (Carter & 
Barratt, 2017). Screening can easily lead to overtreatment and harm, in 
addition to overdiagnosis, in the case of such very slow-growing or non-
progressive cancers. Of course, screening, when followed by successful 
treatment for more rapidly-growing cancers, can prevent death from prostate 
cancer, albeit with the potential for accompanying detriments to health-related 
quality of life. On the other hand, some rapidly-progressing cancers may not 
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benefit from treatment, or treatment may have minimal beneficial effect, with 
death from prostate cancer occurring even with early treatment (Esserman et 
al., 2014). 
Simply put, one ‘opportunity cost’ of PSA screening seems immediately 
apparent: although in the absence of PSA screening, more men would likely 
die from prostate cancer, in the presence of PSA screening, more men would 
likely be overdiagnosed and overtreated. In addition, there may well be 
accompanying negative effects on the health or well-being of the men for whom 
death from prostate cancer is avoided, in addition to any positive effects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  A graphic depicting the heterogeneity of cancer progression 
 
Because the rate of progression of prostate cancer can vary so widely, this 
creates a major problem in quantifying the harms or benefits of screening, at 
least in terms of the presence or absence of overdiagnosis, which, in turn, may 
also severely restrict comprehensive evaluation of the harms and benefits of 
treatment in trials of prostate cancer screening. In fact, although 
overdiagnosis directly affects individuals and their families, the quantification 
of overdiagnosis requires drawing inferences at a population level, modelling 
or other forms of estimation (Carter et al., 2016). It should be noted that a 
wide range estimates of prostate-cancer overdiagnosis have been made, which 
range from 1.7% to 94% (see, e.g., (Loeb et al., 2014) and (Welch & Black, 
2010)). Because of a lack of robust information about the extent of 
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overdiagnosis, e.g., in the FinRSPC, the ability to assess even lower-level 
‘opportunity costs’ of PSA screening in a straightforward manner is restricted. 
Further, it should also be noted that, during the period when men were still 
being invited to participate in FinRSPC screenings (1996-2008) three 
developments occurred. Firstly, there were changes in the application of 
pathologic grading of tumour differentiation. Secondly, there were changes in 
the surgical methods used, and indications, for radical prostatectomy. Thirdly, 
contamination, in the form of opportunistic PSA-based testing, increased year 
on year.  
The first of these may have impacted on men through potential changes in 
over-detection, the second may have impacted on men through, e.g., potential 
changes in over-treatment. To reiterate, some of the main unwanted 
consequences of treatment for PCa have been related to radical prostatectomy, 
including loss of sexual function or incontinence. In a related development, 
active surveillance has been widely adopted and aims to individualise the 
treatment of low-risk prostate cancers (Hardie et al., 2005). Active 
surveillance is likely to have decreased the overtreatment of indolent tumours 
by aiming to provide treatment only for those men with clinically significant 
cancers, although its impact currently seems somewhat limited according to 
one study (Drost et al., 2018). The third of the changes over time was the 
increasingly large proportion of men in the control arm who had had a PSA 
test (Kilpeläinen et al., 2017). Reasons for the increased contamination include 
the prevalence of age-cohort health checks as part of fairly wide-reaching 
occupational health care packages in Finland, as well as, e.g., direct-to-
consumer marketing of PSA testing in shopping centres.  
The study population of the FinRSPC consisted of men aged between 55 
and 71 and resident in the study areas. On the first day of each year from 1996 
to 1999, 8,000 men were assigned at random to the intervention group (the 
screening arm to which systematic invitations to PSA-based mass screening 
were planned) (Finne et al., 2003). The remainder of the age cohort each year 
were assigned to the (larger) reference group (the control arm to which no 
invitations to PSA-based mass screening were sent). As the end result of 
extensive organisation and planning, the FinRSPC intervention offered 
systematic invitations to PSA-based mass screening for men in the screening 
arm, and a standardised, pre-planned approach to clinical follow-up and 
potential diagnosis for screen-positive men. Men were invited to PSA screening 
a maximum of two or three times, at four-year intervals (i.e., if men in the 
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screening arm were aged over 71, or if they had otherwise received a PCa 
diagnosis, they were no longer sent an invitation to participate). The first 
screening round was carried out between 1996 and 1999, the second between 
2000 and 2003 and the third between 2004 and 2007. Further details about the 
study design, methods and results of the FinRSPC are available from Article 
IV, as well as from (Kilpeläinen et al., 2013), Article I and Article II.  
As already noted in Sub-section 5.4, the research presented here is not a 
HTA, nor does it represent a holistic evaluation of a mass-screening 
programme. Indeed, it should be noted that, contrary some of the principles 
found in the widely-referenced guidelines on screening evaluation (such as 
(Wilson & Jungner, 1968), (Butterfield, 1968), (Pole, 1968), (Cochrane & 
Holland, 1971) and (The Danish Council of Ethics, 2001)), the aetiology and 
natural history of prostate cancer are still not well understood. There are only 
weakly-identifiable associations between, e.g., diagnosis of prostate cancer and 
socio-economic status; use of certain pharmaceuticals; hereditary lineage; 
molecular or genetic makeup; or environmental factors. In light of this dearth 
of current knowledge, the current study attempts to focusses on the health-
economic information which may still add some useful information to the 
evidence base, in the hope that the findings herein may be better investigated 
in future, or lead to better future research and better-informed decisions. 
5.7 ‘HRQoL’: review of study design, methods and 
results 
As there was a dearth of evidence of the potential long-term impact of PSA 
screening for prostate cancer on health-related quality of life (HRQoL), the 
objective of Article I was to report the findings gathered from some of the 
health-economic data collected as part of the FinRSPC on HRQoL. This 
attempted to add to the evidence base using postal questionnaire surveys 
which were conducted in 1998, 2000, 2004, and 2011 among men from a 
random subsample of the trial population (n = 2200), as well as among men 
in the FinRSPC diagnosed with PCa (eventual total n = 7011, which included 
all available men prior to each survey). In 2011, for example, 1587 responses 
were received from men with PCa in the screening arm and 1706 from men 
with PCa in the control arm. In addition, e.g., in 2011, from the trial 
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subsample, 549 men in the screening arm and 539 in the control arm provided 
responses.  
Before looking at any analysis from this CEA of the FinRSPC, it is 
important to highlight a few potential causes of bias in any analysis which 
does not take its ‘time origin’ as the point of randomisation (Duffy et al., 
2008). Thus, even within an RCT, length bias and lead-time bias may affect 
any analysis in which the starting point for analysis, or time origin, is taken 
as the point of diagnosis (Baker et al., 2002). Although randomisation 
occurred before consent in the FinRSPC’s population-based age cohort, thus 
likely protecting analyses from biases due to selection or volunteering, 
important biases related to screening, such as length bias and lead-time bias, 
are likely to cause problems for interpretation when the analysis did not use 
the date(s) of randomisation as the time origin(s).  
Analysis, from the point of randomisation, comparing health-state-value 
scores in the intervention and control arms using three HRQoL measures 
(15D, EQ-5D, and SF-6D), was undertaken on questionnaires administered 
in 2011 to the random sub-sample of men from the trial (Booth et al., 2014a). 
In this study, Article III, the average scores calculated from all three HRQoL 
measures were higher in the control arm, but only the EQ-5D measure 
indicated small, statistically-significant advantage in favour of the control 
arm (control vs. screening arm: EQ-5D: 0.85 vs. 0.83, p = 0.039). This finding 
would seem to suggest PSA screening might have reduced the health-related 
quality of life of men in the screening arm in genereal, at the last available 
point of HRQoL follow-up in this study. One other comparison of HRQoL, 
undertaken between patients in a randomised study of treatment and a 
population-based control group of men matched for region and age 
(Johansson et al., 2011), found that significantly more men reported 
moderate to high levels of anxiety as patients, than did men in the control 
group. Although the study by Johansson et al. did not specifically investigate 
screening, it did focus on corollaries of screening, in terms of the effect of 
treatments on some important indicators of HRQoL. In addition, if diagnosis 
leads to treatment with curative intent, e.g., in the form of radical 
prostatectomy or radiotherapy, there is a risk of lifelong treatment-induced 
diseases and states, such as problems relating to urinary or anal leakage, in 
addition to commonly-occuring erectile dysfunction (Steineck et al., 2019). 
Ideally, it would seem reasonable to suggested that future evaluations of 
PSA screening would attempt to concentrate on identifying differences for 
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those men with the biggest (potential) impact (Auvinen et al., 2017), i.e., men 
diagnosed with prostate cancer. However, it may well be the case that there 
is no available method which can be used to correct for length- or lead-time 
biases within an RCT of prostate-cancer screening, i.e., when attempting to 
analyze outcomes for diagnosed men. For instance, methods do not appear to 
be available which can accurately adjust for there being a longer period of 
time when cancers could be found via screening (length bias) or for the follow-
up time from screen detection being longer than the follow-up time from 
clinical detection (lead-time bias) when analyzing outcomes for diagnosed 
men. The above problems would seem to thwart not only the comprehensive 
evaluation of HRQoL effects related to prostate-cancer screening, but also 
the comprehensive evaluation of costs and cost-effectiveness, as well as 
comprehensive evaluation of prostate-cancer screening per se. 
With such hindsight, it seems impossible for definitive conclusions to be 
drawn from any analysis presented in Article I, other than for those results 
relating to the random sub-sample of men from the trial. This is not only 
because the patient data were collected without regard for the point in time 
when each man had been diagnosed; but also, and perhaps more importantly, 
results pertaining to diagnosed men were reported without taking into 
account the likely problems with these results due to length bias or lead-time 
biases. Information in order to fully comprehend the risks of overdiagnosis 
is still lacking (Dempsey, 2019), because the currently available evidence 
may be unable to adequately inform men or organisations facing choices over 
prostate-cancer screening, of all significant benefits or harms.  
Further to the above, a brief exchange occurred in the literature relating to 
Article I (Bergman & Litwin, 2014; Booth et al., 2014b). Subsequent to those 
discussions it seemed clear that generic HRQoL measures commonly used in 
health-economic research and postal administration of questionnaires may not 
be well suited to long-term follow up of men. Reasons for this include the 
potential influence of factors unrelated to the prostate-cancer screening trial 
such as aging; impacts on health unrelated to the trial; socio-economic status; 
and health-related non-response to questionnaires; all of which have the 
potential to skew the results of any HRQoL research, including all analyses 
included in Article I. 
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5.8 ‘Costs’: review of study design, methods and 
results 
Little real-world evidence exists on the impact of prostate-cancer screening 
on healthcare costs, despite cost-related information often being considered 
as a necessary prerequisite to fully-informed evidence-based mass screening 
policy (The Danish Council of Ethics, 2001). Article II estimated differences 
in register-based average costs of publicly-provided healthcare in each arm 
of the FinRSPC at 20 years. 
Article II used individual-level register data on prescription medications, as 
well as on inpatient and outpatient care, in order to estimate healthcare costs 
for the 80,149 men during the first 20 years of the trial and compared average 
healthcare costs for a number of sub-groups by trial arm. Despite this long-
term follow-up of the large FinRSPC age cohort, the 20-year period may be 
too short, or the inherent heterogeneity in costs at the level of individual 
patients too great, to provide robust information about the financial burden of 
prostate-cancer screening to parts of the Finnish health-care system. The 
conventions of Finnish, article-based doctoral theses largely preclude the 
introduction of new results related to the constituent articles. Therefore, it 
must suffice to note that the estimates reported in Article II are problematic 
because most of the analyses do not take account, amongst other things, the 
potential impact of lead time bias, length bias or possible variation in 
treatment practices.  
In addition, journals tend to favour the reporting of between-trail-arm 
differences in average costs at the expense of other results, even when this 
neglects the fact that some of the relevant formal analytic information is the 
entire probability density, rather than only the mean (Manski, 2019). Due, for 
example, to academic journals having word limits which may restrict what is 
allowed to be reported, there often remains relatively little space in many peer-
reviewed medical journals for sensitivity analyses. Simplifying any message 
can easily do an injustice to hard-earned data or time- and resource-consuming 
analysis. Longer-term follow-up and wider-ranging research would be required 
to be better informed about what factors might drive the real costs of, or 
savings from, the potential introduction of PSA-based mass screening.  
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5.9 ‘CEA’: review of study design, methods and 
results 
The register-based ‘CEA’ of a 20-year-long pragmatic randomised trial of 
PSA-based mass screening provides new evidence on costs, comparative 
effectiveness and cost-effectiveness. At the time of writing this thesis, Article 
IV appears to be the only economic evaluation of PSA-screening which 
combines the power of a randomised, controlled trial with extensive follow-up 
via real-world data from comprehensive statutory health-care registers (Booth 
et al., 2019). In line with previous studies, the reported findings do not lend 
support to the idea that PSA-based mass screening in the FinRSPC could be 
classed as ‘cost-effective’ overall. Our study finds that health-care costs seem 
quite similar between the arms on average, even when account is taken of the 
screening-related costs per se. However, again on average, just over one man 
per 1,000 in the screening arm avoided death from prostate cancer during the 
trial (to the end of 2015), and also that, on average, around two additional men, 
per 1,000 men in the screening arm, died. An infographic is included here, 
which is intended to convey, in a concise manner, the main screening-related 
outcomes of the FinRSPC after 20 years of the trial (Figure 5, p. 63). Although 
it should be stressed that no single piece of information can necessarily 
represent the complicated or complex nature of the results of any evaluation 
of prostate-cancer screening, some interpretations can still tentatively be 
drawn from either the infographic, or the ICERs reported in Article IV.  
One interpretation is that systematic prostate-cancer screening is 
associated with a small reduction of prostate-cancer mortality from 1.1% to 
1.0%. In other words, on average, one man per thousand men systematically 
screened has been spared death from prostate cancer during the 20-year 
follow-up period of this trial. Despite there being a potential for 
misclassification of causes of death for men within the trial, it should be noted 
that research has suggested that the accuracy of classification was high in the 
FinRSPC (at least prior to 2003) (Mäkinen et al., 2008), thus it seems unlikely 
that the observed differences would be the result of ‘sticky diagnoses’ (Black 
et al., 2002). However, this interpretation should not be taken in isolation. In 
addition, the fact that overall mortality is found to be higher in the screening 
arm (although not statistically-significantly so) could be a cause for concern; 
because it would be expected, a priori, that if screening reduces prostate-cancer 
mortality it would also reduce (at least ever-so-slightly) overall mortality.  
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Of course the observed differences could simply be due to random variation 
in mortality, especially given that the two arms of the FinRSPC contain many 
men. There have only been two other population-based trials of prostate-cancer 
screening where randomisation occurred before consent, one in Italy and one 
in Gothenburg (Hugosson et al., 2010). Only the Gothenburg trial has 
published separate, peer-reviewed results for all-cause mortality, and although 
in that trial (after 10 years) over three prostate-cancer deaths were prevented 
per 1000 men screened, overall mortality was higher in the screening arm 
(albeit by the smallest possible margin, with a 10-year mortality in the control 
arm of 1,982 versus 1,981 in the screening arm). It is useful to note here that 
although comparisons between all men in each arm would be ideal, in order to 
robustly analyse all-cause mortality our study could need to be about five 
times bigger (Heijnsdijk et al., 2019), and this would not have been practicable 
in Finland in the 1990s, because the men in the FinRSPC already made up 40% 
of Finnish males of that age at that time.  
Of course, as noted in sub-sections 5.7 and 5.8, one interpretation of the 
results presented in Article IV is that the reported results relating to 
diagnosed men are much influenced by length bias or lead-time bias, and as 
such the reported results may not offer clear guidance, or only robust findings, 
to any decision-maker. But it might also be useful to note that cohort studies 
have suggested the possibility of an increased risk of death from suicide and 
cardiovascular death 30 to 90 days after prostate-cancer diagnosis (see, e.g., 
(Fall et al., 2009) and (Fang et al., 2010)). 
Although the secondary analyses reported in Article IV should not be 
regarded as robust, they may still be useful as they can likely give one 
indication, or estimate, of the extent of overdiagnosis in the trial. One line of 
reasoning for this runs as follows: In the FinRSPC, after 20 years of follow-
up, around 14% more men in the screening arm were diagnosed (a 1.14-fold 
cumulative incidence: with 11.9% of men diagnosed in the screening arm 
compared to 10.5% in the control arm, after 20 years of follow-up). In addition, 
around 1‰ of men are spared death from prostate cancer in the screening arm 
(around 1.0% in the screening arm compared to around 0.9% in the control 
arm, after 20 years of follow-up, see Fig 1 in Article IV). Hence, given that 
length of follow-up, around 14 more men needed to be systematically screened 
and diagnosed to prevent one prostate cancer death. As, on average, with the 
follow-up available to the current study, for every 14 men diagnosed, around 
one death from prostate cancer was averted, ten or so were still alive, and 
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around three had died of other causes. If the trends in mortality during the 
last 20 years would continue, then for every diagnosed man who is saved from 
prostate-cancer death, there will likely be two or three diagnosed men that die 
of other causes, remembering that cause-of-death statistics suggest that PCa 
mortality is around 3% (see Figure 2). If prostate-cancer screening in the 
FinRSPC would continue to prevent around 13% of PCa mortality, in line with 
the FinRSPC 20-year results, it might reduce PCa death overall from around 
3% to around 2.7% (by the time all men in the FinRSPC cohort have died). In 
that case, although three less men per thousand might die of prostate cancer, 
at the same time 11% or so, instead of 10% or so, of men from the FinRSPC 
cohort would have likely been diagnosed as a result of systematic screening 
(i.e., around 14 more men per thousand might be diagnosed). According to the 
above relatively crude reasoning, one estimate of ‘overdiagnosis’ would be the 
odds of being diagnosed with, but not dying of, prostate cancer, i.e., around 
11:3 or 10:4, a probability of around 80% or 70%, respectively. Although these 
crude calculations lack precision, in part due to the waning effect on mortality 
attributable to the FinRSPC’s intervention, such estimates would seem to 
provide one potential indicator of overdiagnosis, in terms of one of the most 
robust forms of outcome measure, i.e., mortality.  
Given the current lack of published research related to better 
understanding the effects and extent of overdiagnosis and other biases within 
trials of prostate-cancer screening, extending epidemiological studies to better 
address this dearth of information may be able to usefully supplement the 
existing evidence base. It is claimed here that if the assessment of all-cause 
mortality is thwarted due to lack of statistical power and if epidemiological 
analysis is focussed primarily on prostate-cancer mortality, without due 
regard for problems posed to evaluation by other outcome measures, related 
to overdiagnosis, as well as other biases, then subsequent economic evaluation 
may have weak foundations. Indeed, any weaknesses in the evidence base with 
respect to length bias, lead-time or overdiagnosis bias would also likely affect 
estimation of the impact of prostate-cancer screening on HRQoL and costs, as 
noted in earlier sub-sections, again potentially constraining the ability of 
simplistic CEA models to reliably inform decision-making. 
Given the above, solid evidence directly from randomised controlled trials 
of prostate cancer screening seems likely to remain sparse. Extending both the 
scope of analysis and the follow-up period may help to produce more definitive 
or informative results, but, e.g., gathering of further information on HRQoL 
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of men in PSA trials seems likely to remain deficient. Suggestions in recent 
clinical guidelines that men should be informed of, and understand, the 
benefits and risks of screening would seem difficult to justify, given a reliance 
on current, potentially relatively uninformative, estimates of benefits and 
risks (US Preventive Services Task Force, 2018). For example, the 20-year 
finding that the FinRSPC appears to be associated with high levels of 
overdiagnosis and with increased overall mortality could be interpreted as 
implying that decisions about prostate-cancer screening made prior to the 
appearance of such information were relatively poorly informed. One of the 
potential contributions of evidence-based medicine seems absent; because 
previously-published studies do not typically clearly inform stakeholders 
about the lack of evidence. Without appropriate qualifications relating to the 
evidence base, it is more difficult to be aware of the uncertainties about 
decisions (Tunis, 2007). The ‘best available evidence’ may be unable to make 
men or organisations facing choices over prostate-cancer screening adequately 
aware of all possible benefits or harms, indeed, information in order to fully 
comprehend the risks of overdiagnosis may always remain inadequate 
(Dempsey, 2019). 
The way the FinRSPC is analysed here is as a pragmatic, descriptive or 
exploratory study, not as an explanatory study. Further analysis and more 
data are both beyond the scope of the current study, but either or both would 
likely be necessary to understand how and why the screening intervention 
worked or failed to work (Clarke, 2006). The results of the FinRSPC may 
suggest that prostate-cancer screening has had a variety of impacts, but there 
is no way of deducing what it is that produced these results without costly 
additional analysis (Pawson et al., 2005). When the main effects of an 
intervention are not known with certainty (as in the case of prostate-cancer 
screening), but merely presumed, then a relatively small exploratory RCT 
may not be best equipped to contest those presumptions. The current study, 
which has novel findings from a RCT, could offer important information about 
prostate-cancer screening to supplement that from earlier studies. However, 
given these are the first findings in this direction from a RCT, the information 
should not be considered robust in terms of scientific reproducibility, but it 
may usefully add to earlier evidence from cohort studies (see, e.g., (Fall et al., 
2009)). However, we should not draw conclusions too soon, corroboration or 
contradiction from similar analyses from similar mass‐screening trials should 
be sought first. On the other hand, in the presence of ambiguity about such a 
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potentially fundamental part of the overall impact of screening, warnings 
about the potential for harm may well be appropriate. Indeed, another 
fundamental problem should also be kept in mind when evaluating cancer-
screening trials, given that they can include a high amount of ‘noise’ relative 
to the ‘signal’ of the screening effect, potentially requiring studies to include 
huge numbers of men in order to facilitate comprehensive evaluation (Baker et 
al., 2002). 
In addition, it should be noted that when interpreting any results from 
Articles I, II and IV, the influence of ‘contamination’, i.e., PSA testing that 
occurs outside the organised screening population should always be kept in 
mind. Perhaps most importantly, the results of all three peer-reviewed articles 
relating to the current study were reported without full consideration of the 
likely problems with their results with respect to length- or lead-time -biases. 
The results contained within these three articles were accepted for publication 
after peer review, but little, if any, direct mention was made by any of the 
peer-reviewers about the results being problematic with respect to length- or 
lead-time -biases. Such problems with the published results can be seen, at least 
in part, as a failure of the peer-review system to quality-control research 
output.  
 
5.10   Assessment of economic evaluation methodology 
One partial assessment of the methodology of economic evaluation is provided 
by Article III (Booth, 2019a), but the preceding sections of this study also aim 
to provide details of the main principles related to health economic evaluation. 
This sub-section summarises these descriptions and assessments with much 
brevity. Article III identifies three main approaches to health-economic 
evaluation namely, the extra-welfarist, welfarist, and classical. Table 1 is 
intended to provide a very brief description and summary of these three 
approaches (see (Booth, 2019a) for further details). Article III is based both on 
the author’s reading of the literature and on experiences during the practical 
application of health-economic evaluation as part of this study. Discussion 
about such subjective assessment will continue in subsequent sub-sections, and 
it will be left for the reader to decide if she agrees with the interpretations 
drawn. 
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The first row of content in Table 1 describes welfarist approaches to health-
economic evaluation (WHEE), and it is only this approach which ensures 
adherence to neo-classical (welfare-)economic principles. WHEE typically 
aggregates individuals’ ‘willingness to pay”, using contingent valuation 
methods, in order to produce estimates of ‘social welfare’. Its drawbacks 
include the vagaries of asking individuals to value goods or services about 
which they do not typically have much information (or experience). The second 
row of Table 1 describes extra-welfarist approaches to health-economic 
evaluation (EWHEE). However, this approach has little adherence to neo-
classical economic principles, and instead typically relies on a combination of 
individuals’ health-state -related assessments and some valuation of those 
assessments which is typically an amalgam of both individuals’ preferences as 
well as the preferences or responsibilities of a ‘decision-maker’ (be the decision-
maker hypothetical, mythical or other), rather than the preferences of 
individuals alone. For this reason, this often decision-analytic approach, with 
purported strong emphasis on a ‘decision-maker’, is sometimes referred to as 
the “decision-making approach”. The third row of Table 1 describes a classical 
approach to health-economic evaluation (CHEE). This approach has the 
primary objective of identifying and assessing, rather than defining and 
‘maximising’, societal value health’ or well-being. This involves a process of 
analysis and evaluation which would include quality assessment and checking 
of appropriateness of the health-economic evaluation itself.  
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6 Discussion 
The main focus of the remainder of this thesis is on trying to convey some 
important features of the nature of information provided by health-economic 
evaluation. The review of the literature on health-economic evaluation 
undertaken as part of this study suggests information from CEA should be 
subjected to an evaluative process. The discussion, that follows on from earlier 
sections, attempts to draw together various arguments so as to make the case 
for a more detailed and deliberative approach to the interpretation of 
information produced by health-economic evaluation, especially that 
information which is produced via CEA. It will then put forward some 
suggestions which could be helpful when interpreting economic evaluations.  
6.1 How should health-economic evaluation be 
interpreted? 
The suggestion presented below is that interpretation of information from 
health-economic evaluations should first be assessed through a two-part 
quality-assessment process. The first part of the process would focus on the 
quality of the health-economic information produced by each health-economic 
evaluation, and primarily assess the content or ‘internal’ validity in each case 
(Sub-sections 6.1.2 and 6.1.3). A second part of the process would assess how 
that content fits into the context in question, i.e., it would appraise the 
appropriateness of health-economic evaluation information (Sub-section 6.1.4). 
Together, these two parts can be used to form an overall assessment of the 
‘quality’ for each health-economic evaluation in any given setting (Booth et al., 
2017) and contribute to any relative evaluation (as set out in Sub-section 6.2).  
Before these two foci of preliminary interpretation can be set out more 
fully, it will be instructive to differentiate between ‘measures’ and ‘indicators’, 
in order to better discuss and understand the meaning and interpretation of 
much of the information provided by health-economic evaluations.  
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6.1.1 ‘Measures’, indicators and meaning in CEA 
Numbers can be assigned to act as measures under different rules, but not 
all of these rules are of equal usefulness in all settings (Porter, 1992). The 
numeric results from health-economic evaluation are typically assumed only 
to provide a partial contribution to holistic evaluation, they are intended to 
be an aid to decision making (Sculpher et al., 2005). CEA, in the field of 
health-economic evaluation, appears to be a rather undisciplined collection of 
methods (Bauer, 1992), which does not seem likely to produce wholly 
comparable or commensurate numbers. Indeed, rather than there being a 
lack of recommendations and guidelines suggesting how to undertake CEA, 
there are a plethora of different approaches (Heintz et al., 2016). Two related 
issues should also be noted here, even if one single standard approach did 
exist, firstly, there would likely be difficulties in following that standard 
approach for some applications, given that the information required in any 
standard approach might not be readily available for each and every 
application. Secondly, if one single standard approach existed, it would likely 
neglect to include potentially important elements for some applications. 
Given the lack of a systematic approach, given that the numbers would 
appear to be less than consistent in their meaning, it would seem 
inappropriate to class ICERs as a measure of efficiency, each ICER is merely 
an indicator of one form of efficiency (Stevens, 1959). Given the extensive 
lack of certitude surrounding ICER estimates it would seem even more 
appropriate to see the ICER estimates as merely indicators. As indicators, 
they can give some indication of some specific form of efficiency, or even 
some wider notion of efficiency or value, but their sensible use as indicators 
would seem to require some kind of quality control (Schum, 2009). Although 
these ICERs are numbers, they do not have consistency in meaning, they do 
not seem to adhere to the following meaning of ‘measure’: they do not seem 
to provide a standard, a rule of judgement, etc., against which something 
may be gauged, determined, or regulated (Oxford English Dictionary, 2016).  
Although the existence of measurement or analytical standards are often 
assumed by many health economists (see, e.g., (Eastwood & Maynard, 
1990)), other writers have been much more sceptical that about the extent 
to which objectivity can be attained (Goldenberg, 2006), stressing that such 
numbers should not be interpreted without careful consideration of what 
such information really means (Porter, 1995), including appropriate 
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qualifications as and when necessary (see, e.g., (Boulding, 1966)). This is not 
to say that standardisation, recommendations and guidelines have no role, 
but rather that when these quasi-systematic approaches are utilised, 
practitioners should clearly acknowledge that CEA is typically truncated, 
and may exclude important wider considerations. Further, the diversity in 
estimates of ‘health’ (Maynard & Sheldon, 1997), the diversity in estimates 
of the production of ‘health’ (Lessard & Birch, 2010), and in the diversity in 
the synthetic indicators of the efficiency of producing ‘health’ (Brousselle & 
Lessard, 2011), would seem to make them too heterogeneous to be used in an 
unquestioning manner as a metric (Muller, 2018). Given that information 
produced by health-economic evaluations is often disparate in nature, it is 
suggested here that the resultant numbers might primarily be classified 
towards the nominal end of the measurement-scale spectrum (Porta, 2014, p. 
180). Indeed, the diversity in estimates of the efficiency of producing 
‘health’, i.e., the inherent variability in CEA estimation processes, would 
seem to provide another reason why evaluation of what such information 
means on a case by case basis, including judging its provenance, would seem 
useful (Laine, 2014).  
At least two further related reasons exist for quality assessment of CEA 
information, i.e., for deliberating upon, rather than relying on assumptions 
about, what CEA means. The first is that, buoyed by policy-oriented rhetoric 
(Colvin, 1987), information from health-economic evaluation has long held 
the promise of being an administrative aid (Feldstein, 1963), despite its 
limitations (Walsh & Williams, 1969). Second, the development of certain 
streams of cost-benefit thinking for policy purposes was likely a long-
standing synergistic relationship between industry and government, via 
research institutions, both public (see, e.g., (Mason & Towse, 2008), 
(Cookson & Claxton, 2012) & (Cookson et al., 2016)) and private (see, e.g., 
(Laing, 1972), (Office of Health Economics, 1979) & (Brockis et al., 2016)). 
Although these two latter reasons are not within the primary focus of the 
current study, such sociological or philosophical considerations should 
nevertheless be kept in mind when assessing all evaluative research (see, e.g., 
(Boulding, 1966), (Biderman, 1966), (Ashmore et al., 1989), (Valtonen, 1993, 
p. 193), (Lessard & Birch, 2010), (Howick, 2011) and (Dempsey, 2019)). 
Indeed, mesmerised by the ‘beauty’ and precision of numbers, decision-
makers may easily overlook the simplifications made to achieve such 
(oftentimes spurious) precision in ICER estimates. Neglecting analysis of 
 74 
qualitative factors may overemphasise the importance of abstract or 
ideologically -based calculations to the decision process (Quade, 1967). Given 
all the reasons set out above, appraising the evaluation mechanism per se, 
e.g., its promises, pitfalls and possible biases, would seem to constitute a 
necessary and integral part of any comprehensive evaluation of the meaning 
of information from health-economic evaluations. For this reason, we now 
turn to the first part of a two-part appraisal process, which should involve 
the health-economic evaluation being checked for ‘content’. 
6.1.2 Appraising the content of CEA information 
The previous sub-section on measurement attempted to highlight the need to 
define meaning for information from each health-economic evaluation. Much 
of this type of information does not naturally lend itself to investigation using 
standard terms such as reliability, reproducibility, validity, feasibility and 
sensitivity (Kobelt, 2013), due to a lack of relevant standards against which 
these concepts can be judged in the case of health-economic evaluation. 
However, it is the contention of this thesis that an attempt should be made to 
apply some kind of appraisal to economic evaluation per se, given that 
economic evaluation is made up of estimated outcomes and costs, as well as 
combined with assumptions or some form of analysis, which produce the 
particular efficiency indicator in question. In order to distinguish between the 
appraisal of the content of health-economic information and the appraisal of 
that information in any specific context, the terms ‘credibility’ and 
‘appropriateness’ will be used, respectively. The use of the term ‘credibility’ 
here is intended to express a broad notion, akin to concepts such as ‘construct 
validity’, ‘internal validity’ and ‘plausibility’ found in the epidemiological and 
health-economic literatures. The term credibility will be used to refer to an 
assessment of the components which form the constituent parts of the CEA, 
including both the estimates of costs and effectiveness, as well as the manner 
in which they are combined.  
Subsequently, given the credibility or plausibility of that quality-assessed 
information, its congruence with, or appropriateness to, the policy question 
should also be assessed. In practice this would mean that, subsequent to checks 
for credibility, attention should then turn to the bigger picture; looking at how 
CEA information fits in with other evidence, i.e., if and how appropriate 
‘economic’ evidence would seem to be after being qualified by any other 
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considerations. As the topic to which economic evaluation is applied gets more 
complicated or complex (Shiell et al., 2008), we should be more sceptical about 
the possibility for economic evaluation to provide useful information (Kurtz & 
Snowden, 2003). This does not necessarily mean that no useful information 
will be available, just that care should be taken to challenge anyone who 
suggests CEA is necessarily anything more than sub-optimisation for more 
complex or complicated topics.  
The fundamental problem here is that health interventions can be 
horrendously complicated to assess (Williams, 2004, p. 14). Given the 
inevitable gap between the research that can be offered and what would ideally 
be available for decision-making processes, the suggestion is made that 
researchers would take heed of this and not assume that CEA and related 
methods could be legitimately applied to all topics with equal success. 
Researchers should be wary of the fallacy of composition; that what may 
‘work’ in one area of health care may not ‘work’ in all areas of health care. 
There is no dispute that CEA can work in principle, but here the focus is on 
practical application of health-economic evaluation to health-care 
interventions, sometimes in complex social settings.  
That said, appraising the content of the cost- and effectiveness -indicators 
which have been measured or estimated would typically start by checking 
what entities were measured or estimated and in what way. For example, how 
has the information been derived (e.g., study type)?; duration: months, years, 
or other?; what has been modelled using what information?; is the follow-up 
period sufficient to encompass all important impacts?, et cetera. 
The main problem is that quality seems unable to be assessed in anything 
but a subjective or superficial manner via any of a number of ‘checklists’ 
(Evers et al., 2005; Husereau et al., 2013; Shemilt et al., 2013; Shemilt et al., 
2008) and (Drummond & Jefferson, 1996). Although these checklists are 
available for assessing the ‘methodological quality’ of, or the standard of 
reporting of, health-economic evaluations, they do not necessarily address the 
quality of health-economic evaluations per se. The study by Evers et al. 
suggests that answering checklist questions would tend to require personal 
opinion and judgment, and that the questions they contain would tend to be 
quite cursory (Evers et al., 2005). However, the scope of the current study 
does not include the creation of a more, in depth or detailed, credibility 
assessment instrument, presuming such an instrument would be sensible, or 
even possible, to construct.  
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As an alternative, appraisal of the CEA results for content could be 
facilitated to some extent by the use of an impact inventory for CEA, by 
appropriately appraising each source of evidence for which an impact category 
has been assessed (see Table 2 below (as suggested by (Neumann & Sanders, 
2017))).  
6.1.3 Credibility and the Impact Inventory 
As suggested in the previous sub-section, some of the types of impacts which 
could usefully be checked when considering ‘credibility’ are set out in the table 
below, this template for this table was developed by the Second Panel on Cost-
Effectiveness in Health and Medicine (Neumann et al., 2016, pp. 351-352) and 
is filled in here according to the information available from Article IV: 
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Table 2. Potential impacts related to CEA quality assessment 
Sector 
Type of Impact  
(list category within each sector with unit of measure if 
relevant)† 
Included in this Reference 
Case Analysis from the 
so-called ’… perspective’: 
Notes on 
sources of 
evidence: 
Healthcare 
sector Societal  
Formal healthcare sector 
Health 
Health outcomes (effects) 
Longevity effects   
Health-related quality-of-life effects   
Other health effects (e.g., adverse events and secondary 
transmissions of infections)   
Medical costs 
Paid for by third-party payers   
Paid for by patients out-of-pocket   
Future related medical costs (payers and patients)   
Future unrelated medical costs (payers and patients)   
Informal healthcare sector 
Health 
Patient-time costs NA  
Unpaid caregiver-time costs NA  
Transportation costs NA  
Non−healthcare sectors (with examples of possible items) 
Productivity 
Labour market earnings lost NA  
Cost of unpaid lost productivity due to illness NA  
Cost of uncompensated household production†† NA  
Consumption Future consumption unrelated to health NA    
Social services Cost of social services as part of intervention NA    
Legal or criminal 
justice 
Number of crimes related to intervention NA    
Cost of crimes related to intervention NA    
Education Impact of intervention on educational achievement of population NA    
Housing Cost of intervention on home improvements (e.g., removing lead paint) NA    
Environment Production of toxic waste pollution by intervention  NA    
Other (specify) Other impacts NA    
† = Categories listed are intended as examples for analysts, NA = Not applicable, †† = Examples include activities such as food 
preparation, cooking, and clean up in the household; household management; shopping; obtaining services; and travel related 
to household activity. 
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One point of note about any use of an ‘Impact Inventory’ such as that 
depicted in Table 2 is its ability to highlight all direct or indirect impacts, 
despite the fact that, in practice, many CEAs have not included health 
effects on persons other than the individuals directly affected by the 
interventions (Neumann et al., 2016, p. 92).  
One possible drawback of the Impact Inventory, as presented by 
Neumann et al., is the fact that it does not separate out all health impacts in 
as much detail as it does with cost impacts: it does not appear to leave much 
scope for including health effects under the heading of “Informal health care 
sector”. Of course, any health impacts which fall on ‘important others’, i.e., 
on relatives or carers, could be bundled under the subheading “Other 
(specify)”, itself under the heading “Non-health care sector”. However, all 
other items in this section seem to refer mainly to costs, rather than to health 
per se. Further, the table could be extended to encompass such concerns and, 
thus potentially provide an improved vehicle for assessment of ‘credibility’. 
Naturally these issues will also have importance for the consideration 
outlined in the next section, namely, ‘appropriateness’, too.  
 
6.1.4 Appropriateness: CEA information in context 
Assessing ‘appropriateness’ means assessing the practical relevance of the 
CEA information produced in informing choices. Of course, any assessment of 
appropriateness will naturally include both the relevance of the constituent 
measures used, as well as the method used to combine both costs and effects, 
as set out in the previous sub-section. In addition to the above initial 
assessment of ‘credibility’, the appropriateness of the CEA indicator to the 
policy question should be judged. Assessing the appropriateness of CEA 
information requires assessment of the extent to which the available research 
evidence meets the needs and concerns of decision-makers. It should be 
recognised that CEA information can vary in both its credibility and 
impartiality, as well as keeping in mind that the production of other forms of 
evidence in the health-care sector is not without its problems either (Gøtzsche, 
2019). The extent of the appropriateness of the ‘decision problem’ to the ‘policy 
question’ has central relevance for the way in which CEA informs decision 
making. To put this another way, any approach chosen when undertaking 
CEA is only one of a myriad of possible approaches: appropriateness is not 
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guaranteed, it needs to be earned and assessed. Ideally, assessing the 
appropriateness would also check how far the results of an iterative evaluative 
process, e.g., CEA, remains from the policy question itself (see Figure 1., sub-
section 5.4). In part, appraisal of the CEA results in any specific context can, 
just as when appraising credibility, be facilitated by the use of an impact 
inventory for CEA (see Table 2, sub-section 6.1.3). Appraising the 
appropriateness would typically start by checking what indicators of cost, 
effectiveness and cost-effectiveness, i.e., what impacts are included (Loomes 
& McKenzie, 1989). In addition, of crucial importance is from whose 
perspective(s) are these entities assessed: patient?; health-care payer?; cross-
government?; health-economic?; family?; community?, or a mix of these. 
Appraisal may also touch on both content and context in the following 
categories: the measures or indicators used, the data used, and study design(s) 
in question. Such appraisal, requires judgment about how well the data, the 
records or responses, describe the potential benefits and harms, i.e., how 
responsive they are (see, e.g., (Strech & Tilburt, 2008), (Furlan et al., 2015) or 
(Kobelt, 2013)). In part this appraisal must uncover to what extent each CEA 
in practice matches, or fails to match, ideal ‘utilitarian’ evaluation (Brock et 
al., 2016). Measurement problems, especially surrounding those important 
considerations which are simply not amenable to measurement (see, e.g., 
(Neumann et al., 2016) or (Feeny et al., 2016)), have always been around to 
thwart the utilitarian project (Jonsen, 1986). Given the above, three key 
considerations which should be included when assessing the appropriateness 
of a CEA to a policy question would typically be: 
1. What potentially important costs have been omitted? 
2. What potentially important effects have been omitted? 
3. Are the methods used to combine the costs and effects appropriate?, 
especially in the particular decision context in question. 
As noted before, answers to these questions would require judgments to be 
made about how appropriately each CEA describes the likely relationship(s) 
between ‘important’ costs and effects of the intervention, be they measureable 
or intangible.  
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6.2 Two main ways to interpret CEA 
Armed with a preliminary interpretation of both the credibility of the CEA 
information per se and how the content of that information fits in the context 
of the holistic policy question (its appropriateness), there is now a need for a 
third aspect of interpretation: relative valuation. As noted above, CEA 
estimates are conditional on the methods used and on how successfully those 
methods have been applied, and appropriateness to the policy question of those 
estimates is case specific.  
In this third aspect of interpretation, namely relative valuation, judgment is 
also required relating to the term ‘cost-effectiveness’. Two approaches to this 
will be set out here. First, the dominant extra-welfarist approaches will be 
described, this is one which combines ICERs and a threshold (in the next sub-
section). Subsequently, the rationale for a second approach will be explained, 
this ‘classical’ approach combines, e.g., ICERs with information related to 
budget impact through deliberative processes (in sub-section 6.2.3). Before that, 
it will be useful to clarify the terms ‘cost-effectiveness’ and ‘cost-effective’, in 
order to help understand both of the above approaches to relative valuation.  
In the context of interpreting health-economic evaluation, statements are 
often made which claim that “intervention A is more cost-effective than 
intervention B”. Although even this relative statement is demanding in terms 
of its informational requirements, it merely expresses a comparison of the two 
interventions in relation to each other, i.e., a simple judgment concerning an 
ordinal relationship. The informational requirements referred to above would 
be that the measures or indicators underlying the CEA are of high enough 
quality, and are sufficiently apposite to the policy question, to feel able to draw 
a conclusion about intervention A being more cost-effective than intervention 
B. This expresses a relative, not absolute, valuation. On the other hand, a claim 
that “intervention A is cost-effective” is typically interpreted an absolute 
statement and, in addition to being demanding in terms of its informational 
requirements, requires a reference point. Any such claim is a double-edged 
sword, it inherently requires the use of some kind of ‘threshold’, but it also 
produces a statement which has some level of allocative or normative intent. 
Thus, in order to make statements absolute about ‘cost-effectiveness’ requires 
explicit or implicit value judgements to be made, but also produces a value-
laden conclusion. Two of the main approaches taken to these value judgments 
will be outlined in the next two sub-sections. 
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6.2.1 ‘Extra-welfarist’ interpretation of CEA 
Applications of the extra-welfarist approach generally utilise incremental cost-
effectiveness ratios (ICERs) in the form of mean cost-per-QALY estimates, 
with a notion of opportunity cost of the additional ‘health’ production also 
being expressed as some threshold, i.e., a cost-effectiveness-ratio threshold 
(CERT), somehow defined. The qualification ‘somehow defined’ can be seen as 
very important as although extra-welfarist approaches per se do not specify 
any particular maximand, any threshold, or any comparative standard, would 
ideally be defined in exactly the same terms. A less common approach, which 
ostensibly compares estimates of ICERs for similarly-assessed technologies, 
employs a ‘league table’, i.e., a ranking of comparator interventions (Williams, 
1985). When considering the more common threshold approach (Culyer et al., 
2007), it should be remembered that the QALY approach is itself a concept 
that is applied using many different methods, with a variety quality-
adjustment ‘measures’ available, i.e., different health-related quality-of-life 
indicators capturing any of a range of different dimensions of health status 
and its valuation (Richardson et al., 2016). It should also be noted here that 
similar variations in methods affects the estimation of average changes in the 
number of life years which is also part of the QALY ‘metric’. To summarise 
the above, the claim is made here that the QALY is not really a measure, it is 
more a concept and an approach, i.e., an indicator of quality of life over a 
specified period. 
In a similar manner, although health status is usually assigned a number or 
weight, there are many different processes and rules under which such 
estimates or indicators of health status are produced (Booth et al., 2014a) 
(either in a generic or specific sense (Brommels & Sintonen, 2001)). Further, 
QALY estimates, however they are derived, in practice are typically 
underpinned by a RCT-based, bio-clinical model of inputs and outputs relating 
to the disease in question (Garrison et al., 2018), even this approach has its 
weaknesses. For example, RCTs can provide information on the average 
treatment effect in terms of effects and costs, but in the presence of outliers 
they are likely to be deficient (Deaton & Cartwright, 2018). 
Although it is quite widely thought that QALY approaches can, in many 
circumstances, provide a useful representation of the value of health status, it 
often only provides an inherently partial estimate of changes in ‘health’ 
(Loomes & McKenzie, 1989). To be more precise the QALY approach typically 
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only provides an inherently partial estimate of changes in ‘some health-status-
measure -proxy for a quasi-societal valuation of health’. The practical 
relevance of this is that EWHEE, rather than promoting maximum ‘health’ 
gain, typically only maximises QALYs, which tends not to maximise health 
per se (Mooney, 1989). Despite these limitations, a variety of manifestations 
of the QALY framework are often proffered as the ‘best available’ approach 
for the (quasi-)systematic, quantification of a generic concept of ‘health’  
(see, e.g., (Garrison et al., 2018), (Thokala et al., 2018) or (Neumann et al., 
2016)).  
The suggestion is made that, rather than relying on any such ‘best available’ 
extra-welfarist CEA approach, even merely as a starting point for discussion, 
its every application should be subjected to appropriate quality assessment (in 
line with Sub-section 6.1). The extra-welfarist CEA approach promises much, 
but can fail to deliver on those promises, one way in which this failure can 
occur is the focus of the next sub-section; i.e., on the extra-welfarist approach 
which compares mean cost-per-QALY in relation to some threshold value 
(McCabe et al., 2008). 
6.2.2 Critique of the current state of the art 
The relevance of extra-welfarist approaches to policy-making processes is limited 
in both principle and practice. One practical criticism of extra-welfarist 
approaches is the lack of commensurability between CEAs and, although this 
problem may be mitigated by the use of a reference case, reference cases are only 
guidelines and not always practicable prescriptive rules (see, e.g., (National 
Institute for Health and Care Excellence, 2013) and (Neumann & Sanders, 2017)). 
Indeed, as commensurability is diminished by natural, understandable and 
legitimate variations between CEAs, this would seem to provide one reason 
why a single CERT, i.e., a threshold or threshold range for cost-effectiveness, 
would not seem to be a wholly justifiable standard in practice; either within a 
single organisation (e.g., NICE (National Institute for Health and Care 
Excellence, 2017)), or even within a single programme (e.g., NICE’s single 
technology appraisal (STA) process). Indeed, the current absence of unified 
guidelines for health-economic evaluation would seem to confirm the earlier 
suggestions that, a priori, it is unwise to determine which type of study should 
be performed (Glick et al., 1994; McIntosh et al., 1999; Strech & Tilburt, 2008). 
The rather arbitrary and ad hoc nature of applied health-economic evaluation 
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seems abundantly clear, but, on the basis of the literature review undertaken 
for the current study, seems rarely to have been acknowledged by many of its 
staunchest supporters (Drummond et al., 2015). That said, that hard line 
might now be softening, with one commentator increasingly making reference 
to health-economic evaluation as a skilled art (Culyer, 2014, p. 438; Culyer, 
2018), rather than his previous comments describing it as an applied science 
(see, e.g., (Culyer, 1976, p. viii)). A second reason for doubting the practical 
usefulness of a threshold stems from the fact that a threshold relates to extra-
welfarist principles, the idea of a threshold is little more than a postulate and 
seems only adequate for something akin to abstract Pigouvian theorising 
(Pigou, 1947, p. 31). Such marginalist ideas tend to detach themselves from 
discussions about value, instead ‘value’ in marginalist theory is assumed to be 
encompassed by price (Klarman, 1965, p. 171). These price-based marginalist 
theories of ‘value’ seem to be debunked, on the one hand due to the practical 
heterogeneity of CEA methods and, on the other, by the principled need for 
deliberation and judgment about what society values within decision 
processes. Indeed, weaknesses in the notion of the cost-per-QALY threshold 
can also be a seen as weaknesses in the notion of the label ‘value for money’, 
often used by some health economists. This is because, given the absence of a 
market and the absence of a threshold price, CEA cannot provide more than 
partial information regarding ‘value for money’, as alluded to in the following 
quote: 
“It must ultimately be recognized that only within rather narrow limits can 
human conduct be interpreted as the creation of values of such definiteness and 
stability that they can serve as scientific data, that life is fundamentally an 
exploration in the field of values itself and not a mere matter of producing given 
values. When this is clearly seen, it will be apparent why so much discussion of 
social efficiency has been so futile.” (Knight, 1923) 
As already noted in sub-section 4.3, due to a dearth of widely-accepted 
quality-assessment guidelines for CEA, it typically remains a matter of 
subjective judgment as to what extent any CEA successfully provides robust 
evidence. The estimates of costs, effects and cost-effectiveness are not 
immutable facts (Williams, 1974). Economic evaluation is most often not based 
on wholly systematic, wholly reproducible, or wholly objective scientific 
research, it is merely partial evaluation: in each application of health-economic 
evaluation the economic value framework in question per se provides the value-
laden framework for valuation.  
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One succinct way to convey some of the above reasoning is via a cartoon, 
as in Figure 6, below. This cartoon can, of course, be interpreted in many ways, 
but it does seem to skilfully and aesthetically encapsulate the idea of a ‘market’ 
for QALYs.  
 
Figure 6.  A satirical cartoon about health economics and planning (Paddison, 1986) (reprinted with the 
permission of the artist) 
In line with the rest of the current study, a number of interpretations are 
suggested for this cartoon. It should immediately alert us to the relative inertia 
of CERT estimates: the mythical figure of £30,000 per QALY is still one of 
the most widely quoted in the literature even today, and many health 
economists feel that fact alone should raise alarm bells (Caro et al., 2010).  
Figure 6 could also be interpreted to reveal the power of voice, as described 
by the ‘all-singing, all-dancing’ -members of “Social Class One”, as well as the 
ubiquitous presence and power of civil servants or decision-makers. It nicely 
illustrates that the use of an approach which includes CERTs would 
necessarily include a need for judgment on the part of any single decision 
maker and, fittingly, in this figure there are many. Further, Figure 6, with the 
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brevity only art can muster, describes the lack of reality of a fixed CERT 
(Coast, 2017): this is a sale room. In a sale room, the idea that “a QALY is a 
QALY is a QALY” is soundly rejected, a myriad of factors affect how those 
on display perform, as well as how bidders react. Thus indicating that, rather 
than there being an orthodox, neoclassical, market-clearing price, the 
valuation of QALYs is better depicted as an auction. In an auction, value will, 
in part, always be ‘in the eye of the beholder’ (the bidder), in part being 
tempered to some extent by the other bidders in what could be described as a 
quasi-market. An alternative interpretation would be that the saleroom itself 
(the system of economic evaluation itself) has a purpose, it exists in order to 
serve the needs of the vendors (the most powerful of whom in this case could, 
e.g., be the pharmaceutical industry). However, even if we do not agree with 
the assumptions necessary to create a price-hiking neoclassical economic 
market, i.e., the central tenet of EWHEE approaches, a functioning market, 
seems nonsensical (Self, 1970).  
A fitting paraphrase might now be that “QALYs are not QALYs are not 
QALYs”: they are typically dependent on who gets them, as represented in 
the cartoon by the many and varied potential recipients of priority. Williams 
also offered the following challenge (in a paper published posthumously): 
“The assertion is that, from a public policy perspective we assume that the 
value of a QALY is the same no matter who gets it. Anyone is free to 
challenge that assumption and propose another, and we could then examine 
the differential consequences for priority setting. But some assumption has 
to be made and justified.” (Williams, 2005) 
In response to the challenge Williams laid down, it no longer seems 
sustainable to rely on a fixed cost-per-QALY threshold for heterogeneous 
impacts on difficult-to-measure ‘health’ (Booth, 2019a). The current study 
strongly suggests that value is not confined to QALYs, higher-order values 
and value definitely exist, and would seem to require both respect and 
recognition. A more nuanced approach seems necessary as assuming that the 
value of a QALY is the same no matter who receives it, or assuming that the 
QALY encapsulates all dimensions of value, is simply too abstract for 
uncritical use in robust planning. A suggested alternative approach will be 
outlined in the next sub-section, in line with the idea that a range of different 
evaluative approaches will likely be useful in order to encapsulate these higher-
order values. EWHEE has a tendency to focus on its own efficiency indicators, 
potentially to the detriment of other considerations. Examples include a 
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tendency to ignore any budgetary impact of the efficiency measures it 
produces (Birch & Gafni, 2003; Garrison et al., 2018), as well as its tendency 
to focus on the magnitude of any ICER, even when the absolute size of the 
health impact may carry more weight with many stakeholders (Kelleher, 
2014).  
In addition, the phrase ‘decision rule’, which has a strict meaning within 
abstract decision-analytical approaches, does not necessarily have much 
meaning outside the EWHEE approach in question. Such potentially 
misleading EWHEE terminology may also contribute to the crowding out of 
other values from prioritisation processes, by raising expectations that the 
EWHEE approach could have a direct impact on the decision per se (Booth, 
2019b). To reiterate, the output of these neo-classical economic or 
management science -solutions do not typically offer holistic evaluation, they 
are too partial; they do not normally take into account effects as disparate as 
patient satisfaction, medical-industry profits, or environmental sustainability.  
Orthodox economics makes an abstraction, simplifies choice problems by 
making them peculiarly narrow, perhaps mainly in order to make them 
amenable to the decision-analytic approaches of management science. Simple 
notions of economic efficiency can cause the neglect of higher-level efficiency, 
i.e., the second and higher-order effects of policies, e.g., those related to system 
sustainability or community values. In summary, the main critique of the 
current ‘state of the art’ in extra-welfarist health-economic evaluation is that 
it does not do enough in distinguishing between some of the abstract principles 
related to health-economic evaluation and the information it can provide to 
prioritisation processes (Booth, 2019a). This failure likely results in an 
increased likelihood that we forget the important opportunity costs of taking 
the wider range of into account.  
To largely ignore many of the above issues, as some extra-welfarist 
economists sometimes seem to do (Green, 1990), in rhetoric or in practice, 
seems arrogant. For that reason if no other, an alternative assumption will be 
proposed in the next sub-section to help return to the foundations of HTA 
(Daddario, 1968). This proposal aims to supplement the often simplistic and 
flawed approaches to measurement used by neo-classical economics, in order 
to better take into account the second and higher-order effects of policies.  
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6.2.3 A more classical approach to interpreting CEA 
Given the critique presented in the earlier parts of the current study, and 
especially those outlined in the previous sub-section, the use of approaches 
relying on a single threshold (or threshold range), or on contingent valuation 
methods, are now taken to be soundly rejected as comprehensive solutions. 
The rejection of these mainstream neo-classical economic approaches in part 
stems from the inherent conflict between restricting the scope of measurement 
to a core set of dimensions (in order to facilitate comparability and 
commensurability) and the aim of producing comprehensive valuation. 
Because the measures available cannot always be successfully applied, CEA 
information typically remains incomplete, i.e., truncated and partial analysis 
(see, e.g., sub-sections 4.3, 4.4 or 5.4, or (Quade, 1967)). Quantitative analysis 
is also limited by the presence of intangibles, i.e., entities which cannot be 
measured, or those that cannot be accurately or precisely measured. In order 
to understand what each application of CEA means, it is crucial to be able 
understand what is included, what is left out from almost all of its many forms: 
CEA usually misses out essential dimensions relevant to many prioritisation 
processes (see, e.g., (Quade, 1967), (Wiseman, 1989a) and Article III). To 
recap, any decision-maker must decide the relative worth of the efficiency 
indicator as estimated in the study, and is under no constraint, logical or 
otherwise, to apply a fixed value to, e.g., QALYs in different settings (Evans, 
1984, p. 262).  
For these reasons a more ‘classical’ approach to interpreting CEA is 
proposed below: in line with one original aim of cost-benefit thinking (Franklin, 
1772), of course CEA does indicate a form of economic efficiency, but 
potentially that is all it indicates, it does not, on its own, necessarily indicate 
‘worth’ or ‘value for money’. Therefore, the claim is made here that the most 
appropriate interpretation of information typically provided by CEA is that it 
provides an unreliable indicator of some form of economic efficiency. Broader 
interpretations, i.e., those which could be more closely related to ‘worth’ or 
‘value for money’ would seem better served by a process of judgment, as part 
of what the current study calls classical HEE (CHEE). Under CHEE, value is 
defined by a deliberative process, by deliberative analysis of all the available 
information, rather than by reference to any ‘threshold’ or any associated 
‘decision rule’ under EWHEE, or by accepting the results of, e.g., the 
contingent valuation approach under WHEE. In short, CHEE can be described 
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as a responsive approach, rather than the rather pre-defined frameworks 
typical in EWHEE or WHEE. For example, consideration of the extent to 
which a technology transfers resources from consumers or taxpayers to the 
producer of a technology, i.e., the level of industry profits which necessary, 
normal, optimal or fair may be warranted (Brouwer et al., 2019) 
6.3 CEA in relation to holistic evaluation 
6.3.1 What can deliberative analysis add? 
Previous sub-sections have provided a number of reasons why, in contrast to 
the view of (Drummond et al., 2015, p. 314), health-economic evaluation does 
not provide a thorough assessment of ‘value for money’. Instead, this sub-
section attempts to outline in what ways EWHEE and WHEE typically 
address elements of related policy questions and, just as importantly, fail to 
address ‘efficiency’ in a wider sense (Wildavsky, 1967) as noted in sub-section 
5.10. This outline also proposes the use of CHEE and tries to explain and 
promote that proposition using an ‘economic value plane’, i.e., a representation 
of three dimensions of economic value, in Figure 7. 
In the figure below, some of the reviewed literature on HEE and 
prioritisation is drawn together (e.g., (Norwegian Ministry of Health and 
Care Services, 2017), (Booth et al., 2017) and (Liliemark et al., 2016)). This 
figure depicts three dimensions along which different approaches to HEE 
contribute varying amounts of information about ‘economic value’ to 
prioritisation processes. Depending on the jurisdiction or on the technology 
in question, prioritisation processes may stress differently the importance of 
(1) information about need in terms of the ‘efficiency’ of the technology (in 
the form of a programme’s ICER), (2) information about resource use (in the 
form of a programme’s budget impact), and (3) information about other 
aspects of ‘economic value’ (including both appraisal of the qualities of any 
formal analysis in dimensions (1) and (2), as well as interpretation of any 
other evidence or values in dimension (3), in line with Sub-section 6.1.). It 
should also be noted that, from a strict welfarist perspective, economic 
efficiency cannot be established independently of the budget impact, since 
budget impact determines the resource requirements to be found from 
elsewhere and hence the benefits to be forgone. As a result these two 
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economic elements are not separate dimensions from a WHEE perspective. 
Despite this, it seems instructive to see the potential interplay between likely 
important dimensions of ‘economic value’ in Figure 7. For instance using 
CHEE, a mean ICER estimate for a technology could be relatively high (even 
after the quality of the evidence for the estimated mean ICER has been 
independently assessed) and the estimated budget impact of a technology 
could also be large. However, even in such a case, under CHEE, if there are 
other important ‘economic’ considerations with a positive impact on value, 
then this technology could still achieve a relatively high point on this 
‘economic value plane’ (as marked by the red ellipse, with points towards the 
North-East typically preferable to those in the South-West). In this 
hypothetical example there are also two other small, coloured ellipses, the 
magenta ellipse is gives an example of the ‘economic value’ conferred via 
EWHEE and the navy blue one an example of the ‘economic value’ conferred 
via WHEE. Together these three ellipses show that different economic value 
will be placed on the same technology, by the different approaches to HEE 
(as set out in Article III), in part due to the extent to which they provide 
information on the three dimensions presented. Wider notions of value, from 
other non-economic viewpoints or from other disciplines may, of course, 
further modify their position after this analysis of ‘economic value’ (Dobrow 
et al., 2004). It is also acknowledged that post-HEE deliberation can take 
place under any approach to HEE, and as this could result in all three 
approaches ending up at very near the same value point on a ‘decision-making 
value plane’ (not depicted here). Beyond this ‘economic value plane’, 
dependent on the types of health-economic evaluation sought and obtained, 
there are still obvious opportunities for other values to enter any appraisal 
process. Two significant points should be noted, first that CHEE is unlikely 
to be anything like an exact science (Baltussen et al., 2017; Marsh et al., 
2017), and second that typically each health-economic evaluation will tend to 
produce one single-shot CEA (even though this will be often include 
sensitivity analyses), i.e., one description of ‘economic’ value. 
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Figure 7.  An ‘economic’ value plane 
Other aspects of need, assessed in a quantitative manner could be 
incorporated into the third dimension of this figure (Klarman, 1965, p. 172). 
However, as Figure 7 represents an economic value plane, if qualitative or 
deliberative evidence is included in the chosen approach to economic value, a 
situation could result where ‘economic’ value becomes indistinguishable from 
holistic value. If such a point is reached, then it could be claimed that a ‘cost-
benefit thinking’ -ideal would have had been reached, too. Economic 
evaluation has been transformed into valuation per se.  This plane is intended 
as an informative descriptive device, a helpful representation, to try and help 
users of information from health-economic evaluations think about what 
different forms of health-economic evaluation might offer in terms of a 
holistic interpretation of value, a point to which the thesis will now turn for 
the CEA of the FinRSPC.  
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6.3.2 Interpretation of the FinRSPC’s CEA information 
In this sub-section some of the qualities of the components of the CEA of the 
FinRSPC in relation to the broad policy question mentioned in Section 3: “Can 
economic evaluation help us to know if prostate-cancer screening is 
‘worthwhile’?”, are briefly described. However, when looking at the following 
‘results’, it should also be kept firmly in mind, e.g., that this health-economic 
evaluation of the FinRSPC is an evaluation of historical effectiveness and 
practices, in a particular Finnish setting. All of the results here are therefore 
truncated temporally and in terms of both generalisability or scope.  
As can be seen from Table 3, below, an attempt will be made not oversell 
the results of the health-economic evaluation of the FinRSPC. Table 3 shows 
that, even at a level of granularity suitable to avoid excessive cognitive burden 
(Miller, 1956), numerous questions remain to be answered before being able to 
make informed judgments related to the pros and cons of prostate-cancer 
screening (Steineck et al., 2019). Table 3 is not meant to be a once-and-for-all 
answer as to the ‘economic value’ of prostate-cancer screening, rather it is 
meant to be a work-in-progress and updated iteratively in accordance with 
Figure 1, in Sub-section 5.4.  
Table 3. A preliminary set of results from cost-benefit thinking about prostate-cancer screening, on the 
basis of the FinRSPC after 20 years of the trial. 
Pros of prostate-cancer screening Cons of prostate-cancer screening 
Men saved from prostate cancer death, 
on average? 
Men overdiagnosed with prostate 
cancer? 
Lives of some men lengthened, on 
average? 
Lives of some men shortened, on 
average? 
Positive HRQoL impact in men treated, 
on average? (men (over)treated for 
indolent cancers may rate up their 
HRQoL despite experiencing negative 
side effects) 
An increased need for incontinence pads 
or pants, on average? 
Decreased costs for some groups of 
men, on average? 
Increased costs for some groups of men, 
on average? 
…this list could be supplemented and 
updated as more information becomes 
available, and as deliberative analysis 
proceeds…  
…this list could be supplemented and 
updated as more information becomes 
available, and as deliberative analysis 
proceeds…  
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As noted in Table 3, cost-benefit thinking would be supplemented and 
updated through a deliberative process as more robust and relevant 
information becomes available. The uncertainty described in Table 3 can be 
seen as debilitating, or as empowering, but it is the contention of this thesis 
that the lack of relevant information and the lack of ability to obtain 
appropriate information should be acknowledged (Kay & King, 2020). It seems 
useful to know that this health-economic evaluation of the FinRSPC contains 
few robust results, and clearly only provides a very partial answer to the 
tentative policy question: “Can economic evaluation help us to know if 
prostate-cancer screening is ‘worthwhile’?”. However, one tentative response 
can be given, that health-economic evaluation helps in revealing the lack of 
knowledge about whether or not “prostate-cancer screening is ‘worthwhile’?”. 
This in itself may be an important finding, and is supported by the suggestion 
that incredible certitude should be avoided (Manski, 2019). 
Further, the FinRSPC-study results presented here cannot offer any 
prescriptive conclusion or policy advice, other than that it casts more than a 
little doubt on some aspects of earlier modelling studies. The suggestion of this 
thesis is that information from CEA can be usefully supplemented by other 
information, including health-economic information, is not new (Brousselle & 
Lessard, 2011; Coast, 2004). However, the suggestion that the qualities of 
health-economic evaluation be assessed in relation to what might be expected 
by decision-makers from more holistic evaluation, i.e., that deliberative 
analysis be used, appears to be a rarely-raised one in the current literature on 
health-economic evaluation. Despite challenging entrenched interests, the 
contribution of highlighting misleading language and practices in dominant 
forms of health-economic evaluation is a relatively simple one, and its worth 
will be left for the reader to decide.   
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7 Conclusions 
The primary aim of the current study is not to denigrate economic evaluation, 
but to make its scope clear and to discuss its problems, limitations and 
potentials. The aim is to promote deeper understanding of the information 
which economic evaluation can provide. First, conclusions will be made about 
what it would be useful to understand in general about economic evaluation. 
Namely that, given the terminology of health-economic evaluation, the 
frequent deficiencies in the data or assumptions underlying analysis and the 
intentionally restricted scope of some approaches to economic evaluation, 
there will typically be many benefits in extending and checking the 
information provided by many approaches to health-economic evaluation. 
7.1 What should be known about economic evaluation? 
Economic evaluation tends to focus on measures of efficiency which do not 
encompass all relevant impacts on health, well-being or costs. Further, 
approaches to economic evaluation are usually forced to make strong 
assumptions in the estimation of costs and benefits. The resulting numerical 
representations should only be treated as meaningful when such meaning is 
warranted. In principle at least, this places demands on anyone producing or 
using cost-effectiveness analysis (CEA), as although efficiency can be 
interpreted as a simple concept, when applied to health care it is 
fundamentally complicated by measurement problems. These measurement 
problems include the wholly intangible, as well as the partially intangible: 
such as impacts which may not be captured satisfactorily when undertaking 
health-related quality-of-life measurement using generic health-related 
quality-of-life measures. In order to understand if efficiency indicators are 
misleading, disingenuous, or worse, economic evaluations need to be checked. 
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7.1.1 Efficiency is protean and needs to be checked 
Information about efficiency varies and, therefore, needs to be judged in light 
of its credibility and appropriateness: it needs to be checked. Without the 
appraisal suggested in this thesis, without judgement, there can be an 
unnecessary fear of inefficiency or, alternatively, an unwarranted 
acceptance of being efficient at the wrong thing. As CEA is often performed 
with narrow measures of effectiveness, decision-makers should always judge 
whether or not the effectiveness measure in question offers ‘appropriate’ 
information to each particular decision-making process. 
Sometimes a single efficiency measure will simply not be appropriate, even 
as only a ‘starting point’ for discussion. Because of the inherent variation in 
the quality of information provided by health-economic evaluations, 
generalisations about its usefulness as a concept, as well as the usefulness of 
any information it produces, should not be made. Instead, each CEA must be 
judged on its own merits in the context to which it is being applied. 
7.1.2 Simplification and meaning 
Assessment is fundamental to planning, but the extent to which 
‘measurement’ contributes to planning should depend on the quality and 
relevance of that measurement. By restricting the scope of CEA, consistency 
between evaluations using CEA can be increased. However, this increase in 
consistency will often come at the expense of CEA no longer faithfully 
addressing policy questions. This should also be kept in mind when 
interpreting indicators such as those produced via CEA. On the other hand, 
classical health-economic evaluation (CHEE) is typically more likely to 
require serious thought and discussion, but may be easier to defend to 
stakeholders due to its flexibility in what dimensions of value it can consider. 
Extra-welfarist health-economic evaluation (EWHEE) may place less of a 
cognitive burden on decision-makers. but may be harder to defend, due to its 
often misleading one-size-fits-all approaches.  
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7.1.3 Known unknowns about economic evaluation? 
Information stemming from health-economic evaluation should not be 
allowed to shut down or excessively crowd out awareness and debate about 
other important considerations. Nor should health-economic evaluation be 
allowed to crowd out a wider discussion of what society might want from its 
health and social care systems, or how much they may want to pay for these 
in total. For example, there is likely to be a balance to be struck between 
providing care to patients ‘at any price’ and fuelling the profits of national 
or multi-national private-sector companies. There are numerous impacts 
which may be considered to be legitimate or relevant, but some, like 
shareholder dividends from the medical industry, seem conspicuous by their 
absence from the majority of recent health-economic evaluation literature. 
Other, often relatively hidden or ignored, impacts are those related to the 
environment, the potentially vested interests of healthcare professionals, and 
the vested interests of researchers, to name but three. Prioritisation systems 
might be wise to take into account sustainability in all its forms, both within 
and without the health and social care sectors. 
This sub-section leads to the first key recommendation: In order to be 
put into the correct context, claims about CEA, as a truncated form of 
efficiency indicator, should always be accompanied by an assessment of what 
is covered by the efficiency indicator, how well it is measured and what is left 
out. The credibility and appropriateness of CEA have central a role to play in 
defining its ability to contribute both to decision-making processes and to more 
comprehensive valuation. Only when CEA’s limitations are clear can broader, 
higher-level efficiency, i.e., value, be properly assessed.  
7.2 Evidence about prostate-cancer screening? 
On the basis of the findings added by this study, evidence is still inadequate, 
plenty is still not known. Ambiguity remains, even after 20 years of the 
FinRSPC, as the analysis undertaken here is, given the uncertain public-
health impact of prostate-cancer screening, still a relatively small sample 
population. Due to the relatively short follow-up (in part given the nature of 
prostate cancer as a disease), and given the probable influence of context, 
i.e., of socio-economic, environmental and clinical variation, impacts remain 
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uncertain. That said, the CEA of the FinRSPC so far finds there may be 
causes for concern about the impact of prostate-cancer screening on some 
diagnosed men. However, here the claim will be made that the direction, size 
and nature of many of the impacts of prostate-cancer screening are not fully 
able to be described with sufficient certainty, at least not at this point in 
time and not from this single RCT alone.  
Evidence, even in the presence of many unknowns can be informative, but 
researchers should make it clearer that the evidence on prostate-cancer 
screening is still deficient in many ways and it is unlikely that stakeholders 
can be ‘fully’ informed. It should be clear that ‘evidence-based’ or 
‘evidence-informed’ does not necessarily mean ‘well informed’, because it 
seems unlikely to be possible to fully understand the risks and benefits of 
screening at this point in time. Rather than unthinking repetition (or 
synthesis) of earlier methods or studies, an investment of time and resources 
in RCT and registry-based CEAs could check if the focus of earlier studies has 
been misplaced.  
7.2.1 A need for studies in future? 
Given the uncertainties revealed by this study, further studies trying to 
assess the cost-effectiveness of prostate-cancer screening should be wary 
about their analyses until more is known about the extent to which the 
findings from the current study, especially in terms of men likely 
overdiagnosed in the screening arm, might be generalisable. If registers do 
not contain information on HRQoL or other health-related outcomes, or if all 
treatments are not fully and consistently recorded, then there may be large 
gaps in knowledge within any future research. Robust evaluation would 
require the correct information to be collected at regular and appropriate 
intervals, from a sufficiently large and representative target group.  
Given the above, the second key recommendation is: In order to be better 
informed about the possible benefits and harms of prostate-cancer screening, 
analysis would first need be undertaken to investigate if robust information 
about overdiagnosis or all-cause mortality could be produced. If the 
possibilities for the production of such information are slim, the chronic lack 
of robust information about many of the costs and benefits of screening should 
be more widely acknowledged. 
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7.3 CEA evidence and decisions: what is missing? 
Given the difficulties with application of CEA to as complex a question as 
prostate-cancer mass screening, we should not be surprised by the lack of 
adequate evidence, just humble about what we know, and honest about what 
we don’t know. 
It should be noted that the information that comes from health-economic 
and epidemiological studies has a tendency to be bound to the conventions of 
that type of research. If cancer screening is evaluated in epidemiology 
primarily through analysis of target-cancer-specific mortality, it may miss 
other important effects. If health-economic evaluation follows such 
conventions or, say, the conventions of extra-welfarist modelling, and if any 
of those conventions are misleading in some way, then errors may remain 
undiscovered. 
It also seems useful here to spell out the danger of deciding too hastily 
about prostate-cancer screening, and of appearing too certain about what is 
known. If the average effects, i.e. the indicators, measures and estimates, 
which often underpin health-economic evaluation are deficient or otherwise 
misleading, then the results of CEAs which use them may well be deficient 
or otherwise misleading, too. Perhaps only a mix of disciplines, challenging 
and supporting each other to make progress by challenging research 
conventions can provide a more complete, nuanced and realistic analysis.  
On some occasions formal analysis will undoubtedly play a major role in 
decision-making, on some occasions only a minor role: this uncertainty about 
the role of CEA, the variability in its likely importance, is itself an important 
message. This message is repeated here in an attempt to reduce the 
overselling and arrogance which is problematic within the field of health-
economic evaluation and beyond. 
Sometimes CEA could be a starting point for discussions, sometimes its 
results could even be the deciding factor in discussions, sometimes its results 
mislead, but on all occasions its qualities should be checked. For this reason 
the third key recommendation is that CEA, classical health-economic 
evaluation, as well as deliberative analysis, would all be used as part of 
planning processes. 
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7.3.1 New interpretations of information from CEA? 
The thesis presented here is that, firstly, interpretation of any CEA requires 
an understanding about which of the different approaches to economic 
evaluation is being used and what that particular method can offer in 
principle. Secondly, it requires an understanding of the extent the chosen 
method or methods have succeeded in producing useful information on a case-
by-case basis in practice. Only then can that information gained from those 
assessment processes be appraised in light of other considerations. Each 
application of economic evaluation should be subjected to thorough 
interpretation by each stakeholder, being supplemented by other information 
when necessary. Given the complexities of many of the topics to which 
economic evaluation is applied in the field of health, simple interpretation 
will rarely be possible. 
Stakeholders should be aware of the variability in the quality of economic 
evaluations, as well as the absence of any quality-assessment tool which would 
be capable of distinguishing between economic evaluations that are highly 
relevant, and those that are highly misleading. Given the apparent lack of 
suitable quality-assessment tools, stakeholders could benefit from processes 
which include deliberative analysis, which, in turn, relies on judgment. 
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1. Introduction
Information on the balance of benefits and adverse effects of
screening, which includes quantification of health-related
quality of life (HRQoL), is an important aspect of research
and relevant for both clinical and health-care decision
making [1,2]. There are many ways of measuring HRQoL
aimed at capturing the overall effects of an intervention on
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Abstract
Background: Evidence of the potential impact of systematic screening for prostate
cancer (PCa) on health-related quality of life (HRQoL) at a population-based level is
currently scarce.
Objective: This study aims to quantify the long-term HRQoL impact associated with
screening for PCa.
Design, setting, and participants: Postal questionnaire surveys were conducted in 1998,
2000, 2004, and 2011 among men in the Finnish PCa screening trial diagnosed with PCa
(total n = 7011) and among a random subsample of the trial population (n = 2200). In
2011, for example, 1587 responses were received from men with PCa in the screening
arm and 1706 from men in the control arm. In addition, from the trial subsample, 549
men in the screening arm and 539 in the control arm provided responses.
Outcome measurements and statistical analysis: Health-state-value scores were com-
pared between the intervention and control arms using three distinct HRQoL measures
(15D, EQ-5D, and SF-6D), and statistical significance was assessed using t tests. In
addition, differences over repeated assessments of HRQoL between groups were evalu-
ated using generalised estimating equations.
Results and limitations: In the 2011 survey, a small but statistically significant differ-
ence emerged between the trial arms among men diagnosed with PCa (mean scores,
screening vs control arm: 15D: 0.872 vs 0.866, p = 0.14; EQ-5D: 0.852 vs 0.831, p = 0.03;
and SF-6D: 0.763 vs 0.756, p = 0.06). Such differences in favour of the screening armwere
not found among the sample of men from the trial (15D: 0.889 vs 0.892, p = 0.62; EQ-5D:
0.831 vs 0.852, p = 0.08; and SF-6D: 0.775 vs 0.777, p = 0.88). The slight advantage with
screening amongmenwith PCawas reasonably consistent across time in the longitudinal
analysis and was strongest among men with early-stage disease.
Conclusions: These results show some long-termHRQoL benefit from screening for men
with PCa but suggest little impact overall in the trial population.
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functional capacity, well-being, and health [3]. One
approach, commonly advocated by health economists, uses
utility values for health states (ie, health-state-value
scores), which can subsequently be used in the calculation
of quality-adjusted life-years (QALYs) [4].
This study presents the results of HRQoL surveys carried
out as part of an economic evaluation of the Finnish
population-based randomised controlled trial of screening
for prostate cancer (FinRSPC) [5,6]. The trial has secondary
objectives of evaluating HRQoL and cost effectiveness. We
used three generic measures of HRQoL chosen in line with
the public health focus of the trial to facilitate future cost-
effectiveness estimations [7]. The mean health-state-value
scores are compared between the trial arms, separately
among men diagnosed with prostate cancer (PCa) and a
random subsample of the target population.
2. Methods
2.1. Trial background
The target population of the FinRSPC consisted of men born in from 1929
to 1944 who resided in the Helsinki or Tampere region during the
recruitment period (1996–1999) identified from the population registry
(n = 80 458). An exclusion criterion was a diagnosis of PCa before the
date of randomisation (obtained from the Finnish Cancer Registry). Men
who were known to have died, had prohibited use of their information
for research, or had moved outside the study area between randomisa-
tion and the date of mailing were also considered ineligible (n = 314).
The men in the screening arm were sent an invitation letter to
screening that also explained the study’s purpose and procedures, as
well as general information on PCa. Of the 31 866men contactable at the
time of invitation, 1597 were not sent an invitation because of logistical
problems. The men were invited for second and third screening rounds
Table 1 – Background information for the study participants in the two groups of men*
Random sample of all men in the trial
Screening arm Control arm
n Median IQR n Median IQR
Domicile
Helsinki 573 568
Tampere 180 185
Age, yr
1998 740 58.87 62.80–54.99 733 58.92 62.99–54.97
1999 748 60.09 64.07–56.18 752 60.11 64.19–56.17
2003 683 63.71 67.67–59.85 690 63.77 67.80–59.83
2011 549 71.63 75.70–67.79 539 71.61 75.66–67.83
Socioeconomic statusy
Upper 179 – – 174 – –
Middle 87 – – 92 – –
Lower 238 – – 227 – –
Men diagnosed with PCa
Domicile
Helsinki 2021 – – 1670 – –
Tampere 862 – – 700 – –
Age, yr
1998 146 64.34 67.65–60.31 34 63.81 67.50–60.71
1999 260 65.30 68.51–61.41 94 64.90 68.68–61.34
2003 890 67.46 71.03–63.95 536 67.67 70.83–63.71
2011 1587 73.56 77.08–70.04 1706 73.68 77.54–70.13
Time since diagnosis, yr
1998 145 1.61 2.08–1.17 34 1.78 2.18–1.39
1999 257 2.89 3.50–2.22 94 2.53 3.34–1.83
2003 890 3.63 5.24–1.94 536 2.92 4.22–1.49
2011 1313 8.00 10.81–5.57 1431 6.70 9.01–5.02
Tumour stagez
T1–2 2628 – – 1991 – –
T3–4 255 – – 379 – –
Socioeconomic status
Upper 807 – – 738 – –
Middle 301 – – 300 – –
Lower 1093 – – 890 – –
IQR = interquartile range; PCa = prostate cancer.
* The random sample of all men in the trial (formed in 1998) and the men diagnosed with prostate cancer (with new cases recruited at each round).
y The levels of socioeconomic status are defined in accordance with a classification developed by Statistics Finland [47].
z TNM T cancer stage classification category at the time of diagnosis with PCa [48].
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similarly, 4 and 8 yr after the first screen (although men >71 yr of age
were no longer invited, so those age 67 at the initial screen were invited
only twice). Information on screening invitations and attendance,
screening (prostate-specific antigen [PSA]) and diagnostic test results,
clinical information on PCa, and death were systematically recorded in
the trial database [8]. The control group received no systematic
invitation and were not contacted as part of the FinRSPC [9], except
for those in the trial population subsample who received postal
questionnaires.
2.2. Study materials
Two groups of men from the trial received postal questionnaires
concerning their HRQoL (Table 1 and Fig. 1). One group consisted ofmen
diagnosed with PCa by 1998, 1999, 2003, and 2011 who were identified
from the trial database and/or the Finnish Cancer Registry prior to each
of those time points. The second group of men was randomly sampled
from the men inducted to the FinRSPC in 1998, hereafter referred to as
the trial subsample. This trial subsample consisted of 2200 men: 1100
from the screening arm and 1100 men from the control arm. These same
2200 men were approached four times consecutively (in 1998, 1999,
2003, and 2011), although emigrated, deceased, and otherwise
untraceable men were not eligible. They were all free of PCa at baseline,
but 108 in the screening arm and 84 in the control arm were
subsequently diagnosed with the disease.
Data from the trial database and postal questionnaires for each
individual were interlinked using the Finnish system of unique personal
identity codes. Men with PCa gave consent to link questionnaire
responses with the trial database and cancer registry files in all rounds
of the questionnaire. Men in the 1998 random sample of all participants
(ie, in the trial subsample) consented in the latest questionnaire.
Investigators received authorisation from the Finnish National Institute
of Health and Welfare to use the questionnaire responses from the men
in the trial subsample during the other rounds. The study plan for this
study, as part of the economic evaluation, was reviewed by the Tampere
University Hospital ethics committee (reference number R05053).
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1998 1999 2003 2011
Unit response 733 752 690 539
Unit nonresponse 361 326 316 301
No address or dead 6 22 94 260
15D responses 729 742 688 522
EQ-5D responses N/A N/A N/A 514
SF-6D responses 688 697 656 483
1998 1999 2003 2011
Unit response 740 748 683 549
Unit nonresponse 354 326 328 279
No address or dead 6 26 89 272
15D responses 735 736 682 534
EQ-5D responses N/A N/A N/A 519
SF-6D responses 700 697 653 486
1998 1999 2003 2011
Unit response 36 97 536 1706
Unit nonresponse 3 6 80 613
No address or dead 1 3 55 177
15D responses 34 94 530 1644
EQ-5D responses N/A N/A N/A 1632
SF-6D responses 32 88 486 1521
Men identified from the Finnish Population Registry
as 55, 59, 63, or 67 yr of age in 10 municipalities in
the Helsinki and Tampere area in 1996, 1997,
1998, and 1999 (n = 80 458)
Excluded (n = 314)
Death, prostate cancer, emigration, etc.
Allocated to screening arm (n = 31 866)
No invitation due to logistical problems (n = 1597)
Received invitation (n = 30 269)
Allocated to control arm (n = 48 278)
Received no invitation (n = 48 278)
Trial allocation
Random sample of 1100 men drawn from each trial arm (in 1998)
Randomised (n = 80 144)
Enrolment
1998 1999 2003 2011
Unit response 148 272 891 1587
Unit nonresponse 12 20 86 430
No address or dead 4 14 89 145
15D responses 144 260 879 1539
EQ-5D responses N/A N/A N/A 1536
SF-6D responses 142 245 828 1423
Men diagnosed with prostate cancer
(recruited over the course of the trial)
Fig. 1 – Flowchart illustrating the data collection process. N/A = not applicable.
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The HRQoL questionnaires used in this study are the RAND 36-Item
Short Form Health Survey [10], which can be used to produce the SF-6D
measure [11]; the 15D health state description system [12]; and the EQ-
5D instrument (with the UK-TTO scoring system) [13]. Further details on
each of these measures can be obtained from online resources [14–16].
We used the SF-36 because it is one of the most widely used generic
HRQoL questionnaires and the 15Dmeasure because it is one of themost
comprehensive of the genericmeasures. In 2011, we also used the EQ-5D
because it is reported to be responsive [17] and one of the simplest and
most commonly used measures [18]. In line with standard use of these
measures, no attempt was made to correct for either EQ-5D or SF-6D
item nonresponse, but in cases of missing values for one to three
dimensions of the 15D, replacement values were imputed through linear
regression analysis using the remaining dimensions and age as
explanatory variables [19]. All these HRQoL measures, wherein higher
health-state-value scores are assumed to represent better outcomes, can
produce mean scores at group levels required to construct QALYs, which
can be used to provide information for health care policy decisions [20].
This study comprises both cross-sectional and longitudinal informa-
tion. Differences between the trial arms in the mean scores from the
2011 questionnaires were analysed using two sample mean comparison
tests. The HRQoL scores amongmen diagnosed with PCa were compared
with men from the trial subsample as the reference [21]. Finally,
differences in scores for both groups ofmen over time (longitudinal data)
were assessed using generalised estimating equations (GEEs). This
method can take into account correlations between intraindividual
observations in repeated assessments and makes use of each response
even if a man only responded to one questionnaire. The GEEmethod was
used to investigate the covariates of socioeconomic status, domicile, and
age group in the four rounds of postal questionnaires. For the analysis of
dropout (ie, nonresponse to the questionnaire tomenwith PCa), we used
logistic regression; in addition to investigating the association of
nonresponse with the trial arm, we included information on hospital
episodes during the study period and tumour stage at PCa (t tests),
available from the trial database.
3. Results
Between 1998 and 2011, HRQoL questionnaires with
responses were received from 5516 men in total (ie, from
79.4% of men who were alive and whose addresses were
available during the four questionnaire rounds). A maxi-
mum of four questionnaires were sent to the men with PCa
and four sent to the trial subsample. The total number of
responses from men with PCa during the whole study
period was 2898 in the screening arm and 2375 in the
control arm. The percentage ratio of the responders to the
total numbers of cases was 78.4% in the screening arm and
71.7% in the control arm (see also Fig. 1 [22]). Health-state-
value scores were able to be calculated for most men who
had returned their questionnaire; for example, HRQoL
scores from the 15D measure could be calculated for 94% of
respondents. The ability to calculate scores was similar,
although slightly lower, for the other HRQoL measures, the
EQ-5D and the SF-6D (Fig. 1).
3.1. Cross-sectional analyses
In 2011, the differences in mean HRQoL scores between the
trial arms were statistically significant only with the EQ-5D
measure and only among men with PCa (Fig. 2). The
difference in the EQ-5D score was an increment of 0.016 in
favour of the screening arm (p = 0.017); however, the 15D
also showed a smaller non-statistically-significant differ-
ence in HRQoL score (p = 0.007), for example. Regression
analysis confirmed that these results were also robust to
adjustment for time since diagnosis and PCa stage (not
shown).
For men from each arm of the trial subsample, no
statistically-significant differences were observed for any of
the measures (Fig. 3). Although when men diagnosed with
PCa were excluded from the analysis of the trial subsample,
scores were higher in the control arm (15D: 0.890 vs 0.895,
p = 0.55; EQ-5D: 0.830 vs 0.857, p = 0.04; and SF-6D: 0.777
vs 0.779, p = 0.80, not shown).
In the 2011 survey, the decrement in the mean HRQoL
scores of men with PCa relative to the trial subsample was
slightly more pronounced in the control arm than in the
screening arm (Fig. 4). In the control arm, themean scores of
all HRQoL measures for men with PCa were lower than
those for men from the trial subsample, whereas in the
screening arm men with stage T1 or T2 PCa had higher or
similar mean HRQoL scores than men from the trial
subsample (Fig. 5). Among men with stage T3 or T4 PCa
in both arms, a decrement in mean HRQoL scores was
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Fig. 2 – Differences in mean health-related quality-of-life scores in 2011
between the Finnish prostate cancer (PCa) screening trial arms for men
diagnosed with PCa (p values refer to two-sided t tests).
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Fig. 3 – Differences in mean health-related quality-of-life scores in 2011
between the Finnish prostate cancer screening trial arms in a random
sample of trial participants (p values refer to two-sided t tests).
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apparent for men in the control arm and the screening arm,
in comparison with the reference group of men from the
trial subsample (Fig. 6).
3.2. Longitudinal analysis
In the longitudinal data analysis for men from the trial
subsample, using data collected between 1998 and 2011,
only age and socioeconomic status were statistically
significant determinants of the 15D score (Table 2), but
no such differences were found between trial arms or
localities (domicile in the Helsinki or Tampere area). For
men with PCa, the mean 15D scores in all surveys for
men in the screening arm were higher (by an increment of
0.01) than in the control arm after adjustment for age,
domicile, and socioeconomic status (see Table 3 and Fig. 7).
Statistically significant reductions in 15D scores were also
associated with lower socioeconomic status, residence in
the Tampere area, and increased age.
Table 4 extends the analysis to compare the HRQoL
scores ofmenwith screen-positive PCa to those ofmenwith
PCa in the control arm. The regression results were very
similar to those in Table 3, but the screen-positive men in
the screening arm had a larger increment, 0.016, in their
mean 15D scores.
3.3. Nonresponse analysis
In the dropout analysis for the 2011 survey among men
with PCa, no statistically significant difference in nonpar-
ticipation was observed between the trial arms (Table 5).
Being older age and advanced cancer (stage T3–4 compared
with T1–2) were associated with nonresponse, and a lower
risk of nonresponse was associated with an episode of
hospital care during the study period. Similar analysis was
undertaken for the 2003 survey, with comparable results
(not shown).
4. Discussion
The public-health impact of PCa screening potentially
involves mortality reduction, changes in the use of
health-care resources, and an impact on morbidity by
reducing advanced PCa, but also adverse effects of
screening. Here we used several generic measures of health
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Fig. 6 – Differences in mean health-related quality-of-life (HRQoL) scores
in 2011 between men diagnosed with advanced prostate cancer and a
random sample of all men in the respective trial arm.
Table 2 – The effect of trial arm, domicile, socioeconomic status,
and age on health-related quality of life in a random sample of all
trial participants*
Coefficient Robust
standard error
p value
Screening arm
(control arm
as reference)
0.000 0.004 0.934
Tampere (Helsinki
as reference)
0.002 0.005 0.724
Socioeconomic status
(highest socioeconomic
group as reference)
Middle 0.008 0.006 0.188
Lowest 0.039 0.005 0.000
Age, yr 0.002 0.000 0.000
Constant 1.083 0.013 0.000
Observations = 5315
* Longitudinal analysis of 15D scores in the Finnish prostate cancer
screening trial between 1998 and 2011 with generalised estimating
equations.
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Fig. 4 – Differences in mean health-related quality-of-life (HRQoL) scores
in 2011 between men diagnosed with prostate cancer and a random
sample of men in each trial arm.
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Fig. 5 – Differences in mean health-related quality-of-life (HRQoL) scores
in 2011 between men diagnosed with organ-confined prostate cancer
and a random sample of all men in each trial arm.
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status to evaluate the long-term HRQoL effects of screening
on all men in a screening trial as well as those diagnosed
with PCa. Our results suggest a small overall benefit among
men with PCa, although a statistically significant difference
was not observed at all time points or for all measures. The
effect size (ie, the difference observed in HRQoL scores) is
small, both in absolute terms and relative to the variance of
the scores. No clear differences were found overall in a
random sample of men in the trial, although in a subgroup
analysis, a slightly lower overall score was seen if men with
PCa were excluded from the analysis.
We did not attempt to compare the results given by the
three different HRQoL measures but rather provided a
description of the HRQoL scores. However, of the three
measures, the 15D had the smallest variance and the
highest HRQoL scores, the EQ-5D had the largest variance
and scores slightly lower than the 15D, and the SF-6D
measure had variance slightly larger than 15D and
produced the lowest HRQoL scores. All three measures
agreed on the direction of the effects, but the absolute size
of the differences, and the most statistically significant
results, were found using the EQ-5D scoring system. This is
consistent with some recent research comparing these
measures [23,24].
No improvement was found overall for men in the
screening arm of the trial subsample, which can be
expected because a cancer screening programme is
unlikely to yield large long-term benefits among men
not diagnosed with PCa. However, in a subgroup analysis,
for those men in the trial subsample free of PCa in 2011, an
overall benefit was suggested formen in the control arm. It
is unclear if this represents a negative impact of screening
because the short-term impact of attending screening on
HRQoL was previously often found to be minor and
transient [25]. In the trial subsample, it is likely that the
relatively higher mean scores of men with PCa in the
screening arm helped to raise the overall mean scores for
men in the screening arm, thus negating any small increase
in the overall mean scores for men in the control arm. For
these reasons, the existence of any long-term detriment
overall in the screening arm would need substantiation
through further study. One repeated finding from our
analyses was lower HRQoL associated withmore advanced
age and lower socioeconomic status.
Our material was based on a large population-based trial
and provides evidence about the impact of mass screening
on the general population. Here, even small differences,
below those conventionally regarded as clinically relevant,
may be of public health interest [26–28].
4.1. Strengths of the study
Although research on PCa patients’ HRQoL has been
conducted [29–32], few studies have examined the effect
of screening on HRQoL, and even fewer have examined data
from a randomised screening trial [33–35]. The setting of a
randomised trial is a major advantage and regarded as the
gold standard for evaluating medical and public health
Table 3 – The effects of trial arm, domicile, socioeconomic status,
and age on health-related quality of life among men with prostate
cancer*
Coefficient Robust
standard error
p value
Screening arm
(control arm as reference)
0.010 0.003 0.002
Tampere (Helsinki as
reference)
0.018 0.004 0.000
Socioeconomic status
(highest socioeconomic
group as reference)
Middle 0.014 0.005 0.003
Lowest 0.021 0.004 0.000
Age, yr 0.004 0.000 0.000
Constant 0.986 0.009 0.000
Observations = 4054
* Longitudinal analysis of 15D scores in prostate cancer (PCa) in 1998 and
2011 in the Finnish PCa screening trial with generalised estimating
equations.
Table 4 – The effects of domicile, socioeconomic status, and age on
health-related quality of life among men diagnosed with prostate
cancer restricted to screen-positive men in the screening arm*
Coefficient Robust
standard error
p value
Positive screen result
(relative to the men
with PCa in the
control arm)
0.016 0.003 0.000
Tampere (Helsinki as
reference)
0.018 0.004 0.000
Socioeconomic status
(highest socioeconomic
group as reference)
Middle 0.014 0.005 0.003
Lowest 0.022 0.004 0.000
Age, yr 0.004 0.000 0.000
Constant 0.985 0.009 0.000
Observations = 4054
PCa = prostate cancer.
* Longitudinal analysis of 15D scores in four questionnaire surveys of PCa
carried out between 1998 and 2011 with generalised estimating equations.
Table 5 – Dropout analysis: relationship of trial arm, prior
hospitalisation, age, and tumour stage to participation*
Odds ratio Robust
standard error
p value
Screening arm
(control arm as reference)
0.995 0.067 0.942
Hospital care (no recorded
hospital episodes as
reference)
1.359 0.098 0.000
Age, yr 0.972 0.008 0.000
Advanced stage PCa
(T3–4 relative to
organ-confined T1–2)
0.755 0.076 0.005
Constant 19.432 11.586 0.000
Observations = 4526
PCa = prostate cancer.
* In the postal questionnaire survey in 2011 among men diagnosed with PCa.
E U RO P E AN URO LOG Y 6 5 ( 2 0 1 4 ) 3 9 – 4 744
interventions. Our primary analysis followed the intention-
to-screen principle, rather than applying screening-
received analysis, to improve validity and generalisability
[6,36]. This means that, in our analysis, nonparticipants
were included in the screening arm and men having
opportunistic PSA testing were included in the control arm,
which is likely to give smaller effect than comparing
screened and unscreened men but a more realistic estimate
of the impact of population-based screening. We did not
control for the effect of treatment or stage of PCa because it
is likely affected by screening and hence would lead to
overadjustment.
We evaluated the HRQoL over a 13-yr period: during the
first, second, and third screening round, as well as after
completion of the intervention (Fig. 7). Therefore, the
results complement earlier work focusing on the short-term
impact of the screening process, diagnostic procedures, and
treatment [29–31,34,35].
4.2. Limitations of the study
Postal administrationwas used to reach bothmen diagnosed
with PCa andmennot otherwise contacted as part of the trial
in a similar manner, with response proportions in both
groups relatively high [37]. This Finnish patient cohort is
particularly homogeneous in termsof ethnicbackgroundand
socioeconomic status. Therefore, it may be inappropriate to
generalise these findings to heterogeneous populations with
wider variations in ethnicity and socioeconomic status. One
of the main limitations of this study is that we found some
indication of selectionbias,with nonrespondents beingolder
andmore likely to have advanced stage PCa at diagnosis, but
nonresponsewasnotassociatedwith the trialarm.Therefore,
we did not use imputation methods for unit nonresponse:
The assumptions involved are necessarily arbitrary [38].
However, because of the differences in age distribution,
especially those between the group of menwith PCa and the
group of men from the trial subsample, the differences in
mean health-state-value scores in 2011, as shown in Figures
4–6, may not be amenable to simplistic interpretation. If
these differences in age distribution were not present and
selection bias was not a problem, it might be appropriate to
estimate the partial impact of screening in terms of
morbidity-related QALYs. Such an estimation involves
multiplying the mean differences between HRQoL scores
for menwith PCa and those from the trial subsample in each
arm (Fig. 4) by the cumulative incidence of PCa in each arm
(as per Schro¨der et al. [6]). In our study, the appropriate
comparator for the men with PCa was taken to be all men in
their respective arm of the trial subsample, rather than just
those without a PCa diagnosis. As an example of such a
simplistic calculation, using the 15D scores collected in2011,
the estimate would be a gain of less than one morbidity-
related QALY per 1000 trial participants in that year.
In general, our results may also reflect opportunistic
PSA testing in the control arm—increasing levels of
contamination within the trial—which may reduce the
relative benefit found from systematic mass screening [39].
In addition, lead-time bias, length bias, and overdiagnosis
are likely to lead to larger numbers of small early cancers
being detected at a younger age in the screening arm, which
may overestimate the screening benefit. However, this
would not affect the comparison of all men in the trial
(when men with PCa are included).
We used three validated Finnish-language HRQoL
questionnaires that can produce health-state-value scores
as indicators of overall health impact. None of these are
disease-specific measures, and it remains somewhat
unclear how comprehensively they can assess the adverse
health outcomes typical for PCa. It also remains unclear
what results would have been obtained if a disease-specific
measure, such as the UCLA Prostate Cancer Index, had been
used [40]. Despite the fact that they have been developed
for the evaluation of key aspects of disease and ill health
limiting everyday life, generic HRQoL measures are less
likely to react to small or insidious changes in health status
than major or acute changes. Furthermore, the impact of
PCa may well be masked by other medical conditions.
Generic HRQoL measures such as those used here may not
be wholly suitable for describing the effects of palliative
care [41] or, for example, the effects of illness on family
members. Assessment of the challenges posed by response
shift [42,43], scale recalibration, or adaptation [44] was not
undertaken here, and, of course, the HRQoL measures may
not faithfully represent the societal value of changes in
health status [45]. Instead, each HRQoL measure generates
alternative valuations of respondents’ subjective responses
to systematic questions addressing their health status.
Further, these measures are aimed at detecting differences
in group-level HRQoL, rather than clinically important
changes at the individual patient level and hence are rather
more suitable for guiding policy than for guiding clinical
decision making concerning individual patients [46]. These
HRQoL results should be set in the appropriate context;
namely, judgements concerning the overall merits of
screening are generally a combination of mortality effects,
morbidity estimates (such as the HRQoL information
presented here), and disease-specific traits, as well as other
health-related, economic, and cultural values. Regardless of
[(Fig._7)TD$FIG]
Fig. 7 – Longitudinal differences in mean 15D scores (with 95% confidence
intervals) for men diagnosed with prostate cancer (PCa) by arm in the
Finnish PCa screening trial.
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the rather small effect observed, subsequent application
of these HRQoL scores to describe health state utilities in
cost-effectiveness analyses remains a possibility.
5. Conclusions
This study shows a small advantage in mean HRQoL scores
for the screening arm over the control arm for men
diagnosed with PCa. These differences were small and
not detected by all of the generic indicators at all times in
the course of the 13-yr follow-up. Using these HRQoL
measures, this study provides little evidence that mean
health-state-value scores differed markedly between the
trial arms for the trial population overall.
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Introduction
lthough there is some evidence of the effectiveness of
ganised screening in reducing prostate cancer (PCa)
ortality [1], there has been a dearth of published
pirical analyses of the actual impact of such mass
reening on healthcare costs in real-world settings.
rostate-specific antigen (PSA)ebased screening poten-
ally provides a means of altering the clinical course of
e PCa and thereby improving prognosis and outcomes
]. However, a presumption is often made that early
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rough a pragmatic randomised controlled trial (RCT)
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reening for Prostate Cancer (FinRSPC), primarily
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Methods
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jective of which is to investigate the impact of mass
SA-screening on PCa mortality [8]. Secondary objec-
ves of the FinRSPC include the investigation of the
ial’s impact on costs and health-related quality of life,
d then the combination of these sources of informa-
on to provide information on cost-effectiveness [9].
he target population of the FinRSPC was selected
om the Finnish population registry and consists of
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nd analytical methods
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r [11]. The main data sources used in this
scribed in the Appendix: these are the
l database, the Care Register for Health
) and the prescription-medicine reim-
gister (PMRR). The costs of the screening
ave been estimated to be approximately 50
reen (including the organisation of the
drawing of the blood sample and the PSA
s), and this figure is used in all analyses.
verage Euro amounts we report in our re-
ded to the nearest 100 Euros, as this gives
el of precision for these cost estimates. The
n screening and healthcare costs from all
rces is specific to each man in the trial and
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Results
ltogether, there were 31,867 men in the SA and 48,282
en in the CA (Fig. 1). Cost-related data were recorded
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rds were not found for 198 men in the CA and for 119
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(Table 1). Th
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Abstract
Objectives. Proceeding from a basic concept underpinning economic evaluation, opportunity
cost, this study aims to explain how different approaches to economics diverge quite dramat-
ically in their ideas of what constitutes appropriate valuation, both in principle and practice.
Because the concept of opportunity cost does not inherently specify how valuation should be
undertaken or specify how appropriate any economic value framework (EVF) might be, the
three main economics-based approaches to providing evidence about value for health technol-
ogy assessment are described.
Methods. This paper describes how the three main EVFs—namely, the extra-welfarist, welfar-
ist, and classical—are most typically understood, applied, and promoted. It then provides
clarification and assessment of related concepts and terminology.
Results. Although EVFs differ, certain underlying characteristics of valuation were identified
as fundamental to all approaches to economic evaluation in practice. The study also suggests
that some of the rhetoric and terms employed in relation to the extra-welfarist approach are
not wholly justified and, further, that only the welfarist approach ensures adherence to
welfare-economic principles. Finally, deliberative analysis, especially when connected with a
classical economic approach, can serve as a useful supplement to other analytical approaches.
Conclusions. All three approaches to economic evaluation have something to offer assessment
processes, but they all display limitations too. Therefore, the author concludes that the language
of economic evaluation should be used with sufficient humility to prevent overselling of EVFs,
especially with regard to the qualities of evidence they provide for priority setting processes.
In a recent commentary piece in this journal (1), Professor Culyer usefully highlighted many
of the issues in economics surrounding costs and context in health-economic evaluation for
health-technology assessment (HTA). Although making appropriate reference to both health
economics and economics in general, Culyer neglected to mention that economics for HTA
can encompass more than the extra-welfarist approach and that other economic value frame-
works (EVFs) exist. Although his commentary helps to demystify the topic, still greater clarity
and humility with regard to “economic” perspectives on valuation could contribute to
improved HTA processes. Indeed, assessing the quality and relevance of EVF outputs as infor-
mation for priority setting processes may become easier once the fundamental assumptions
and value judgments related to EVFs are clarified.
This paper highlights two main alternatives to extra-welfarist economic value frameworks
(EWEVFs)—the welfarist (WEVF) and the classical (CEVF)—and it describes how both can
inform HTA decision making processes. Each of the three economic approaches here depends
on particular sets of premises (in essence, “political” judgments) as to which sorts of value count
and the extent to which those dimensions of value are covered. Hence, as Culyer and Jönsson
note (2, p. 2), these can be seen as vital for correctly judging the applicability or relevance of any
given EVF.
Theoretical Understanding of Opportunity Cost
This paper supplements earlier studies by clarifying several factors related to economic
evaluation for HTA. Conceptual clarity is especially important both when defining opportu-
nity costs and when actually carrying out any corresponding economic evaluation, on account
of the implicit or explicit assumptions made, the limitations and uncertainties surrounding the
measurement instruments, and the challenges involved in estimating any form of “economic”
efficiency. A clear, transparent approach is important also with regard to terminology: as
Williams argued several decades ago, the role of economic evaluation in setting priorities
for health technologies is easily oversold (3), and the relevance of this has been reaffirmed
many times since (4;5). Another important reason to strive for clarity lies in a shift witnessed
in economic evaluation away from more welfarist views (6, p. 64) and toward more narrowly
focused extra-welfarist EVFs (7). Although the Culyer piece offers a textbook parable related to
opportunity cost, it bears remembering that economists have utilized the concept at least as far
back as Adam Smith’s day (8, Book I, Chapter VI, p. 1). The term
“opportunity cost” itself was coined by Green, with the thrust of
his definition already involving “the opportunities foregone in
accepting a certain line of action” (9). Differences between schools
of economic thought notwithstanding, Green’s definition seems
to have been reinforced—by, among others, both Alchian (10)
and Buchanan, with the latter stating that “opportunity cost is
the evaluation placed on the most highly valued of the rejected
alternatives or opportunities” (11). Though there is fairly wide-
spread agreement that economic evaluation is intended to inform
HTA decision making processes, how this principle gets applied
in practical analysis of opportunity costs will reflect both the pol-
icy problems facing decision makers and the research questions
involved, along with the specific EVF chosen (1;12).
At the conceptual level, identifying opportunity costs entails a
two-part approach: first, the value of the “new” technology at
issue is estimated or defined; then, the estimate obtained is
compared with the value placed on the class of all “practicable”
alternative technologies, however specified. The first of the two
evaluative components assigns a value to the given health technol-
ogy relative to at least one other way of serving the same group.
This valuation addresses not only the estimated additional
resource requirements of the new technology, but also takes
into account its effectiveness; that is, this first valuation reports
or estimates a value for at least one of the outcomes produced
by the health technology. The second component places a value
on what would have to be forgone for to supply the resources
needed for the chosen technology. The objective of any reputable
economic evaluation is therefore to provide evidence on
whether the technology’s economic value (ascertained in the
first component) outweighs the economic value of what is fore-
gone (ascertained in the second component). The likely utility
of economic evaluation for decision making purposes is markedly
lower when either of the two evaluative components lacks plausi-
bility. Accordingly, this paper focuses on clarifying the nature of
economic evaluations’ information inputs to priority setting
processes. From this perspective, it outlines the orientation of
three EVFs, which, to varying extents, can address policy prob-
lems and identify different forms of opportunity cost (1). The
aim is a critical review of economists’ attempts to adopt and
operationalize these concepts, bundled as they are with particular
aspirations, conditions, and premises.
Concepts of Opportunity Cost in Practice
There are three main “economics”-based approaches to determin-
ing whether a given technology’s economic value exceeds the value
of any action forgone. Each type of EVF—the extra-welfarist, the
welfarist, or the classical—imposes its own boundaries on how
the valuation is undertaken. For each of the two components
described above, the frameworks typically identify (or tacitly
accepts) their own sources of “value” and/or metrics thereof.
These differences between EVFs stem predominantly from what
is deemed to be of value, though EVFs also diverge in how the
valuation is conducted.
For a backdrop to examination of differences between EVFs, it
is useful to outline the scope of investigations that are possible as
part of the economic evaluation of health-care technologies.
There are at least five distinct levels at which concepts of oppor-
tunity cost can be considered: (i) choices from among particular
portfolios of public expenditure (13); (ii) choices from among
the technology portfolios that constitute the basket of publicly
provided services (7); (iii) choices between treatments within
the limits set for total disease-specific expenditure (14); (iv)
choices between mutually exclusive treatments (15); and (v) esti-
mates of what may be forgone through using a specific input to
the production process, or “resource opportunity cost” (16).
The focus here is on level (ii), because the portfolio-of-technology
level represents the most prevalent scope adopted by economic
evaluations aimed at informing processes of health-care resource
allocation (17).
Differences between EVFs
The objective for extra-welfarist approaches is often characterized
as being to “maximize health” (18), where the matter of how
“health” is defined can be considered very important because of
proxying; typically in EWEVFs, rather than “health” per se
being maximized, only an indicator of health is maximized.
Under EWEVFs, “health” usually refers to the amalgam of (i)
an indicator reflecting some dimensions of perceived health status
with (ii) “health-state valuations” connected with that indicator
(19). Both many of the indicators, and many of the valuations
thereof, are typically engineered by health economists themselves.
Although extra-welfarist approaches do not dictate a given maxi-
mand, most EWEVF applications center on maximizing a combi-
nation of precisely this sort of “social valuation” of states of health
with estimates of length-of-life impacts, normally operationalized
in the form of quality adjusted life-years (QALYs). Under
EWEVFs, the first evaluative component’s output, typically a
cost-per-QALY estimate, is compared with the second “output,”
which represents “opportunity cost” (an estimated mean cost
per unit of health forgone through diverting resources from
other activities). Thus, in principle, EWEVFs address whether
total “health” will increase if the new technology is introduced,
but do so with an implicit assumption that both the new technol-
ogy and the activities from which resources are diverted are, as
economic theory suggests, perfectly divisible with constant returns
to scale. However, as noted by Drummond (6) and illustrated by
Birch and Donaldson (20), ascertaining the new technology’s
impact on efficiency (net impact on health) in a theoretically well-
grounded manner requires avoiding such strict assumptions,
which demands a mathematical-programing approach.
The aim with welfarist approaches to economic evaluation is to
maximize “welfare,” where analysis is undertaken to identify the
improvements in the aggregate welfare of individuals (21).
Valuation using WEVFs is based on the utility individuals gain
from how the available resources are used, inclusive of any welfare
impacts arising from the way commodities or outcomes are dis-
tributed within the population in connection with different uses
of resources (22). “Social welfare” or “well-being” can be defined
in terms of total net willingness to pay (WTP) (23), with contin-
gent valuation methods constituting the main source of valuations
in WEVFs (24). In more general terms, WEVF-based analysis
compares the additional well-being produced by the new technol-
ogy with that forgone through diversion of the required resources
from elsewhere to support the new technology.
Finally, in classical approaches to economic evaluation, one of
the central objectives is to supplement EWEVFs and WEVFs by
accounting for preferences or values that are ascertainable only
via deliberative methods. The label “classical” refers to the long
history of valuation in economics before such developments as
the marginal revolution (25). With CEVFs, the goal is to identify
and assess, rather than to define and maximize, “health” or
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“well-being.” That is, in place of a formalized maximand, the tar-
gets in a classical approach (26, p. 136) might involve satisficing
(27) or sufficiency (28), in addition to interpreting, for example,
some EWEVF- or WEVF-derived indicator of “economic”
efficiency. Often, CEVFs operate with other, non-quantitative
information too, and typically encompass deliberation (29).
Perhaps their most important element is an attempt to avoid
being constrained to focus on formal economic efficiency, that is,
on the type of neo-classical economic efficiency which is the result
of quantitative or mathematical analysis.
EVFs, Opportunity Cost, and the Two Components of
Valuation
As the name “economic value framework” suggests, each EVF has
its own approach to valuation embedded within it. Under
EWEVFs, one frequent approach to judging what is forgone is
to assume, both in principle and practice, that it is possible to
quantify an opportunity cost and that this quantity is invariant
to the size of the program being evaluated, that is, that there
can be a fixed “cost per QALY” (30). However, this is inconsistent
with the economic notion of resource scarcity and the general
finding that the marginal utility of a good or service decreases
as consumption increases. When EVFs employ comparison to
some fixed monetary valuation of opportunity cost, they tend to
ignore factors such as the potential budgetary impact of the inter-
vention and the “lumpiness” of health technologies (31;32).
Although all three EVFs entail estimating cost and effect
differences for a new technology relative to a comparator, the
discussion above should render it clear that there may be little
deeper commonality in how EVFs assign value to alternative
health technologies that might be displaced. The onus is generally
on the user of the research to identify the possible implications
of the chosen value system for the decision making process it
is purported to serve (33). The discussion below attempts to
make the relevant implications clearer for each of the three
main EVFs.
Valuation and Opportunity Cost in EWEVFs
Under EWEVFs, the first evaluative component in defining oppor-
tunity cost is generally based on cost-effectiveness analysis, which
yields an estimate of the mean cost-per-unit health benefit
produced by the chosen intervention—that is, an incremental cost-
effectiveness ratio (ICER). In EWEVFs, this ratio, an estimate of
the inverse of the mean rate of return on the additional investment
required to fund the technology, is typically employed in an
economic-efficiency metric entailing comparison with some pre-
determined benchmark ICER, that is, some cost-effectiveness-ratio
threshold (CERT) (34). The latter is usually exogenous to the study
at hand. Only rarely under EWEVFs do the activities displaced by
the additional investment of resources in the technology get
identified, or be valued, on a case-by-case basis. Although some
CERTs involve estimates from econometric analysis of possible
relationships between current resource use and health-related
outputs (35;36), they may also simply represent an arbitrary figure
or diktat (37). Indeed, CERTs will generally fail to fully reflect the
actual displacement resulting from the technology’s adoption (38).
Many researchers continue to propose CERTs, of various types,
despite evidence suggesting that thresholds are merely an
economic abstraction and that a single appropriate CERT is likely
to remain elusive in most contexts (39).
WEVF-Related Valuation and Opportunity Cost
Under WEVFs, analysis focuses on individuals’ preferences and
technologies are evaluated for their impacts on “well-being” (20).
In some of these frameworks, the two evaluative components are
brought together in a single model for analysis of portfolio choice
through mathematical optimization. By incorporating resource
constraints into the model explicitly, thereby focusing attention
on the well-being generated from the entire resource budget as
opposed to a single program’s share of that budget, the approach
addresses opportunity cost considerations directly without requir-
ing the separate valuation of the foregone alternatives that is typical
under EWEVFs (40). Hence, the emphasis in WEVFs is on com-
paring across the well-being generated by various combinations
(or portfolios) of “health technologies” that the available resources
can sustain, and on determining which combinations could
improve “welfare.” In addition, the approach can accommodate
any other concrete constraints on preferences, in line with policy
considerations related to equity, need, and so on. (40). It is also
important to note here that, in practice, WEVF utilizes WTP
estimates which typically rely on methods such as contingent val-
uation to compare WTP between the new technology in aggregate
and whatever must be forgone (41).
Valuation and Opportunity Cost in Classical Economic
Approaches
CEVFs can be viewed as a reaction to various limitations of
EWEVFs and WEVFs in practice, especially as the latter are
designed to “maximize” via an objective function of one type or
another. CEVFs represent an alternative approach, one that
need not focus on a single maximand (as EWEVFs typically
do) or on a single source of preferences (as is typical under
WEVFs, the source being individuals) yet CEVFs can still be in
line with conventional interpretations of opportunity cost (5).
How CEVF Approaches can Help in HTA
In light of the above, CEVFs are proposed as an alternative that
affords wider scope than either “health maximization” under
EWEVFs or “maximization of economic welfare” under WEVFs,
as they allow for qualitative use of preferences from groups of indi-
viduals, or directly from other stakeholders. Rather than rejecting
use of the other EVFs, the CEVF approach supplements them with
further information or deliberative analysis, such as incorporating
community values (42) canvassed through various evidence-
gathering processes (43–45).
A CEVF approach can help inform HTA in three main ways.
First, CEVFs can add information to evidence provided by
EWEVF and WEVF approaches on the relative efficiency with
which “health” and “welfare” are produced, respectively. Although
WEVFs may include strong evidence about budget or resource
impacts, additional, related information (with either a short or a
long time horizon) can still be produced or utilized within a
CEVF (46). Second, CEVFs can identify any qualifications or
caveats to the EWEVF or WEVF findings, aiming to ensure that
the information they provide is interpreted correctly, through an
appropriate appraisal of their quality. Although such appraisal is
already addressed by many existing HTA processes, it could have
greater value due to being integral to a CEVF approach, in line
with an iterative, classical vision of valuation (26). The third main
advantage would be that CEVFs can provide fuller awareness of
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the nature of the research question and its connection with the
policy problem, as well as of the types and levels of uncertainty
and relevance carried by information from other EVFs (47;48).
One major contribution that CEVFs can make to HTA processes
is to force more clarity into the terminology surrounding EVFs.
This point will be returned to below.
CEVFs allow inclusion of dimensions of value that might not be
measurable in the commensurate units “required” by EWEVFs or
WEVFs (49). Because they can take into account informal analysis
during an iterative process of deliberation, CEVFs could prove
highly relevant for decision makers (50). This might involve, for
instance, (a) confirming, doubting, or disproving the suitability
of standard health-economic outcome metrics for the technology
in question, partly through questioning the assumptions underly-
ing information outputs from other EVFs, and (b) establishing
additional objectives or outcome measurements relevant for the
technology in question (51, p. 149). For item (a), deliberative
analysis may assist in identifying any need to supplement other
EVFs, because it is probable that no single overriding “efficiency”
principle meets all the desiderata for allocation, and there may be
good reasons to consider multiple prioritization principles (29).
For instance, some opportunity costs may not be quantifiable
(52) and might lend themselves only to deliberation, as in the
case of rights-based deontological or paternalistic considerations
(53). In addition, with regard to item (b), for some technologies
there may be little pertinent quantitative information available
from formal analysis, and stakeholders may hold diverse, conflict-
ing views (54). The appraisal process may embody a range of
considerations that might not all be well-defined prior to, or
even during, economic evaluation. There are numerous situations
in which deliberative analysis via CEVFs may provide a useful
extension that improves on purely formal analysis, and a variety
of evidentiary inputs may be used, as necessary, on a case-by-case
basis (1;55).
In general, although analytic endeavors within EWEVFs or
WEVFs can reveal some of the implications of particular choices
(33), CEVFs may add a platform that stimulates discussion of
more communitarian values (e.g., (56;57)). With CEVFs, the
aim is what some have called “higher-level efficiency,” rather
than efficiency in the more neo-classical sense found in the
more formal approaches of EWHEE and WHEE (58, p. 125).
Discussion
Each mode of economic thinking outlined in this paper can offer
useful information for priority setting processes, even though each
EVF involves its own particular aims, assumptions, and value
judgments. Whichever EVF is applied, evaluating opportunity
cost requires some valuation of what is given up (59); hence,
the aim here is not to denigrate or promote any particular
mode of economic evaluation but to promote solid awareness of
the information that each can provide. In all cases, it should be
acknowledged that economic approaches to assessing opportunity
costs are information-intensive in their input requirements and
that their use often suffers from a lack of appropriate information
(60), especially as pathways to health are often quite complex (61).
One should also bear in mind that any method which gives con-
sistent or accountable answers in a systematic manner is unlikely
to yield truly comprehensive evaluation (62). There are many
circumstances wherein measurements fail to cover relevant
aspects of the changes in “states of health” (32;63) or do not cap-
ture changes in capabilities or in patient-reported experiences, not
to mention the fact that “social valuations” of such changes in the
health status do not fully capture society’s values (5). On account
of the measurement issues surrounding WTP, there may be many
situations in which no valid and reliable methods of operational-
izing WEVFs exist (41;64).
Problems with the EVF Lexicon
Although choice processes for allocating health-care resources
should lead to transparent mechanisms for valuation of the vari-
ous options and their opportunity costs (65, p. 138), terminology
can make economic evaluation more opaque. This is evident from
the declining use of terminology relating to intangibles and
incommensurability, which could be seen as arrogant in a sub-
discipline that often preaches humility. On account of space
restrictions, the discussion here focuses on the terms “cost,”
“threshold,” “decision rule,” and “value for money.”
“Cost” has multiple meanings in both lay and specialist use, as
Culyer noted when deeming it naïve to employ the term “cost” for
undesirable attributes (1). An alternative interpretation to that
offered by Culyer is to take the undesirable attributes of an inter-
vention as also representing a cost. Of course, at the level of
valuing what may be forgone through using a specific input to
the production process, or “resource opportunity cost,” that is,
at the level of building the pool from Alchian’s and Culyer’s exam-
ples, then “undesirable attributes” should not be referred to as
costs. On the other hand, the use of the term “cost” for an unde-
sirable attribute, a harm, or a negative benefit, could legitimately
be used to refer to its part in an estimate of higher-level opportu-
nity cost, that is, when assessing the value of the pool per se.
Indeed, at the portfolio-of-technology level, such undesirable
attributes can be seen as an essential component of any EVF.
Undesirable attributes are important when forming a valuation;
Alchian expresses it thus: “The decision maker must choose
among events that are amalgams of goods and bads” (10).
Therefore, in addition to the things forgone, such as the financial
costs and the resources tied up, other aspects of the value forgone,
the “costs” in terms of harms to health will also have a legitimate
place in economic evaluations’ definitions of (opportunity) costs
(66). In practice, economic evaluations do typically include unde-
sirable attributes in their analysis; for instance, EWEVFs do tend
to utilize something akin to Alchian’s amalgam approach when
they promote a metric expressing the estimated cost divided by
the estimated incremental overall population-“health impact.”
For the purposes of HTA, it seems reasonable to suggest that
any sound economic evaluation involves taking both pros and
cons into account: focusing on both the undesirable and the desir-
able attributes of technology, in line with the foundations of tech-
nology assessment (67). Although, obviously, pain and suffering
need not involve resources per se, the principle of opportunity
cost encompasses the benefit forgone, so any robust measurement
of higher-level opportunity cost should also take the “cost,” in
terms of related pain and suffering, into account.
Some extra-welfarist economists and even some HTA practi-
tioners take the perspective that “thresholds” can and should be
quantified. However, economizing in line with these assumptions
may be less intuitive for others involved in prioritization processes
and seem rather perfunctory with respect to “societal values”
(68;69). As is noted above, defining opportunity cost as a single
threshold estimate can be seen as a typical economic abstraction.
Although economic evaluation must always operate at some level
of abstraction in practice, the fairy tale of a single threshold
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(CERT), or threshold range, can be regarded as unhelpful. As no
such one-size-fits-all threshold exists in reality, even within a well-
bounded single jurisdiction, employing the term “threshold”
seems to oversell EWEVFs. The problematic terminology is com-
pounded by the use of connected phrasings such as “decision
rules” and “value for money.” For instance, the real-world appli-
cability of so-called decision rules of EWEVFs is crucially reliant
on the framework’s inherent value judgments and assumptions.
Indeed, these “rules” are typically valid only within the confines
of the EWEVF in question, and there is a danger that the term
“decision rules” could be construed to carry a similar meaning
beyond this arcane hypothetical setting. Furthermore, claims of
ICERs revealing “value for money” seem quite arrogant, in that
EWEVFs often offer only a highly abstracted indicator of value.
Although the concise term “value for money” may be much easier
to sell to HTA decision makers than, for example, “estimated
mean valuation of estimated change in mean health status divided
by the estimated change in mean health-care costs,” the former
loses too much in precision; it seems much less honest. Because
loose language could result in dire consequences of economic
evaluation being oversold to the HTA community, it should be
avoided at all costs.
Conclusions
Rather than economists holding a uniform, all-encompassing view,
there are three main approaches to economic thinking for HTA,
accompanied by a multitude of ways to implement each of these.
Instead of a single notion of economics embodied by one EVF,
the study found EWEVFs, WEVFs, and CEVFs, each with the cor-
responding problems and potential. Therefore, all approaches to
economic evaluation should be checked for quality and relevance
before being used to inform prioritization processes. Applying
more precise vocabulary, coupled with greater understanding of
the limits to analysis of any kind, should help decision makers
engage in appropriate deliberation and interpretation in their
HTA endeavors. The ways in which notions of opportunity cost
are translated into practice and interpreted are likely to have
great importance, not only for priority setting but also for the
long-term health and sustainability of health-care systems.
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Abstract
In contrast to earlier studies which have used modelling to perform cost-effectiveness analy-
sis, this study links data from a randomised controlled trial with register data from nationwide
registries to reveal new evidence on costs, effectiveness, and cost-effectiveness of orga-
nised mass prostate-cancer screening based on prostate-specific antigen (PSA) testing.
Cost-effectiveness analyses were conducted with individual-level data on health-care costs
from comprehensive registers and register data on real-world effectiveness from the two
arms of the Finnish Randomised Study of Screening for Prostate Cancer (FinRSPC), follow-
ing 80,149 men from 1996 through 2015. The study examines cost-effectiveness in terms of
overall mortality and, in addition, in terms of diagnosed men’s mortality from prostate cancer
and mortality with but not from prostate cancer. Neither arm of the FinRSPC was clearly
more cost-effective in analysis in terms of overall mortality. Organised screening in the
FinRSPC could be considered cost-effective in terms of deaths from prostate cancer: avert-
ing just over one death per 1000 men screened. However, even with an estimated incre-
mental cost-effectiveness ratio of below 20,000€ per death avoided, this result should not
be considered in isolation. This is because mass screening in this trial also resulted in
increases in death with, but not from, prostate cancer: with over five additional deaths per
1000 men screened. Analysis of real-world data from the FinRSPC reveals new evidence of
the comparative effectiveness of PSA-based screening after 20 years of follow-up, suggest-
ing the possibility of higher mortality, as well as higher healthcare costs, for screening-arm
men who have been diagnosed with prostate cancer but who do not die from it. These find-
ings should be corroborated or contradicted by similar analyses using data from other trials,
in order to reveal if more diagnosed men have also died in the screening arms of other trials
of mass screening for prostate cancer.
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Introduction
There has been a wide range of evidence published on the effectiveness of systematic prostate-
specific-antigen±based screening in reducing prostate-cancer mortality [1±4]; however, associ-
ated estimates of costs and cost-effectiveness from real-world data have received much less 
attention [5, 6]. Organised mass screening based on prostate-specific antigen (PSA) testing 
potentially offers systematic early detection of aggressive prostate cancer at a curable stage and 
thereby reduction of mortality [7]. However, the PSA test is not specific for cancer, as 
increased PSA levels can equally indicate benign changes in the prostate, so the PSA test has 
the potential to lead to harmful overtreatment [8]. Of course, questions extend beyond the 
clinical realm: policy-level ones can be asked, about what PSA-based organised screening 
might ªcostº in relation to the ªbenefitsº produced [9, 10]. Such relationships between costs 
and effectiveness (i.e., economic efficiency) are often described through some form of cost-
effectiveness analysis (CEA) [11, 12]. While modelling-based CEA can provide useful informa-
tion, its results typically are highly dependent on both the data and the assumptions used, 
which may sometimes be flawed or inaccurate [13, 14]. The need for assumptions can be mini-
mised and the data quality maximised by drawing conclusions directly from the results of a 
pragmatic randomised controlled trial; we take this approach here, benefiting, e.g., from Fin-
land's well established statutory health-care registries [15±17].
In light of the above considerations, a CEA was conducted with the primary aim of provid-
ing empirical estimates of some of the relationships between costs and effects of PSA screening 
from the Finnish Randomised Study of Screening for Prostate Cancer (FinRSPC) after 20 
years of the trial, using intention-to-screen analysis of health-care costs, mortality, and cost-
effectiveness.
Materials and methods
The FinRSPC
The complete age-based cohort for the FinRSPC was selected by staff at the Finnish population 
registry and consists of all men born in 1929±1944 residing in the Helsinki or Tampere region 
and alive on the date of randomisation (January 1 of each year from 1996 through 1999, a total 
of 80,458 men were randomised). Those men randomised to the screening arm were systemat-
ically invited for organised tests (serum PSA determination) at a local clinic, while those in the 
control arm received no such invitation as part of the trial. Three screening rounds were 
arranged, at four-year intervals, with men above 71 years of age no longer invited. Serum PSA 
was used for the primary screening test, with a cutoff of 4 ng/mL and ancillary testing for men 
with PSA 3.0±3.9 (digital rectal examination in 1996±1997, free/total PSA ratio from 1997 
onwards). Randomisation occurred before consent, i.e., in order to prevent self-selection 
biases all men in the target age cohorts were randomised to one of the two arms without their 
consent being sought, this was undertaken in full accordance with Finnish legislation at that 
time. Follow-up started on January 1 in the year of randomisation and ended at death, upon 
emigration, or on the common closing dates for analyses of both costs and effectiveness
(December 31, 2012±2015).
Register-data permissions and sources
The collection of data for this research was approved by the relevant Institutional Review 
Boards: by the Finnish data-protection authority, by the National Institute for Health and Wel-
fare (THL), by Statistics Finland (TK-53-1330-18), and by the Ethics Committees of the 
participating university-hospital districts. The need for consent from the men assigned to 
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the trial was waived by a ruling from THL for the current register-based study
(Official decision number: THL/36/5.05.00/2009). Data were obtained from several registries 
and entered in the FinRSPC database, using each man's unique Finnish personal identity code 
as the key for deterministic record linkage. Cancer cases were identified from the Finnish Can-
cer Registry (FCR), causes of death from Statistics Finland; episodes of hospital care from the 
THL-maintained Care Register for Health Care (CRHC), and prescription-medicine reim-
bursements from the nationwide register (PMRR) maintained by the Social Insurance Institu-
tion of Finland. The PMRR contains information on the exact costs of outpatient prescription 
medications paid by the healthcare sector in Finland. The CRHC is a comprehensive national 
register which covers inpatient stays in, and outpatient visits to, hospitals. To classify and 
identify resource use, we used the Finnish version of the Nordic Diagnosis Related Group
(NordDRG) -system [18]. Identifiable individual-level data cannot be shared publicly because 
of Finnish legislation governing the protection of personal data. The data underlying the 
results presented in the study can be obtained from the relevant Finnish authorities for 
researchers who meet the criteria for access to confidential data. The funding organisations 
did not play a role in the study design, data collection and analysis, decision to publish, or 
preparation of the manuscript and only provided financial support in the form of authors' sala-
ries and/or research materials. Fimlab Laboratories provided support in the form of a salary 
for PK, but did not have any additional role in the study design, data collection and analysis, 
decision to publish, or preparation of the manuscript.
Costs
Our CEA follows a healthcare-sector perspective using register-based costs; utilising individ-
ual-level data on publicly-provided secondary and tertiary health-care visits and stays for men 
in the FinRSPC during the 20-year trial. In addition, the PMRR provides, to the nearest cent 
(¢), the costs of outpatient prescription medications paid by the Social Insurance Institution of 
Finland. For costs of secondary and tertiary care we used the most applicable NordDRG cost 
weights (in euros), which the THL had gathered from Finnish hospitals, for both inpatient and 
outpatient costs. The cost of the screening intervention itself was estimated by the FCR to cost 
approximately 50 euros per screen (including organisation of invitations, drawing of the blood 
sample, and PSA determinations but not any diagnostic evaluations, since the costs of diagnos-
tic tests are captured in our other cost estimates). All results are rounded to the nearest 100 
euros to yield a level of precision suitable for comparative estimates of cost and cost-effective-
ness. Our base case analysis uses a discount rate of 3% per annum [19], and all euro amounts 
were adjusted using the most appropriate price indices available from Statistics Finland. Fur-
ther details about these data sources and costs, as well as about the study design and trial regis-
tration have been provided in earlier FinRSPC or European Randomised Study of Screening 
for Prostate Cancer (ERSPC) publications ([3, 5, 20] or [2]).
Analyses
The register data available on both costs and effects were analysed in accordance with the 
intention-to-screen principle; that is, they were examined in accordance with the initial trial-
arm assignment. We used mortality as the measure of effectiveness, because no other register-
based effectiveness data were available (e.g., on health-related quality of life) [20]. All follow-
up is truncated at 17 years, with men who were randomised on January 1 1996 were followed 
up until December 2012, whereas, e.g., men who were randomised on January 1 1999 were fol-
lowed up until December 2015. All tests of statistical significance are two sided, with Cox pro-
portional hazards regression used in the mortality analysis. Our CEA calculates incremental
CEA of PSA mass screening combining RCT and register data
PLOS ONE | https://doi.org/10.1371/journal.pone.0224479 November 5, 2019 3 / 17
cost-effectiveness ratios (ICERs) by means of the data from the FinRSPC and national registers
on costs and effects [21]. Our health-economic approach focuses on differences in mortality,
including comparisons of the numbers of men dying between the two arms [19]. These health-
economic comparisons are reported in line with current standards, with the primary result
reported here being the overall ICER for the FinRSPC in terms of overall mortality [13], with
additional CEA analysis for two subgroups, firstly for men who died from prostate cancer and,
secondly, for men who died with, but not from prostate cancer [22]. All data handling and
analysis, including the merging of data from different registers, was performed using Stata
[23].
Results
In all, 31,867 men were assigned to the screening arm and 48,282 to the control arm, with
3,788 men in the screening arm (11.9%) and 5,050 men in the control arm (10.5%) being diag-
nosed with prostate cancer, respectively (Fig 1 [24]). Data on both costs and effectiveness were
recorded in the registers used in our study for 31,740 men in the screening arm (100%) and for
48,075 men in the control arm (100%). However, no cost records were found for 127 men in
the screening arm and 207 men in the control arm, including one man in the screening arm
who was diagnosed with and subsequently died of prostate cancer.
After 20 years of the trial, no statistically significant differences were observed between the
arms in terms of the estimated average health-care costs of all men (Table 1). Although average
costs for the 792 men who died of prostate cancer were around 10% higher in the screening
arm (not statistically significant), there were negligible differences in total costs between the
arms, since relatively few men died from prostate cancer in the screening arm. While average
Fig 1. Enrollment and health-related outcomes.
https://doi.org/10.1371/journal.pone.0224479.g001
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costs for the 1,610 men who died with but not from prostate cancer were approximately 5%
lower in the screening arm (not statistically significant), a small substantive increase in total 
health-care costs for this subgroup was observed in the screening arm, as the rightmost column 
in Table 1 shows. This is because more men in this arm, i.e., a higher percentage of men in the 
screening arm, died with prostate cancer but not from it.
There was no statistically-significant difference in all-cause mortality (hazard ratio (HR) = 
1.006, 95% confidence interval [CI], 0.98 to 1.03; P = 0.625) (Fig 2, Panel (A)). However, among 
diagnosed men there was a reduction in prostate-cancer-specific death in the screening arm: 
HR = 0.78, 95% CI, 0.68 to 0.90; P = 0.001 (Fig 2, Panel (B)). In addition, non-prostate-cancer 
mortality for men diagnosed with prostate cancer was higher in the screening arm than in the 
control arm: HR = 1.16, 95% CI, 1.05 to 1.27; P = 0.004 (Fig 2, Panel (C)). This increase in the 
rate of non-prostate-cancer mortality for men diagnosed with prostate cancer in the screening 
arm, seems to be most pronounced over five years after randomisation (as Fig 2, Panel (C) 
shows). Overall, differences in mean health-care costs and mean effectiveness for diag-nosed 
men between the trial arms were relatively small with regard to both prostate-cancer mortality 
and non-prostate-cancer mortality, with relatively high standard error (Table 2).
Our primary CEA produced a ICER which shows there was a health-related harm at less 
cost. This primary CEA result is presented in Fig 3, Panel (A), and shows that 95% confidence 
intervals are not able to be defined due to the uncertainty surrounding this estimate. Although 
not statistically significant, after 20 years, the impact of the FinRSPC equates to just under two 
additional deaths overall for every 1,000 men in the screening arm, with negligible savings in 
health-care costs. This finding reflects approximately 63 more deaths overall in the screening
arm, which in turn reflects the negative contribution of approximately 174 more deaths 
observed in the screening arm for men diagnosed with prostate cancer, after having adjusted 
for the difference in size of the trial arms (Figs 1 and 2 and Table 2). Therefore, the ICER esti-
mated for the FinRSPC overall, can be expressed qualitatively as a statistically non-significant 
reduction in costs accompanied by a statistically non-significant increase in the number of 
deaths (Table 2).
The estimated ICER for men diagnosed with, and who died of, prostate cancer, is 19,400€ per 
prostate-cancer death averted. This reflects the 38 or so fewer deaths from prostate cancer
Table 1. Comparisons and statistical tests of the real-world health-care cost estimates. Results comparing trial arms during the 17-year follow-up.
Estimated all-cause health-care
costs (register-based)
N in control
arm
Mean in
control arm
N in screening
arm
Mean in
screening arm
Difference between
means
(standard error)
Two-sided t-
test
Difference² in total
costs
(in millions)
All men 48,075 €37,800 31,740 €37,600 -€200
(€400)
p = 0.65 -€5.3
Men not diagnosed with prostate
cancer
43,025 €36,100 27,953 €35,600 -€500
(€400)
p = 0.26 -€29.2
Men diagnosed with prostate cancer 5,050 €38,800 3,787 €39,300 €400
(€1,100)
p = 0.64 €23.9
Men who have survived with a
prostate cancer diagnosis
3,372 €46,300 2,524 €46,700 €300
(€1,100)
p = 0.76 €14.7
Men who died with, but not from,
prostate cancer
865 €62,400 745 €60,000 -€2,400
(€3,100)
p = 0.43 €9.7
Men who have died of prostate
cancer
500 €63,600 291 €68,500 €5,000
(€4,700)
p = 0.29 -€0.5
² = Differences are calculated as total costs in screening arm minus total costs in control arm and adjusted to take account of the relative size of the trial arms (rounded
to the nearest hundred thousand euros).
https://doi.org/10.1371/journal.pone.0224479.t001
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being observed in the screening arm after 20 years of the FinRSPC. However, only if a deci-
sion-maker's willingness to pay per `prostate cancer death averted' is over 120,000€ could the
screening arm of the FinRSPC be considered `cost-effective' at conventional levels of statistical
significance (Fig 3, Panel (B)).
Fig 2. Nelson±Aalen estimates of risk of dying, from point of randomisation. Panel (A): Death from any cause,
during follow-up, by trial arm. Panel (B): Death from prostate cancer, for men diagnosed during follow-up, by trial
arm. Panel (C): Death with, but not from, prostate cancer, for men diagnosed during follow-up, by trial arm.
https://doi.org/10.1371/journal.pone.0224479.g002
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The analysis of cost-effectiveness above suggests a need to report on one further CEA too,
this one focusing on death from other causes than prostate cancer among men diagnosed with
prostate cancer (Fig 3, Panel (C)). This secondary analysis reports estimated cost-effectiveness
for the men diagnosed with prostate cancer, 174 more of whom perished in the screening arm
from causes other than prostate cancer, i.e., just over five additional deaths per 1000 men
screened. Fig 3, Panel (C) also reflects the likelihood that these additional deaths also come at a
cost in terms of health-care (of around 20,000€ per additional death).
Discussion
We examined the costs, effectiveness, and cost-effectiveness connected with a large popula-
tion-based comparative-effectiveness trial of organised PSA screening for prostate cancer. Tak-
ing each of these elements in turn, firstly, costs; in terms of mean health-care costs, we found
no indications of statistically-significant differences overall. However, such differences may
not be discernible due to the extensive heterogeneity observed in the trial participants' utilisa-
tion of health-care services; i.e., extremely high health-care costs for some men in the trial
reduced the mean estimates' ability to fully describe the cost impact [5, 25]. For example, aver-
age and total overall costs for men not diagnosed with prostate cancer were, somewhat surpris-
ingly, somewhat lower in the screening arm, even though men in the screening arm were
attributed the additional cost of screening (Table 2). This may suggest differences in health-
Table 2. Comparisons between the screening and control arms. Register-based health-care cost estimates, observed effectiveness and incremental cost-effectiveness
ratios, after 17 years of follow-up.
Control arm Screening arm Differences
(screening armÐcontrol arm)
Incremental cost-
effectiveness ratio
(ICER)
Mean cost
in euros
Mean effect
(percentage of
deaths)
Mean cost
in euros
Mean effect
(percentage of
deaths)
in mean
cost in
euros
in mean effect
(percentage of
deaths²)
in number of
deaths averted³
Point estimate
[effectiveness measure]
All men in the trial, using the effectiveness measure of deaths from any cause:
Mean
(total)
37,800 0.327 37,600 0.329 -100 0.001 -63 reduction in costs and
increase in deaths§
[death from any cause](standard
error)
(300) (0.002) (300) (0.003) (400)¶ (0.001)¶
Men diagnosed with prostate cancer, using the effectiveness measure of deaths from prostate cancer:
Mean
(total)
38,800 0.010 39,300 0.009 400 -0.02 38 19,400€k
[death from prostate
cancer](standard
error)
(600) (<0.001) (600) (<0.001) (900)¶ (0.006)
Men diagnosed with prostate cancer, using the effectiveness measure of cause of death something other than prostate cancer:
Mean
(total)
38,800 0.018 39,300 0.023 400 0.02 -174 increase in costs and
increase in deaths#
[death with, but not
from, prostate cancer]
(standard
error)
(600) (<0.001) (600) (<0.001) (900)¶ (0.008)¶
² = percentages expressed as decimals;
³ = adjusted to take account of the relative size of the trial arms (rounded to the nearest integer);
§ = a 95% confidence interval is not able to be defined due to the uncertainty surrounding this estimate (see Fig 2, Panel (A));
¶ = bootstrap standard error;
k = an increase in mean costs (not statistically significant), and a statistically-significant increase in deaths averted (see Fig 2, Panel (B));
# = an increase in mean costs (not statistically significant) and a statistically-significant reduction in deaths averted, i.e., a statistically significant increase in deaths (see
Fig 2, Panel (C)).
https://doi.org/10.1371/journal.pone.0224479.t002
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Fig 3. Scatterplots of bootstrap replications of incremental cost-effectiveness ratios in terms of the number of
deaths. Panel (A): Estimates of incremental cost-effectiveness ratios in terms of death from any cause (for all men in
the trial). Panel (B): Estimates of incremental cost-effectiveness ratios in terms of death from prostate cancer (for men
diagnosed with prostate cancer). Panel (C): Estimates of incremental cost-effectiveness ratios in terms of death from
causes other than prostate cancer (for men diagnosed with prostate cancer).
https://doi.org/10.1371/journal.pone.0224479.g003
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care costs in our study may have more to do with random fluctuations or outliers in health-
care costs than screening itself. Of course, ideally the time horizon necessary for a comprehen-
sive cost-effectiveness analysis would be one that is long enough for all relevant costs (and out-
comes) to manifest (see, e.g., [26] or [19]). However, our analyses did not attempt to make
predictions about future costs or survival for the trial population, as robust methods were not
available to extrapolate from the health-care costs and mortality effects observed for men in
the FinRSPC who have already died, to those who may die in the coming years [27]. One fur-
ther reason for not extrapolating data beyond the within-trial horizon, is that the follow-up
period of the trial covered an expanse of time that witnessed many changes in prostate-cancer
treatment protocols.
Secondly, effectiveness, in exploratory mortality analyses prompted by our CEA findings in
terms of all-cause mortality and prostate-cancer mortality, we also evaluated comparative
effectiveness in terms of non-prostate-cancer mortality among the men diagnosed with pros-
tate cancer. We undertook these secondary analyses because it was apparent from our other
analysis results that, although on average prostate-cancer mortality was lower in the screening
arm among men diagnosed with the disease, all-cause mortality was higher in the screening
arm overall (even though this latter result was not statistically significant). To determine
whether or not our CEA findings in terms of all-cause mortality were due to chance and given
that the main impact of screening is, a priori, likely to be upon men diagnosed with prostate
cancer, we undertook further analyses of mortality among men diagnosed with prostate can-
cer. The above secondary analyses are not, of course, undertaken in full accordance with the
intention-to-screen (ITS) principle, however, three results reported in Fig 1, which do use the
ITS principle, should be noted. The first result of note is that, relative to the control arm, on
average 13% more men were diagnosed with prostate cancer in the screening arm (11.9% ver-
sus 10.5%). The second result of note is that, relative to the control arm, on average 13% less
men died from prostate cancer in the screening arm (0.9% versus 1.0%). The third result of
note in Fig 1 and, perhaps, the most important one here is that, relative to the control arm, on
average 27% more men in the screening arm died with, but not from, prostate cancer (2.3%
versus 1.8% in the control arm). A partial explanation for the result that, relative to the control
arm, on average 27% more men in the screening arm died with, but not from, prostate cancer,
could be related to overdiagnosis; with 13% more men on average diagnosed in the screening
arm, relative to the control arm. Such a `labelling' effect could plausibly account for approxi-
mately half of the observed additional non-prostate cancer deaths in diagnosed men. A second
plausible explanation could be linked to competing causes of death; if more men are on aver-
age spared from death from prostate cancer due to PSA mass screening they may die of other
causes. However, analysis using a proxy for survival time±i.e., the follow-up time in each arm±
as the outcome measure (instead of number of deaths) also revealed an overall decrease in `sur-
vival time' in the screening arm, for men diagnosed with prostate cancer. Put together, how-
ever, even the possible explanations listed above would still only seem to partially explain the
finding of higher mortality for screening-arm men who have been diagnosed with prostate
cancer but who do not die from it.
Although increased cardiovascular mortality due to endocrine therapy or the fear or stig-
matization associated with cancer diagnosis may play some role in our findings about non-
prostate-cancer mortality in men diagnosed with prostate cancer, such explanations remain
only speculations as to why more men in the screening arm died with prostate cancer but not
from it. In addition, we were not able to identify any single specific cause of death (or groups
of causes of death), such as deaths related to intentional self-harm, or other underlying differ-
ences between the arms, which could explain these mortality differences. The most marked
increases in non-prostate-cancer mortality were among those men in the screening arm with
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Tumor-Node-Metastasis -stage T1c cancers at diagnosis (i.e., impalpable cancers detectable
only by PSA testing [28]). Although our data suggest mid-level socioeconomic status may have
been associated with an increase in non-prostate-cancer mortality when men were diagnosed
with prostate cancer at any other than stage than stage T1c, these findings were not statistically
significant. Possibly due to the relatively small number of observed deaths at this stage, such
adjustments for socioeconomic status had minimal material impact on the differences between
the arms in terms of mortality among men with prostate cancer. Further explanatory analysis
is beyond the scope of this exploratory study.
Thirdly, we turn to the results relating to the cost-effectiveness of organised screening in
the FinRSPC, which varied according to the outcome measure used. We present three ICERs:
there was negligible impact of mass screening in the FinRSPC in terms of death from any
cause in all men, (what can be interpreted as) a positive impact for death from prostate cancer
in diagnosed men, and (what can be interpreted as) a negative impact for death with, but not
from, prostate cancer in diagnosed men. Sensitivity analysis showed that using a discount rate
of 5% and 1% does not result in major changes in the differences in costs or cost-effectiveness
between the two arms in any of these analyses. In their assessment of the cost-effectiveness of
screening, epidemiological studies have focused mainly on disease-specific mortality [2, 29,
30], often to the exclusion of any other effects on mortality [31]. In contrast to earlier CEAs
[32±36] our approach to health-economic evaluation considers not merely prostate-cancer
mortality; but characterizes all-cause mortality too, along with non-prostate-cancer mortality
in men diagnosed with prostate cancer. One potential pitfall in modelling cost-effectiveness in
a manner which does not adequately question the underlying epidemiology is that, accord-
ingly, any errors in the choice of outcome measures may be compounded in the act of model-
ling. If the choice of outcome measure is restricted by epidemiological convention this may
obscure relevant effects of the intervention, resulting in models neglecting to include a poten-
tially relevant health state, such as non-prostate-cancer mortality in men diagnosed with pros-
tate cancer. Incorporating all potentially important mortality impacts should be seen as central
in any health-economic evaluation [37].
The interpretation of incremental cost-effectiveness ratios is not a straightforward matter,
as the process of interpretation is typically specific to both the ICER's content and the deci-
sion-making context in question. In the field of health-economic evaluation, a cost-effective-
ness ratio usually represents some indicator of the amount of health gained divided by some
estimate of the financial costs associated with that estimated `health' gain. Only relatively infre-
quently, as in the secondary analysis presented here, does the cost-effectiveness ratio represent
some indicator of the amount of health lost divided by some estimate of the financial costs of
that estimated `health' lost. When we report that, for men diagnosed with prostate cancer, the
estimated health-care cost per additional death is around 20,000€, this means that the data sug-
gests the trial was economically efficient at increasing non-prostate-cancer mortality for those
men. It should be clear from the results presented here that cost-effectiveness ratios can con-
tain or omit a wide range of factors. For this reason, understanding the content of each incre-
mental cost-effectiveness ratio is important when they are interpreted, for example, how well
costs and health effects are measured and analysed, and what costs and effects are, or are not,
included in the analysis. In Table 3 we set out the main research assumptions and key compo-
nents which underpin the health-economic evaluation of the FinRSPC.
In practice, interpretation of cost-effectiveness information requires understanding of the
components and qualities of that information [39]. Table 3 is intended to provide a useful
starting point for interpretation of the information about costs, effects and cost-effectiveness
provided by our study [40]. Interpretation of CEA results is also usually influenced by the
interplay between the decision-making context and the specific information provided by the
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Table 3. Main assumptions. Key elements of the health-economic evaluation of the FinRSPC.
A) Key elements of the analysis related to the FinRSPC:
strengths · Assignment to the trial arms occurred without prior consent (but with the permission of the
authorities)
· The men randomised represented the whole target population of the Tampere and Helsinki areas
during the period, i.e., all registered male citizens of the selected age groups were included
· Long-term register-based follow-up was available for practically all men (>99.9%)
limitations · Neither Finnish registries or the trial database includes consistent follow-up of either many of the
possible health-related impacts, or some of the costs, associated with prostate-cancer screening
· The FinRSPC is limited by its context, e.g.:
· clinical practice today may be quite different to that of the late 1990s
· PSA testing became more prevalent in the population over the period of the trial, which seems
likely to have had a significant effect on the impacts of the screening intervention [38]
· The long duration of follow-up may also mean that more influences unrelated to the screening trial
are reflected in its results, i.e., that there is more `noise' in the data
· Clinical trials such as the FinRSPC typically can only provide robust information on average
treatment effects for the whole trial population. This is also the case for this trial, which practically
precludes robust analysis by, e.g., geographical- or age-related±subgroup
B) Key elements of the analysis related to costs:
strengths · The analysis uses well-established registers covering both use of hospital services (inpatient and
outpatient) as well as reimbursements for almost all outpatient prescription medications
· The registers provide almost complete coverage of these (hospital and prescription-medication) costs
for almost all men in the trial for almost the whole duration of the 20-year study
limitations · In principle, ideally all costs associated with PSA mass screening for prostate cancer and its
consequences might be included as part of a cost-effectiveness analysis, at least when attempting to
gauge the robustness of the results to the inclusion or omission of a range of cost items.
· Although information relating to primary care costs is typically included, such information was not
readily available from Finnish registers or the trial database, so is not included here
· Various cost drivers, such as costs to patients, costs which fall on the social-care budget, and costs of
lost productivity in the economy, were not included in our analyses
· Although the registers provide an identical source of data for men in both arms of the trial, and
although price indices and discount rates were applied uniformly in both arms, the register-based
cost estimates presented here are based on NordDRG cost weights, the cost estimates are, at best,
merely rough indicators of the magnitude of the true current costs which might be associated with
PSA mass screening for prostate cancer
C) Key elements of the analysis related to health-related outcomes:
strengths · The analysis presented here focuses on one of the most important and robust impacts related to
health outcomes, i.e., mortality
· The analysis uses data from well-established registries and precise cause-of-death registers with
practically complete coverage (at least for men who did not emigrate)
limitations · No direct measurement of health-related quality of life or patient satisfaction was possible using the
available register data
D) Key elements related to the cost-effectiveness analysis per se:
strengths · Each incremental cost-effectiveness ratio (ICER) presented looks at a different aspect of mortality,
together the three ICERs presented provide an a variety of useful indicators of the efficiency of mass
screening for prostate cancer in terms of the main impacts on mortality
· Although the cost drivers used in our analysis are limited in scope, as noted above (in section B) of
the table), the data provides almost complete coverage of two main costs: hospital care and
prescription medications
limitations · Each incremental cost-effectiveness ratio (ICER) presented looks at a different aspect of mortality,
none of the ICERs alone provide an all-encompassing indicator of the efficiency of organised PSA
mass screening for prostate cancer
· As noted above (in section C) of this table) our analysis does not incorporate health-related quality
of life considerations or considerations relating to patient satisfaction. For this reason the ICER
estimates presented here provide only a truncated representation of the efficiency of PSA mass
screening for prostate cancer and do not take into account important effects, e.g., on quality of life
https://doi.org/10.1371/journal.pone.0224479.t003
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incremental cost-effectiveness ratios in question. Therefore, judgment will typically be needed,
in every separate case and context, to gauge to what extent any estimated incremental cost-
effectiveness ratios provide an indication of `value'. Many elements of the chosen approach to
health-economic evaluation can markedly influence the results of cost-effectiveness analyses
[41]. When CEAs are based on a single randomised controlled trial, CEAs naturally are heavily
dependent on that source of information. Although randomised controlled trials are typically
seen as one of the best research methods to inform public health policy, it should be noted that
they do have their weaknesses [25, 42, 43]. Further details about the strengths and limitations
of our study will be set out below.
Strengths of the study
Our register-based cost-effectiveness analysis combines the power of a randomised controlled
trial with extensive follow-up via real-world data from comprehensive health-care registers. By
avoiding reliance on many of the assumptions typically necessary for modelling costs and out-
comes, our study represents a potentially significant application of CEA to improve the knowl-
edge base about organised screening for prostate cancer. Although numerous modelling-based
studies have been reported upon [32±36, 44], their estimates or forecasts typically do not pro-
ceed from data alone, with a frequent cascading effect wherein cost estimates are based on pre-
vious estimates of outcomes. Our results can be regarded as a groundbreaking contrast, in that
this is the first report on CEA based on real-world data derived from one study of PSA mass
screening. The men in the FinRSPC, i.e., in the Finnish arm of the ERSPC, were a complete
age cohort of the men in and around two main Finnish conurbations, Helsinki and Tampere.
The men were assigned to the two arms before randomisation, thus minimising problems
associated with selection to either group. Although the FinRSPC does not provide a perfectly
valid assessment of organised screening versus no screening, it likely provides a potentially
valid assessment of organised screening versus current clinical practice. The contamination by
opportunistic PSA-testing experienced during this trial is more likely to be generalizable to
current clinical practice than would `no screening', by providing evidence of the likely impact
of organised screening over and above opportunistic testing [19]. In addition, the data over the
20 years of the trial (with 17-year median follow-up time), from fairly comprehensive data on
health-care costs and on effectiveness (in terms of mortality), help in obtaining potentially gen-
eralizable cost-effectiveness estimates, which realistically account for the diluting effects of
contamination.
Truncation of the follow-up at 17 years was undertaken to limit our analysis to only the
most robust data, because as age cohorts were selected from the population the on January 1 of
each year from 1996 through 1999, analysis without truncation would mean that follow-up
beyond 17 years would only be possible for fewer and fewer men each year until the maximum
of 20 years of follow-up. Truncation in this study produces more conservative results, with
analysis using all available data producing both larger effect sizes and more statistically-signifi-
cant associations.
Another strength of our study lies in its ability to inform current and future choices of suit-
able metrics for effectiveness [45]. For instance, our finding that over the 20 years of the
FinRSPC trial, mortality from causes other than prostate cancer among diagnosed men
increased in the screening arm has potentially significant implications for future research. Our
analysis likely provides a useful building block in that its findings could be input for testing
existing cost-effectiveness models' sensitivity to new information, which has been shown to be
useful elsewhere [46]. In addition, similar analyses from comparable trials of organised screen-
ing could provide illuminating corroboration or contradiction of the findings presented here,
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because we are not aware of any other published analyses of mortality from causes other than
prostate cancer among diagnosed men in trials of PSA mass screening for prostate cancer [47].
Limitations of the study
As set out in parts of Table 3, this study is limited in scope for a number of reasons, e.g., that
no direct analysis of health-related quality of life or patient satisfaction was possible using the
available register data [48]. The estimates from a pragmatic trial in Finland presented here are
not necessarily indicative or representative of the impacts of organised PSA screening likely in
other health-care systems. Indeed, these estimates are unlikely to represent exact health-care
costs, effectiveness (in terms of mortality), or cost-effectiveness in other settings. However, this
is unavoidable for any pragmatic long-term, real-world study. The generalizability of our anal-
ysis to other settings is dependent on how well the manner of implementing the screening
intervention and subsequent care pathways in the FinRSPC can be generalized and also on
contextual elements such as the treatment patterns and the relative homogeneity of the
FinRSPC participants (the vast majority being Finnish and Caucasian). More generally, the
health-care system in which the trial took place (in the largely publicly-funded Finnish health-
care system) may limit generalizability. Despite these limitations, this trial of comparative
effectiveness does represent an important source of evidence, which can be used to supplement
earlier evidence from modelling studies. Of course, the authors acknowledge that, just as
modelling-based CEA depends on assumptions that may sometimes be flawed or inaccurate,
the relevance of empirical CEA to a wider population or time horizon also depends on
assumptions that may sometimes be flawed or inaccurate. In addition, all our results should be
interpreted in consideration of the likelihood of high levels of contamination in the control
arm [49], since most of the men in the control arm had a PSA test at some point in the trial
and the cumulative incidence of T1c cancers was, for example, only approximately 20% higher
in the screening arm than in the control arm. Although almost 75% of men in the screening
arm of the FinRSPC participated in the organised screening, we cannot know exactly which
men underwent non-systematic screening, i.e., opportunistic testing [38]. Further, the results
presented here for the subgroups of men diagnosed with prostate cancer are not necessarily
causally linked to randomisation, they are the result of randomisation followed by diagnosis,
so the intention-to-screen-analytic comparison between the arms is uncertain in this respect
[25]. However, the results of the intention-to-screen analysis show mortality effects of similar
magnitude to those in the subgroup analysis presented here. It should also be noted here that
health-economic evaluations are information-intensive in their input requirements and that
their use often suffers from a lack of appropriate information [50], especially as pathways to
health are quite complex [51]. For example, the main costs analysed were from secondary and
tertiary care, so various cost drivers, such as costs of lost productivity to the economy, costs of
primary-care treatment, and costs due to social care, were not considered. One of these, pri-
mary-care costs, were not included in our study as data were not available from registers for
the majority of the follow-up period (except to the extent that prescription medication use, as
part of primary care, was covered). However, we are not aware of any strong reason why pri-
mary care costs would differ substantially between the groups when, e.g., there were no major
differences in the costs of secondary or tertiary care. One further limitation (or, conversely,
potential strength), is that our study employed a fixed time horizon, setting it apart from many
model-based studies, which vary the time horizon modelled. On the other hand, models that
attempt to estimate ªlifetimeº costs and effectiveness typically rely on assumptions that could
seem out of place in light of the findings presented here, especially since we cannot know with
any certainty which direction the impacts of PSA screening will take next.
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Conclusion
Our primary analyses showed no major difference in overall health-care costs or in overall
mortality within the 17 years of follow-up. However, in further analysis, relatively minor
reductions in prostate-cancer mortality at the expense of increased costs in the screening arm
were found, but these may be outweighed by an increase in mortality from other causes for
men diagnosed with prostate cancer in the screening arm. Our analysis could be usefully sup-
ported or contradicted by similar analyses using data from comparable trials of mass screen-
ing. Longer-term follow-up may also allow more robust conclusions as to the balance of the
benefits and harms of introducing organised PSA mass screening.
Acknowledgments
The authors would like to express thanks to all those who have helped in collating the trial data
over the past 20 years but especially to Liisa MaÈaÈttaÈnen, formerly of the Finnish Mass Screen-
ing Registry, for her continued support related to the trial database, even in retirement. The
corresponding author would also like to thank Jani Raitanen and Pasi Aronen for numerous
helpful discussions about matters statistical and analytical. Any mistakes that may remain are
the responsibility of the corresponding author.
Author Contributions
Conceptualization: Neill Booth, Pekka Rissanen, Teuvo L. J. Tammela, Anssi Auvinen.
Data curation: Neill Booth, Ulf-Håkan Stenman, Kirsi Talala.
Formal analysis: Neill Booth, Anssi Auvinen.
Funding acquisition: Neill Booth, Pekka Rissanen, Teuvo L. J. Tammela, Kimmo Taari, Anssi
Auvinen.
Investigation: Neill Booth, Paula Kujala, Kimmo Taari, Kirsi Talala.
Methodology: Neill Booth, Pekka Rissanen, Paula Kujala, Anssi Auvinen.
Project administration: Neill Booth, Kirsi Talala.
Supervision: Pekka Rissanen, Anssi Auvinen.
Validation: Neill Booth, Anssi Auvinen.
Visualization: Neill Booth.
Writing ± original draft: Neill Booth, Anssi Auvinen.
Writing ± review & editing: Neill Booth, Pekka Rissanen, Teuvo L. J. Tammela, Paula Kujala,
Ulf-Håkan Stenman, Kimmo Taari, Kirsi Talala, Anssi Auvinen.
References
1. Schro¨der FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Prostate-Cancer Mortal-
ity at 11 Years of Follow-up. New England Journal of Medicine. 2012; 366(11):981–90. https://doi.org/
10.1056/NEJMoa1113135 PMID: 22417251
2. Schro¨der FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V, et al. Screening and prostate
cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer
(ERSPC) at 13 years of follow-up. Lancet. 2014; 384(9959):2027–35. https://doi.org/10.1016/S0140-
6736(14)60525-0 PMID: 25108889
3. Kilpela¨inen TP, Tammela TL, Malila N, Hakama M, Santti H, Ma¨a¨tta¨nen L, et al. Prostate cancer mortal-
ity in the Finnish Randomized Screening Trial. Journal of the National Cancer Institute. 2013; 105
(10):719–25. https://doi.org/10.1093/jnci/djt038 PMID: 23479454
CEA of PSA mass screening combining RCT and register data
PLOS ONE | https://doi.org/10.1371/journal.pone.0224479 November 5, 2019 14 / 17
4. Pinsky PF, Miller E, Prorok P, Grubb R, Crawford ED, Andriole G. Extended follow-up for prostate can-
cer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian random-
ized cancer screening trial. BJU Int. 2019; 123(5):854–60. https://doi.org/10.1111/bju.14580 PMID:
30288918
5. Booth N, Rissanen P, Tammela T, Taari K, Talala K, Auvinen A. Costs of screening for prostate cancer:
Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up
using register data. European Journal of Cancer. 2018; 93:108–18. https://doi.org/10.1016/j.ejca.2018.
01.111 PMID: 29501976
6. Krahn M, Zagorski B, Laporte A, Alibhai SMH, Bremner KE, Tomlinson G, et al. Healthcare costs asso-
ciated with prostate cancer: estimates from a population-based study. BJU International. 2010; 105
(3):338–46. https://doi.org/10.1111/j.1464-410X.2009.08758.x PMID: 19594734
7. Yates DR, Anderson JB. Screening for prostate cancer. In: Tewari A, editor. Prostate Cancer: A Com-
prehensive Perspective. London: Springer-Verlag; 2013. p. 333–46.
8. Haines IE, Ablin RJ, Miklos GLG. Screening for prostate cancer: time to put all the data on the table.
BMJ. 2016; 353. https://doi.org/10.1136/bmj.i2574 PMID: 27226459
9. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices.
New England Journal of Medicine. 1977; 296(13):716–21. https://doi.org/10.1056/
NEJM197703312961304 PMID: 402576
10. Russell LB, Sinha A. Strengthening Cost-Effectiveness Analysis for Public Health Policy. American
Journal of Preventive Medicine. 2016; 50(5, Supplement 1):S6–S12. https://doi.org/10.1016/j.amepre.
2015.11.007 PMID: 27102861
11. Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied Methods of Cost-effectiveness Analy-
sis in Health Care. Gray A, Briggs A, editors. Oxford: Oxford University Press; 2011.
12. Neumann PJ, Kim DD, Trikalinos TA, Sculpher MJ, Salomon JA, Prosser LA, et al. Future Directions for
Cost-effectiveness Analyses in Health and Medicine. Med Decis Making. 2018; 38(7):767–77. https://
doi.org/10.1177/0272989X18798833 PMID: 30248277
13. Glick H, Doshi J, Sonnad S, Polsky D. Economic Evaluation in Clinical Trials. Gray A, Briggs A, editors.
Oxford: Oxford University Press; 2014.
14. Noordzij MA, Blanker MH. Re: Cost-effectiveness of prostate cancer screening: a simulation study
based on ERSPC data. Journal of the National Cancer Institute. 2015; 107(6):djv110. https://doi.org/10.
1093/jnci/djv110 PMID: 25888716
15. Auvinen A. Prostate cancer screening: What can we learn from randomised trials? Translational Androl-
ogy and Urology. 2018; 7(1):12–7. https://doi.org/10.21037/tau.2017.12.13 PMID: 29594015
16. Ramsberg J, Neovius M. Register or electronic health records enriched randomized pragmatic trials:
The future of clinical effectiveness and cost-effectiveness trials? Nordic Journal of Health Economics.
2017; 5(1):62–76. https://doi.org/10.5617/njhe.1386
17. Sackett DL. The arrogance of preventive medicine. CMAJ. 2002; 167(4):363–4. PMID: 12197692
18. The Nordic Classification Centre. NordDRG Users’ Manual 2012 [19/06/19]. http://www.nordcase.org/
eng/materials/manuals/.
19. Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis
alongside clinical trials II–an ISPOR Good Research Practices Task Force report. Value in Health.
2015; 18(2):161–72. https://doi.org/10.1016/j.jval.2015.02.001 PMID: 25773551
20. Booth N, Rissanen P, Tammela TLJ, Ma¨a¨tta¨nen L, Taari K, Auvinen A. Health-related quality of life in
the Finnish Trial of Screening for Prostate Cancer. European Urology. 2014; 65(1):39–47. https://doi.
org/10.1016/j.eururo.2012.11.041 PMID: 23265387
21. European Network for Health Technology Assessment (EUnetHTA). Methods for health economic eval-
uations—a guideline based on current practices in Europe. http://www.eunethta.eu/sites/5026.fedimbo.
belgium.be/files/2015-04-29-ECO-GL_Final%20version_0.pdf. 2015.
22. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health
Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: A Report of the
ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
Value in Health. 2013; 16(2):231–50. https://doi.org/10.1016/j.jval.2013.02.002 PMID: 23538175
23. StataCorp LLC. Stata statistical software: Release 15.1. College Station, TX. 2019.
24. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: Updated guidelines for report-
ing parallel group randomized trials. Ann Intern Med. 2010; 152(11):726–32. https://doi.org/10.7326/
0003-4819-152-11-201006010-00232 PMID: 20335313
25. Deaton A, Cartwright N. Understanding and misunderstanding randomized controlled trials. Social Sci-
ence & Medicine. 2018; 210:2–21. https://doi.org/10.1016/j.socscimed.2017.12.005 PMID: 29331519
CEA of PSA mass screening combining RCT and register data
PLOS ONE | https://doi.org/10.1371/journal.pone.0224479 November 5, 2019 15 / 17
26. Basu A, Maciejewski ML. Choosing a Time Horizon in Cost and Cost-effectiveness Analyses. JAMA.
2019; 321(11):1096–7. https://doi.org/10.1001/jama.2019.1153 PMID: 30789668
27. Goodwin P, Wright G. The limits of forecasting methods in anticipating rare events. Technological
Forecasting and Social Change. 2010; 77(3):355–68. https://doi.org/10.1016/j.techfore.2009.10.
008
28. Sobin LH, Wittekind C, Gospodarowicz MK. TNM Classification of Malignant Tumours. Oxford: Wiley-
Blackwell; 2010.
29. Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, et al. Reconciling the Effects of
Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann Intern Med. 2017;
167(7):449–55. https://doi.org/10.7326/M16-2586 PMID: 28869989
30. Editorial. DIfferent effects of screening on prostate cancer death in two trials. Annals of Internal Medi-
cine. 2017.
31. Prasad V, Lenzer J, Newman DH. Why cancer screening has never been shown to ‘save lives’–and
what we can do about it. BMJ. 2016; 352. https://doi.org/10.1136/bmj.h6080 PMID: 26740343
32. Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R. Economic analysis of prostate-specific antigen
screening and selective treatment strategies. JAMA Oncology. 2016; 2(7):890–8. https://doi.org/10.
1001/jamaoncol.2015.6275 PMID: 27010943
33. Shteynshlyuger A, Andriole GL. Cost-Effectiveness of Prostate Specific Antigen Screening in the United
States: Extrapolating From the European Study of Screening for Prostate Cancer. The Journal of Urol-
ogy. 2011; 185(3):828–32. https://doi.org/10.1016/j.juro.2010.10.079 PMID: 21239021
34. Pataky R, Gulati R, Etzioni R, Black P, Chi KN, Coldman AJ, et al. Is prostate cancer screening cost-
effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia,
Canada. International Journal of Cancer. 2014; 135(4):939–47. https://doi.org/10.1002/ijc.28732 PMID:
24443367
35. Shin S, Kim YH, Hwang JS, Lee YJ, Lee SM, Ahn J. Economic evaluation of prostate cancer screening
test as a national cancer screening program in South Korea. Asian Pac J Cancer Prev. 2014; 15
(8):3383–9. https://doi.org/10.7314/apjcp.2014.15.8.3383 PMID: 24870726
36. Heijnsdijk EAM, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, et al. Cost-effective-
ness of prostate cancer screening: A simulation study based on ERSPC data. Journal of the National
Cancer Institute. 2015; 107(1). https://doi.org/10.1093/jnci/dju366 PMID: 25505238
37. Mullahy J. Health and evidence in health economics. Health Economics. 2019; 28(10):1163–5. https://
doi.org/10.1002/hec.3926 PMID: 31264292
38. Kilpela¨inen TP, Pogodin-Hannolainen D, Kemppainen K, Talala K, Raitanen J, Taari K, et al. Estimate
of opportunistic prostate specific antigen testing in the Finnish Randomized Study of Screening for
Prostate Cancer. The Journal of Urology. 2017; 198(1):50–7. https://doi.org/10.1016/j.juro.2017.01.048
PMID: 28104375
39. Booth N. On value frameworks and opportunity costs in health technology assessment. International
Journal of Technology Assessment in Health Care. 2019. https://doi.org/10.1017/S0266462319000643
PMID: 31530332
40. Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact anal-
ysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II
Task Force. Value in Health. 2014; 17(1):5–14. https://doi.org/10.1016/j.jval.2013.08.2291 PMID:
24438712
41. Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny M-P, et al. Cost-effectiveness
thresholds: pros and cons. Bulletin of the World Health Organization. 2016; 94(12):925–30. https://doi.
org/10.2471/BLT.15.164418 PMID: 27994285
42. Krauss A. Why all randomised controlled trials produce biased results. Annals of Medicine. 2018;
50(4):312–22. https://doi.org/10.1080/07853890.2018.1453233 PMID: 29616838
43. Manski CF. The lure of incredible certitude. Economics and Philosophy. 2019:1–30. https://doi.org/10.
1017/S0266267119000105
44. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate
cancer: A decision analytic view. JAMA. 1994; 272(10):773–80. PMID: 7521400
45. Quade ES. Introduction and overview. In: Goldman TA, editor. Cost-effectiveness analysis: new
approaches in decision-making. New York: Praeger; 1967. p. 1–16.
46. Laxy M, Wilson ECF, Boothby CE, Griffin SJ. Incremental Costs and Cost Effectiveness of Intensive
Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An
Update with Empirical Trial-Based Cost Data. Value in Health. 2017; 20(10):1288–98. https://doi.org/
10.1016/j.jval.2017.05.018 PMID: 29241888
CEA of PSA mass screening combining RCT and register data
PLOS ONE | https://doi.org/10.1371/journal.pone.0224479 November 5, 2019 16 / 17
47. Heijnsdijk EAM, Csana´di M, Gini A, ten Haaf K, Bendes R, Anttila A, et al. All-cause mortality versus
cancer-specific mortality as outcome in cancer screening trials: A review and modeling study. Cancer
Medicine. 2019; 8(13):6127–38. https://doi.org/10.1002/cam4.2476 PMID: 31422585
48. McNaughton-Collins M, Walker-Corkery E, Barry MJ. Health-related quality of life, satisfaction, and eco-
nomic outcome measures in studies of prostate cancer screening and treatment, 1990–2000. J Natl
Cancer Inst Monogr. 2004;(33):78–101. https://doi.org/10.1093/jncimonographs/lgh016 PMID:
15504921
49. Shoag JE, Mittal S, Hu JC. Reevaluating PSA Testing Rates in the PLCO Trial. New England Journal of
Medicine. 2016; 374(18):1795–6. https://doi.org/10.1056/NEJMc1515131 PMID: 27144870
50. Mooney G. Priority setting in mental health services. Applied Health Economics and Health Policy.
2002; 1(2):65–74. PMID: 14619253
51. Birch S. As a matter of fact: evidence-based decision-making unplugged. Health Economics. 1997;
6(6):547–59. PMID: 9466138
CEA of PSA mass screening combining RCT and register data
PLOS ONE | https://doi.org/10.1371/journal.pone.0224479 November 5, 2019 17 / 17



